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I Foreword by the EMCDDA Director
The document I present here is crucial for the life of the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and it reflects the important changes that the organisation is 
undergoing. Not only is this the agency’s first multiannual single programming document (SPD), 
it is also the first one to be implemented under the new long-term strategy that, at the start of 
my mandate as EMCDDA Director, I have committed myself to developing and implementing.
We have derived this new strategy and the SPD from the 2016–18 strategy and work 
programme, which was adopted in December 2016 and set out an ambitious vision for the 
EMCDDA: to contribute to a more secure and healthier Europe.
The document reflects our focus on becoming a valuable and reliable service provider to our 
customers, particularly policymakers within the EU institutions and the Member States. Our 
mission is to provide them with information and analysis that can make a difference to the drugs 
situation and can ultimately contribute to the security and the health of European citizens.
To this end, the solid core EU monitoring system that we have built up over the past 20 years will 
continue to play a key role in collecting the data we need, in close collaboration with our Reitox 
partners. However, as the drugs phenomenon is increasingly complex and its implications are 
global, greater emphasis will be placed on capturing information from new data sources, and on 
better linking EU findings with international developments. This forms part of our strategic 
analysis capability, one of the agency’s main assets.
Our analysis is of little value, however, unless we deliver it in a timely manner using means that 
are most suitable for our customers. With this in mind, we will continue to refine our 
communication channels to provide faster and more targeted services. We aim not only to 
respond to demands, but also to anticipate them. As an EU agency with a monitoring system 
that is unique in the world, which includes complex networks of experts and partners, we are 
best placed to understand drug trends and advise our stakeholders promptly on the implications 
they may have.
At organisational level, during 2017–19 we will also develop a new internal structure; this 
structure will be designed to meet the needs of the long-term strategy and to ensure that its 
goals are fulfilled.
I could not conclude this first Foreword as EMCDDA Director without expressing my gratitude to 
our partners in the Member States, particularly to the Reitox network of national focal points, as 
well as to our EU and international partners, who, together with my staff, will make possible the 
successful implementation of this programming document.
Alexis Goosdeel 
Director, EMCDDA
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I List of abbreviations
AHCC authority authorised to conclude contracts
AP action plan
BCP Business continuity plan
BPP Best practice portal
CA Contract agent
CADAP Central Asia Drug Action Programme





CEOS Conditions of Employment of Other Servants of the EU
CEPOL European Union Agency for Law Enforcement Training
CHAFEA Consumer, Health, Agriculture and Food Executive Agency
CICAD Inter-American Drug Abuse Control Commission
COM Communication unit
COPOLAD II Cooperation Programme between Latin America, the Caribbean and the EU on Drugs 
Policies
COSI Standing Committee on Operational Cooperation on Internal Security
DG Directorate-General
DG HOME Directorate-General for Migration and Home Affairs
DG NEAR Directorate-General for Neighbourhood and Enlargement Negotiations
DG SANTÉ Directorate-General for Health and Food Safety
DRD drug-related deaths
DRID drug-related infectious diseases
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDMR European Drug Markets Report
EDND European Database on New Drugs
EDPQS European Drug Prevention Quality Standards
EDR European Drug Report
EDRR European Drug Responses Report
EEAS European External Action Service
EFCA European Fisheries Control Agency
EFSQ European facility survey questionnaire
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform against Criminal Threats
EMQ European Model Questionnaire
EMSA European Maritime Safety Agency
ENP European Neighbourhood Policy
EPI Prevalence, data management and content coordination unit
EPSO European Personnel Selection Office
ESPAD European School Survey Project on Alcohol and Other Drugs
EU European Union
EU-ANSA EU Agencies Network for Scientific Advice
Euro-DEN European Drug Emergencies Network
Eurojust the European Union’s Judicial Cooperation Unit
Europol European Union’s law enforcement agency




GPS general population survey(s)
HDG Horizontal Drugs Group, Horizontal Working Party on Drugs
HFPs heads of national focal points
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HIV human immunodeficiency virus
HR human resources
IAJM Inter-agency job market
IBS Consequences, responses and best practices unit
ICT information and communication technology
IPA Instrument for Pre-Accession Assistance
JHA Justice and Home Affairs
KA key area
KI key epidemiological indicator
KPI key performance indicator
M&E monitoring and evaluation
MIS management information system
MoU Memorandum of Understanding
MSPP Multi-annual staff policy plan
NFP national focal point
NPS new psychoactive substances
OAP operational action plan
OSI open source information
PCC potential candidate countries
PDU problem drug use
PHARE Programme of Community aid to the countries of Central and Eastern Europe
PhV pharmacovigilance
POD Perspectives on Drugs
PWID people who inject drugs
RA risk assessment
Reitox European Information Network on Drugs and Drug Addiction
SAT Supply reduction and new drugs unit
SCORE Sewage Biomarker Analysis for Community Health Assessment
SDI Scientific division
SNE seconded national expert
SOCTA Serious and Organised Crime Threat Assessment
SPD Single Programming Document
SR Staff regulations
SWP strategy and work programme
TA temporary agent
TAIEX Technical Assistance and Information Exchange
TDI treatment demand indicator
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNGASS United Nations General Assembly Special Session
UNODC United Nations Office on Drugs and Crime
VAT Value-added tax
WHO World Health Organization
WP work programme
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I Mission statement
Independent, science-based information is a vital resource to help Europe understand the 
nature of its drug problems and better respond to them. It was upon this premise, and in the 
face of an escalating drugs phenomenon, that the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of 
the European Union’s (EU’s) decentralised agencies.
The agency’s founding regulation was recast in 2006 and defined the role of the EMCDDA as 
being to provide the EU and its Member States with a factual overview of European drug 
problems and with a solid evidence base to support the drugs debate. The agency offers 
policymakers the data and analysis they need for drawing up informed drug laws and strategies, 
and it helps professionals and practitioners working in the field pinpoint best practice and new 
areas of research.
The priorities in the recast regulation, which form the bedrock of this new strategy and work 
programme, are (a) monitoring the state of the drugs problem, in particular using 
epidemiological indicators, and monitoring emerging trends; (b) monitoring the solutions applied 
to drug-related problems, providing information on best practices in the Member States and 
facilitating information exchange among them; (c) assessing the risks of new psychoactive 
substances and maintaining a rapid information system; and (d) developing tools and 
instruments to help Member States to monitor and evaluate their national policies, and the 
European Commission (EC) to monitor and evaluate EU policies.
In fulfilling its tasks, the agency relies on a large number of partners and, in particular, the 
European Information Network on Drugs and Drug Addiction — the Reitox network of national 
focal points (NFPs). The NFPs exercise the critical role of providing national data from the 30 
countries that report to the EMCDDA, namely the 28 EU Member States, Norway and Turkey. 
Together with the information collected from other networks of experts and partners, these data 
feed the European and global analyses performed by the EMCDDA, thereby forming the basis of 
its world-renowned knowledge and its reputation as a centre of excellence on drugs in Europe.
The EMCDDA approaches the drugs problem from a range of different disciplines and 
perspectives. This is necessary because the drugs issue has an impact on society, public health, 
security and crime. This multidisciplinary and holistic approach is one of the core strengths of 
the agency’s work. It also underpins the EMCDDA’s long-term vision, which is to contribute to 
a more secure and healthier Europe. The agency’s mandate, as well as its knowledge, expertise 
and the strategic partnerships it has developed over the 20 years of its existence, places it in 
a privileged position to achieve this.
As an organisation, the agency is guided by a core set of values to ensure that its work is of the 
highest standard. These values are:
■■ scientific rigour;
■■ neutrality and independence; and
■■ service orientation.
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The specific business principles that sustain these values include:
■■ maintaining the relevance and timeliness of the reporting system to allow a responsive 
analysis of the drugs situation;
■■ capitalising on established partnerships and building new ones, with a view to further 
developing synergies;
■■ maximising the impact of communication activities: getting the right information to the right 
people at the right time using the right medium;
■■ implementing a state-of-the-art performance measurement system, to ensure that work is on 
track and that it delivers its intended outcome and meets the expectations of the agency’s 
stakeholders.
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SECTION I
General context
|  Continuity and change: building on the 2016–18 strategy and work programme, towards a more 
integrated programming approach
This is the first EMCDDA Single Programming Document 
(SPD) and it covers the period 2017–19. The document 
presents, for the first time under one umbrella, the agency’s 
integrated multiannual strategic planning perspective. It links 
the core components of the planning process, namely the 
operational planning and the planning of resources (human 
and financial), within one common programming framework.
In compliance with the new timeline defined by the EMCDDA’s 
Financial Regulation, the drafting of the SPD was carried out 
in parallel with the finalisation of the new three-year strategy 
and work programme (SWP) for 2016–18, which was adopted 
by the Management Board in December 2015. Therefore, the 
SPD is very much grounded in the SWP; it capitalises on its 
core principles, which allow the EMCDDA to build further 
blocks towards accomplishing its ambitious vision to 
contribute to a more secure and healthier Europe. It also 
follows the same structure (which has been adjusted to 
comply with the template imposed by the EC on the agencies) 
and a similar intervention logic.
|  Meeting the growing needs and expectations of key stakeholders and partners
The EMCDDA has always been in close contact with its key 
stakeholders and partners, especially with the EU institutions 
and the Member States, in particular with the Reitox network, 
but also with other EU agencies, international organisations 
active in the field of drugs and relevant third countries. This 
has allowed the agency to create and maximise synergies, to 
drive the exchange of knowledge on the drugs situation in 
Europe and to contribute to global developments.
Another benefit of pursuing a close collaborative approach is 
to be able to better understand the needs and expectations of 
our key stakeholders and partners.
We conducted an extensive external consultation exercise, 
which involved the Member States, the agency’s Scientific 
Committee, EU bodies, international organisations and third 
countries, and the general public, prior to the preparation of 
the 2016–18 SWP, on which this document is based. 
Furthermore, when drafting this SPD, we have taken into 
account the recommendations formulated by the EC and the 
Scientific Committee through their formal opinions on the 
2016–18 SWP.
Further consultation of key stakeholders took place in 2016, 
when the EMCDDA was preparing its long-term strategy to 
2025. One of the key priorities of the new strategy will be to 
serve the needs of the EMCDDA’s primary stakeholders, which 
are the EU institutions, the national decision-/policymakers in 
the Member States and the professionals working in the drugs 
field.
| Responding to EU needs in 2017–19
For more than 20 years now, the EMCDDA has demonstrated 
its ability to act as a catalyst for data collection and strategic 
analysis in a complex policy area that cuts across crime, 
health and security issues, both within European countries 
and in the international context. The agency is seen as 
a credible partner by the European institutions, national 
policymakers and experts working in its technical areas, and it 
is an internationally recognised centre of excellence.
This capacity for impartial scientific expertise provides 
additional value to the future work of the EC, especially to the 
Directorate-General for Migration and Home Affairs (DG 
HOME), the partner DG of the EMCDDA, to the Directorate-
General for Health and Food Safety (DG SANTÉ) and to the 
Directorate-General for Neighbourhood and Enlargement 
Negotiations (DG NEAR). Furthermore, by scaling up 
partnerships with other agencies and institutions, the 
EMCDDA’s proven technical and analytical capacity can 
deliver new opportunities for European policy and 
interventions.
In 2017–19, the EMCDDA will enhance its contribution to 
a more secure and healthier Europe, taking advantage of its 
evidence-based, multidisciplinary approach. It will do this by 
being more proactive and giving greater emphasis to 
knowledge transfer, strategic analysis and threat assessment.
In terms of security, the agency will fulfil the obligations arising 
from the EU Agenda on Security 2015–20. The EMCDDA will 
contribute its information and analysis to tackling the three 
priorities set up by the policy document, namely terrorism, 
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serious and organised cross-border crime, and cybercrime. 
The document highlights the weight of drug-related criminal 
activities within the overall EU security threats and states that 
‘organised crime also feeds terrorism and cybercrime through 
channels like the supply of weapons, financing through drug 
smuggling, and the infiltration of financial markets’. The 
document also notes that ‘the market for illicit drugs remains 
the most dynamic of criminal markets, with a recent trend 
being the proliferation of the new psychoactive substances 
(NPS)’. Illicit online trade in drugs is also pointed out as one of 
the key components of the ‘ever-growing threat’ of cybercrime.
Cooperation with other EU agencies, in particular with the 
European Union’s Law Enforcement Agency (Europol), the 
European Union Agency for Law Enforcement Training 
(CEPOL) and Eurojust, will be further strengthened in 2017–
19, in order to contribute effectively to addressing the 
priorities of the EU Agenda on Security. This cooperation is 
already well established within the EU policy cycle for 
organised and serious international crime (the policy cycle), 
which represents the framework within which the EU Member 
States coordinate common priorities and operational action. 
The Standing Committee on Operational Cooperation on 
Internal Security (COSI) steers this process and brings 
together law enforcement officials from the Member States, 
the Commission and specialised EU agencies. Two of the 
priorities in the 2014–17 policy cycle specifically concern 
drugs: reducing the production and trafficking of cocaine/
heroin; and synthetic drugs, including NPS. A new Serious and 
Organised Crime Threat Assessment (SOCTA) report will be 
published by Europol in 2017 as part of the EU policy cycle on 
organised and serious international crime. The SOCTA will 
define the main threats to the EU, and from among these, the 
Member States will define the priorities for 2018–19. It is fully 
expected that drugs will feature among these priorities and 
that the EMCDDA will have a more prominent role in 
contributing to the operational action plans, particularly in 
producing threat assessments, providing expertise and 
delivering training.
Furthermore, in 2017 the EMCDDA will take over the 
chairmanship of the Justice and Home Affairs Agencies 
Network (JHA network) from the EU Agency for Fundamental 
Rights (FRA). This will provide the EMCDDA with an 
opportunity to present and highlight its expertise, knowledge 
and competences in the EU security area and its 
complementarity with the activities and mandates of other 
JHA agencies.
To this end, working closely with Europol, and where 
appropriate Eurojust and other JHA agencies, the EMCDDA 
will strive to strengthen and enhance its capacity for strategic 
analysis. The most representative example is the joint 
EMCDDA–Europol European Drug Markets Report, which 
offers a state-of-the-art strategic analysis of the drug markets 
in the European Union. The second edition of this key report 
was published in 2016 and the third edition will be drafted in 
2018, for publication in 2019. To better understand the 
importance of this strategic output, it is worth mentioning that 
its first edition, published in 2013, has become a key reference 
document for EU policymakers. For example, it supported the 
Council conclusions on improving the monitoring of drug 
supply in the EU, adopted at the Economic and Financial 
Affairs Council meeting in November 2013, and it was factored 
into the policy cycle priorities of the COSI and the 
corresponding operational action plans (OAPs) 2014 and 2015 
of the cocaine/heroin and synthetic drugs priority areas.
Furthermore, as emerging threats and trends are identified, 
rapid joint analyses and more detailed threat assessments will 
be conducted with Europol in order to enhance responses. 
Such threat assessments will be done both in the context of 
the EMCDDA–Europol cooperation as well as through the 
OAPs when this approach is agreed by the Member States. 
Furthermore, the EMCDDA will focus on providing technical 
expertise in support of EU-wide capacity-building exercises 
for law enforcement, such as training activities organised by 
the CEPOL.
The period 2017–19 will be a time for bedding down and 
enhancing the monitoring of drug supply in the European 
Union, in line with the EU drug strategy 2013–20, which sets 
a priority for the EU to ‘work towards more effective policy in 
the field of drug supply reduction by reinforcing policy 
evaluation and analysis to improve the understanding of drug 
markets, drug-related crimes and effectiveness of drug-related 
law enforcement responses’. The EMCDDA plays a key role in 
meeting this challenge; our information model, informed by 
both supply- and demand-side data, provides critical situation 
analysis and timely threat assessments. The agency will 
further develop and progressively implement key indicators 
(KIs) on drug supply and drug supply reduction as outlined in 
the 2013 Council conclusions on improving the monitoring of 
drug supply in the EU.
A holistic approach is needed, as drug markets can be 
properly understood only if we look at drug-related crime and 
drug supply reduction activities as well as drug use and 
drug-related harms. Through a combination of structured 
monitoring and analysis, the EMCDDA will provide a better 
understanding of the nature and scale of the online market 
and of new developments, at both consumer and supply 
levels, and also provide early identification of new trends and 
threats.
As far as security of the EU is concerned, there is an obvious 
link to the area of international cooperation. Here the EMCDDA 
has a long tradition in supporting the EC in implementing its 
technical assistance projects in priority third countries — 
especially candidate countries (CC), potential candidate 
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countries (PCC) and countries of the European 
Neighbourhood Policy (ENP) area. In 2017, the agency will 
complete the implementation of the fifth Instrument for 
Pre-Accession Assistance (IPA) project with seven beneficiary 
CC and PCC, which started in 2015. The sixth IPA, with the 
Western Balkans, may also start in 2017. Further to the 
successful completion of the first ENP project for seven 
beneficiary countries in 2016, the agency submitted to the EC 
a proposal to continue to provide technical assistance 
activities with ENP countries. The agency brings to these 
countries the EU’s balanced approach to and knowledge 
about drug monitoring, which supports the improvement of 
national data, in line with EU standards and for later 
integration into EMCDDA analyses.
These activities, together with data collected from other 
international partners, help improve our global understanding 
of the drugs phenomenon, which translates into a more 
complete perspective for our EU stakeholders, providing them 
with a better capacity to react to — and even anticipate — 
external threats.
So the EMCDDA, with the help of its partners, will make 
a significant contribution to the security of EU citizens over 
the next few years. However, fulfilling the agency’s vision for 
2017–19 also means contributing to their health.
To this end, the agency will continue the successful 
collaboration with its partners, in particular with the European 
Centre for Disease Prevention and Control (ECDC), the World 
Health Organization (WHO) and the Consumer, Health, 
Agriculture and Food Executive Agency (CHAFEA), in the 
prevention of infectious diseases among people who inject 
drugs (PWID), with a major focus on human immunodeficiency 
virus (HIV) and hepatitis C, which remain important public 
health concerns with a significant burden on the life of 
individuals and society overall. We have planned some new 
initiatives (joint events and publications) including the 
co-organisation of two major events in 2017, on hepatitis 
C and on prison, with the ECDC and the WHO respectively.
Furthermore, in recent years the EMCDDA has strengthened 
its capacity to react promptly to emerging threats and provide 
its expert advice. The assessment missions carried out jointly 
with the ECDC to support Member States are probably the 
best example in this area. These activities will continue in 
2017–19 as part of the overall EMCDDA strategy to scale up 
the early warning and threat assessment component of its 
work (see Key area 2).
We will also pursue collaboration with other partners with 
a view to enhancing the measurement of, understanding of 
and responses to drug-related deaths, which claim the lives of 
thousands of people every year.
Activity in the prevention area will be further developed in 
2017–19. This is an important task for the agency, as it allows 
the identification and promotion of factors that can potentially 
reduce drug uptake at an early stage, or at least reduce its 
intensification or prevent escalation into high-risk drug use. In 
addition to helping diminish other societal costs, there is an 
obvious link between drug prevention and crime prevention. 
With this in mind, we will pilot and gradually implement 
a training programme for professionals jointly with partners 
and we will collect new evidence on effective prevention 
practice and disseminate it through the EMCDDA’s Best 
practice portal (BPP). We will also produce further analysis of 
contextual, cultural and systemic determinants of 
implementing drug prevention.
Within the framework of the recently adopted Council 
conclusions on the implementation of the EU Action Plan (AP) 
on Drugs 2013–16 regarding minimum quality standards in 
drug demand reduction in the EU (CORDROGUE 70 (SAN 
279)), the EMCDDA will refine its approach to gathering 
evidence on effective interventions in the Member States, and 
it will promote this evidence to support EU decision-making.
Moreover, the agency will launch a new strategic analysis, the 
European Drug Responses Report. This report, the first edition 
of which will be published in 2017, aims to provide a state-of-
the-art overview of the responses to drug use across the EU 
and their effectiveness as well as recommendations for action. 
It will serve as the ‘companion’ to the European Drug Markets 
Report. Together with the annual European Drug Report, 
these two reports will provide the complete picture of the 
drugs phenomenon and comprise the essential information 
and analysis package for policymakers from the EU and 
beyond (see Key area 1). The second edition of the Responses 
Report will be drafted in 2019, for publication in 2020.
NPS pose one of the most rapidly growing threats for the 
health and security of EU citizens (see Key area 2). Since 
1997, the EMCDDA has played a central role in Europe’s 
response to NPS. Its main responsibilities in this field are to 
operate the EU Early Warning System (EWS), with our partner 
Europol, and to undertake risk assessments of new 
substances when necessary. The EWS works by collecting 
information on the appearance and spread of new substances 
from the 30 national early warning systems reporting to the 
EMCDDA and then monitoring them for signals of harm, 
allowing the EU to respond rapidly to emerging threats. In the 
past few years, the importance of this work has grown 
following a dramatic increase in the number, type and 
availability of NPS in Europe.
In 2017, it is expected that the new proposed legislation 
(Regulation of the European Parliament and of the Council 
amending Regulation (EC) No 1920/2006 as regards 
information exchange, early warning system and risk 
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assessment procedure on new psychoactive substances 
(COM/2016/0547 final — 2016/0261 (COD)) will enter into 
force. This will entail new tasks for the EMCDDA, as well as 
shorter deadlines for the already existing ones (see Section 
II.3, ‘Human and financial resources outlook for 2017–19’).
There were 98 NPS detected on the EU drug market for the 
first time in 2015 (the last year for which complete data were 
available at the time of drafting this document); together with 
the NPS notified in 2014, this represents 40 % of the total 
number of NPS monitored by the EWS since 1997. This brings 
the total number monitored by the EMCDDA to more than 
600 — more than double the number of substances controlled 
under the United Nations (UN) international drug control 
conventions — and more than half of these were reported in 
the last three years alone.
The growth in the market is also responsible for the increase in 
serious harms reported to the EMCDDA in recent years. Most 
of these concern non-fatal intoxications and deaths, but they 
also include broader social harms, such as those caused by 
high-risk drug users switching from injecting heroin to 
synthetic cathinones. Since 2014, serious harms that required 
urgent attention have led the EMCDDA to set up a signal 
management and a toxicovigilance system. This has resulted 
in more and better public health alerts being issued. Since 
2014, eight new substances have required risk assessment by 
the EMCDDA’s Scientific Committee at the request of the 
Council of the EU (almost three times as many as during the 
entire period 2010–13, and over one third of the total number 
of risk assessments ever conducted).
It is likely that the growth of the market in new psychoactive 
substances will continue to pose a range of challenges for 
public health and drug policy over the next few years. The 
major drivers of many of these are the speed at which they 
appear, their open sale, and the fact that there is little or no 
information on their effects and harms. There is a need, 
therefore, for a strong EU EWS, which is able to provide 
a timely response to protect public health. In this regard, the 
EMCDDA will continue to play a critical role, together with its 
partners, in ensuring that the EU EWS meets the growing 
challenges ahead and fulfils its critical role in protecting the 
health of EU citizens.
The EMCDDA will make an important contribution to 
implementing EU policy objectives and to providing ongoing 
high-quality expertise to its stakeholders, especially to the EC, 
other EU institutions, and the EU Member States (see Key 
area 1). This will be especially important in 2017–19 because 
the period falls in a particularly important phase in the field of 
drugs, which will shape the policy landscape around us and 
will bring new requirements, but also new opportunities, for 
the agency. At European level, 2017 is the starting date of the 
new EU AP 2017–20, and the EMCDDA will contribute to its 
implementation, as required. The agency may also be required 
to provide support to the EC in the final evaluation of the EU 
drug strategy 2013–20. Internationally, in 2016, the UN 
General Assembly Special Session (UNGASS) on drugs 
reviewed the world drug situation; in 2019, the UN Member 
States will review progress made through the implementation 
of the UN political declaration and plan of action on drugs 
adopted in 2009. It is likely that these events will generate 
increased attention on the drugs situation in all regions of the 
world, including Europe, and will increase the number of 
requests to the EMCDDA for technical support.
A key element for the implementation of this three-year 
programming document will be the amount of resources 
available to the EMCDDA during this period, and also to our 
national data providers in the Member States. The 
Communication of the European Commission to the European 
Parliament and the Council on the programming of human and 
financial resources for decentralised agencies for 2014–20 
(COM (2013) 519 final of 10 July 2013) provided a first 
estimate of the EU subsidy planned for the EMCDDA. 
Pursuant to this information and without prejudice to the 
actual decision to be taken by the EU budget authority for the 
adoption of the EU annual subsidy to the EMCDDA and the 
establishment plan of the latter, it is estimated that by 2019 
the EMCDDA will operate with an annual subsidy from the EU 
of EUR 15 million. Without prejudice to the possible allocation 
of supplementary resources to cope with new tasks, this 
would reflect the status quo compared with the amount of EU 
annual subsidy received in 2015 and 2016.
Finally, the fourth external evaluation of the EMCDDA will be 
carried out by the EC in 2018. The purpose of this exercise is 
to evaluate the agency’s success in implementing the three-
year strategy and work programme for 2016–18, as well as the 
previous strategy and work programme for 2013–15. This will 
be complemented by the EMCDDA’s annual monitoring effort 
set up to measure progress achieved in the implementation of 
each of the upcoming annual work programmes derived from 
this SPD, of which the first one will be for 2017. Key 
performance indicators (KPIs) have been set up for each of 
the objectives defined in the 2017 work programme.
| Structure of the document
This SPD has been prepared in line with the provisions of 
Article 32 of the EMCDDA Financial Regulation and in full 
compliance with the template provided by the EC (‘the 
template’) in the Guidelines for programming document for 
decentralised agencies (Communication from the 
Commission C(2014) 9641 final).
The document therefore incorporates the information 
contained in four different programming documents, which 
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used to be provided separately, as follows: the multiannual 
work programme, the relevant annual work programme, the 
applicable multiannual staff policy plan and the financial 
statement.
The SPD will need to be updated each year, on a rolling basis.
13 / 86 
SECTION II
Multiannual programming 2017–19
I  Introduction: the EMCDDA’s value chain ― transforming information into state-of-the-art analysis for decision-making
The substantive part of this SPD is structured around the 
areas defined in the recently adopted EMCDDA 2016–18 
strategy and work programme. The document is built around 
six strategic areas. Three of them are key areas (KAs): 
communicating evidence and knowledge exchange; early 
warning and threat assessment; and situation, responses and 
trend analysis. The other three are cross-cutting areas (CCAs): 
information collection and management; quality assurance; 
and cooperation with partners. Together, these areas cover 
the agency’s core tasks and form the conceptual building 
blocks needed to assemble a comprehensive understanding 
of the European drugs phenomenon.
This structure reflects the EMCDDA’s production flow as an 
information agency, from inputs to outputs, through 
monitoring and analysis processes (Figure 1).
In addition, two corporate areas ― Governance, and 
Administration and information and communication 
technology (ICT) ― present the management and support 
activities which are key to ensuring that the work planned 
within the strategic areas can be successfully performed.
FIGURE 1
EMCDDA production flow
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| Key areas
These three areas are the pillars of the EMCDDA’s information 
and analysis chain.
The first area, communicating evidence and knowledge 
exchange (KA 1), incorporates the key outputs (products and 
services) that the EMCDDA will provide to its customers 
(audiences) during 2017–19. This area also includes capacity 
building and training activities, which are an integral part of 
the knowledge transfer that the agency instigates each year 
for the benefit of its customers: stakeholders and partners, as 
well as other audiences (such as academia and professionals).
However, these outputs are just the end result visible to our 
audiences and are derived from complex monitoring and 
analysis processes, which our highly specialised staff perform 
on a daily basis. These critical processes are presented in the 
other two key areas.
Early warning and threat assessment (KA 2) includes the rapid 
monitoring component of the EMCDDA’s overall monitoring 
system. It is composed of two main parts: the EWS and the 
risk assessment of NPS; and emerging trends and threats. 
Both of these rapid-response components detect new trends 
in the drugs phenomenon, assess the threats and issue alerts 
in a timely manner. Because of the very dynamic nature of 
these emerging trends and their threats to EU citizens, routine 
monitoring is not sufficient to capture, analyse and report on 
them quickly. Special rapid-response mechanisms are 
necessary and they are all included in this key area.
Situation, responses and trend analysis (KA 3) encompasses 
the core monitoring and analysis activities of the EMCDDA, 
which provide an annual state-of-the-art overview of drug 
demand and supply, together with the responses to tackle 
them and the core trends in these domains. These activities 
are based on established tools and processes, which are 
regularly assessed to ensure that they are fit for purpose. 
These tools are complemented by the development of new 
ones that allow the monitoring of novel areas, as necessary. 
Together, these methodological activities ensure the relevance 
and efficiency of the EMCDDA’s core monitoring system. 
Moreover, it is of utmost importance that this system provide 
valid, reliable and accurate information, to inform sound 
decisions for policy and practice.
| Cross-cutting areas
Activities in these areas are horizontal in that they feed, and 
thus significantly contribute to, the key areas.
The first cross-cutting area (CCA A), information collection and 
management, encompasses all the activities related to data 
collection and management at the EMCDDA. This is the entry 
point (input) into the EMCDDA’s monitoring systems, for rapid 
monitoring (KA 2) and for core monitoring (KA 3). This area 
includes both the tools for data collection and storing (Fonte, 
the agency’s online data collection system; the Data 
warehouse; and the European Database on New Drugs, 
EDND) and the processes for managing these data (checking 
and validation). This area also includes management of the 
Reitox network of NFPs, the EMCDDA’s main data providers.
The second cross-cutting area (CCA B), quality assurance, 
comprises all the activities which ensure that the agency’s 
core business inputs, processes and outputs meet the quality 
standards in place at the EMCDDA. Activities related to the 
Scientific Committee and scientific coordination tasks are 
included in this area.
The third cross-cutting area (CCA C), cooperation with 
partners, presents the activities carried out by the EMCDDA 
together with and/or for the benefit of its key partners, at EU 
level (Member States, the institutions and other agencies) and 
at non-EU level (international organisations and third 
countries).
| Corporate areas
The corporate area Governance encompasses the activities 
related to the EMCDDA’s Management Board and to the 
overall management and leadership of the agency, including 
internal control, corporate planning and performance 
measurement.
The corporate area Administration and ICT comprises the 
tasks related to the management of resources (human, 
financial, material) and the management of the ICT services 
and infrastructure.
KPIs are defined within each area for each specific objective 
set up in the annual work programme (see Section III, 
‘EMCDDA work programme 2017’). These specific objectives 
are clearly linked to the strategic objectives presented above.
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| 1. Multiannual objectives
Area Strategic objective
KA 1: Communicating evidence 
and knowledge exchange
Serve as European central reference point for drug-related information and analysis, and by 
doing so provide policy and practice with better evidence for decision-making and action
KA 2: Early warning and threat 
assessment
Support rapid EU response to new threats by providing EU institutions and Member States 
with prompt and scientifically sound information for action on new psychoactive substances 
and emerging drug trends
KA 3: Situation, responses and 
trend analysis
Provide a holistic picture of the drugs phenomenon, through an integrated and coherent core 
monitoring system
CCA A: Information collection and 
management
Maintain the EMCDDA data collection and reporting system and ensure its validity, 
consistency, reliability and timeliness, including through the efficient management of, and 
support to, the Reitox network of NFPs
CCA B: Quality assurance Ensure that the EMCDDA’s tools, processes and outputs remain of high quality and fit for 
purpose through a process of continuous improvement and evaluation of efforts
CCA C: Cooperation with partners Enhance the EMCDDA’s strategic understanding of the drugs phenomenon, by maintaining 
and further developing our strong partnership with key players at European and global levels, 
as well as continuing our successful knowledge exchange with EU priority third countries and 
regional programmes. Ultimately, this will result in high-quality services (information and 
analysis) provided to EU and Member States stakeholders (see KA 1)
Corporate area Governance Function as a modern, efficient and forward-looking EU administration, which is committed to 
providing high-quality services to its stakeholders and to the EU’s citizens in general; in 
achieving this, the agency will be guided by good governance, steered by sound management 
and leadership and operated by a highly motivated and well-performing workforce
Corporate area Administration 
and ICT
Ensure sound allocation and management of financial and human resources and assets, and 
management of the ICT services and infrastructure, by further rationalising and automating 
relevant processes, enhancing efficiency and synergies, and developing the quality of 
services and support
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| 2. Multiannual programme
| 2.1  Key area 1: Communicating evidence and knowledge exchange
The ultimate purpose of the work performed by the EMCDDA 
is to inform sound decisions in the field of drugs at the level of 
the EU and its Member States. The results of the data 
collection, monitoring and analysis process provide the 
evidence that policymakers and professionals from across the 
EU need in order to tackle the drugs phenomenon effectively.
This evidence is communicated by the EMCDDA by different 
means, depending on the needs of its audiences. The agency 
regards its audiences as its customers and assimilates their 
needs. The most important means are the outputs ― products 
and services ― that the agency provides to its customers. 
These outputs are complemented by a range of knowledge 
exchange activities, which include the dissemination of best 
practice as well as capacity building and training initiatives.
The EMCDDA’s main customers are its key stakeholders: the 
EU institutions (the European Parliament, the Council of the 
EU, the EC) and the European External Action Service, and the 
Member States. Key partners also include relevant EU 
agencies, as well as other international partners.
Furthermore, in line with the recommendations received from 
the EC and building on the work already started in 2015 with 
the publication of a report on drug policies at city level, the 
EMCDDA will explore expanding the exchange of information 
with local authorities, keeping the respective NFPs informed, 
as appropriate; this would allow the agency to gain a further 
insight into regional approaches to established and emerging 
drug problems and to improve its understanding of best 
practices at this level.
EMCDDA stakeholder relations will be proactive and based on 
cooperation models aimed at generating mutual benefit. They 
will have their roots in the agency’s communication core 
values, namely relevance, quality, efficiency, transparency and 
consistency. This will be guided by the EMCDDA’s new 
long-term strategy, which was developed in 2016. As part of 
this strategic exercise, the agency will seek to gain a better 
understanding of the needs of its key customers, namely the 
EU institutions and the Member States, and the most effective 
means to address these needs.
In recent years, the EMCDDA has streamlined its product 
range with a view to improving timeliness and offering better 
access to higher-quality information while reducing 
production costs. This work will be continued in 2017–19, 
taking on board developments in digital publishing when 
defining products and their formats.
The agency produces timely and high-quality information, 
together with strategic and situational analyses and threat 
assessments to inform policy and practice. A comprehensive 
annual situation assessment of trends and developments in 
drug use in Europe will continue to be provided by the 
European Drug Report (EDR) package, the annual flagship 
publication of the EMCDDA. The package includes the 
multilingual Trends and Developments report, the Statistical 
Bulletin and the new Country Drug Reports. The Statistical 
Bulletin, one of the pillars of the EDR, underwent a major 
transformation to distinguish better between reported data 
and data analysed by the EMCDDA. The main four 
components of the Statistical Bulletin were identified as (a) 
a data bank containing the data reported to the EMCDDA in an 
easy-access format; (b) methods and definitions, harmonised 
where possible, and including general information related to 
the indicator and country-level information; (c) factsheets, 
providing short analyses of the data and supporting the 
content of the Trends and Developments report; and (d) data 
visualisation of the main data sets. Work will continue within 
2017–19 to develop and populate this structure. The EDR 
package will be launched every year and its content and 
format will continue to be improved to meet the changing and 
growing needs of its audiences.
The EDR will be complemented by two triennial state-of-the-
art strategic analyses of established and emerging challenges. 
These are the European Drug Markets Report (EDMR), 
produced jointly with Europol, and the new European Drug 
Responses Report (EDRR).
The first two editions of the EDMR were launched in 2013 and 
2016. The document combines the EMCDDA’s ongoing 
monitoring and strategic analysis of the drugs phenomenon 
with Europol’s operational understanding of trends and 
developments. Following its publication, the report has 
become an essential reference tool for policymakers and law 
enforcement professionals in the EU and beyond. The third 
edition of the EDMR is now planned for production in 2018 
and publication in 2019.
The first EDRR will be published in 2017. This new 
comprehensive strategic analysis aims to provide a state-of-
the-art overview of the responses to drug use across the EU 
and their effectiveness as well as implications for actions. It is 
designed as the companion to the EDMR; together with the 
annual EDR, these reports will provide the complete picture of 
the drugs phenomenon and will represent the essential 
information and analysis package for policymakers in the EU 
and beyond. The periodicity of the EDRR is planned to 
coincide with the beginning and end of the new EU action plan 
2017–20 (first edition in 2017 and second edition in 2020).
In addition to the three major outputs described above, in 
2017–19 the EMCDDA will produce and publish smaller and 
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focused strategic analyses based on emerging topics, 
geographical developments and the information needs of 
different stakeholder groups, in accordance with policy 
requests.
Furthermore, in line with the agency’s commitment to further 
develop its rapid monitoring system (see KA 2), the EMCDDA 
will produce prompt and focused products to immediately 
disseminate critical information relevant to safeguarding 
public health and safety (threat assessment reports). They will 
include (as appropriate) outputs related to the implementation 
of the applicable legal framework on NPS, in particular the 
EMCDDA–Europol Joint Reports and the EMCDDA Risk 
Assessments; trendspotting case studies/reports; and joint 
analyses (with Europol and the ECDC). Other joint products 
will be produced, as appropriate, based on the most relevant 
topics and following a synergistic approach.
The agency will also publish thematic outputs on topical 
developments and emerging issues in all areas. Examples 
include analyses on specialised drug law enforcement, 
treatment, harm and harm reduction in the EU, emergency 
rooms and polydrug use (including the misuse of medicines).
Online communication will remain the agency’s preferred 
channel for disseminating up-to-date knowledge on all facets 
of the drugs problem, with the EMCDDA’s website at its core. 
A new website launched in 2016 offers the EMCDDA’s 
audiences easier access to more interactive products, tools 
and multilingual elements. In 2017–19, the website will be 
regularly updated and further developed. Online top overviews 
and updates on emerging issues will be published for all the 
substantive areas. Furthermore, the EMCDDA will provide 
improved access to its data to interested third parties, mainly 
through improved presentation of the country data provided 
by the NFPs (see CCA A). Social media and multimedia 
channels will be used to communicate events and findings 
and engage more actively with our audiences in real time.
At EU level, the agency will continue to support sound 
policymaking through its high-quality technical input. As 
required, the EMCDDA will contribute to the implementation 
of the new EU AP that starts in 2017, and will provide support 
to the EC for the final evaluation of the EU drug strategy 
2013–20. Furthermore, the agency will fulfil the obligations 
arising from the EU Agenda on Security 2015–20. Specifically, 
the EMCDDA will contribute its information and analysis to 
tackling the three priorities set up by the document, namely 
terrorism, serious and organised cross-border crime, and 
cybercrime (see Section I, ‘General context’).
Internationally, in 2016 the UNGASS on drugs reviewed the 
world drugs situation and in 2019 the UN Member States will 
review achievements made by implementing the UN political 
declaration and plan of action on drugs adopted in 2009. 
Upon request, the EMCDDA must be prepared to offer the 
necessary technical support to the EU and its Member States 
to ensure follow-up on the conclusions of the 2016 UNGASS 
and in the preparatory work for the 2019 assessment of the 
political declaration.
The EMCDDA has extensive expertise in relations with third 
countries, especially those that are a priority for the EU, 
namely the CC and PCC and the neighbouring countries (see 
CCA C). The agency will continue to provide technical support 
to the EC in this area. Furthermore, the information collected 
from the partner countries in this cooperation will feed into 
the strategic and threat assessments produced by the 
EMCDDA.
Knowledge exchange will be an ongoing task in 2017–19. 
Among other work, it will involve the dissemination of best 
practice, in line with needs and available resources, as well as 
the design and implementation of capacity building and 
training activities.
Identifying and disseminating information on best practice 
and the effectiveness of interventions across the EU and 
beyond is a key area for the EMCDDA. The main dissemination 
channel is the BPP. Targeted at practitioners and 
professionals working in the drugs field, this essential tool is 
designed as a practical and reliable source of information on 
what works, and what does not, in the areas of drug-related 
prevention, treatment, harm reduction and social 
reintegration. In 2017–19, the new-look portal will continue to 
help users identify tried and tested interventions quickly; 
allocate resources to what is effective; evaluate and improve 
interventions, by applying practical tools, quality standards 
and guidelines; and make better decisions, gaining from 
experience and expertise across Europe. The existing modules 
will be updated regularly and new modules on emerging topics 
will be added (as appropriate).
Furthermore, the Council conclusions on the implementation 
of the EU AP on Drugs 2013–16 regarding minimum quality 
standards in drug demand reduction in the EU, which were 
issued in September 2015 (CORDROGUE 70 (SAN 279)), 
invite the agency to ‘continue gathering evidence on effective 
interventions and services in drug demand reduction and 
provide Member States with technical support and expertise 
in the implementation of these standards, in line with available 
resources and information available from Member States’.
Another effective means of disseminating knowledge is 
training activities. In 2017–19, these activities will include 
training for professionals and law enforcement officers in the 
EU Member States and third countries, through Reitox 
Academy training programmes and other training initiatives 
carried out in cooperation with partners, such as JHA 
agencies or academia.
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As the EMCDDA is an information agency, a core aspect of its 
work involves disseminating its knowledge in the field by 
face-to-face communication at institutional events, 
conferences, seminars and expert meetings as well as 
receiving visits to the agency. These events allow focused 
messages to be delivered to a specialised audience; they also 
provide excellent multiplier potential.
The EMCDDA targets the media as a prime conduit of 
information to its target audiences and is committed to 
providing journalists with a high-quality, timely and balanced 
information service about drugs. Through its professional 
approach to media relations, the agency aims to increase its 
reputation and visibility, disseminate the results of its work 
and raise awareness among its key stakeholders. In 2017–19, 
continuous effort will be made to sustain strong and positive 
media relations with drug-specialised journalists in Europe, 
who act as effective multipliers.
|  2.2 Key area 2: Early warning and threat assessment
Responding to NPS ― EU EWS and risk assessment
Strengthening the EMCDDA’s capacity to identify, assess, 
prioritise and respond to new threats as part of its core 
activity of monitoring emerging trends will continue as a top 
priority for the 2017–19 programming period. Activities 
conducted in support of the EU mechanism to monitor and 
respond to NPS represent a key component in this area. This 
mechanism, established by the Joint Action from 1997 
concerning the information exchange, risk assessment and 
the control of new synthetic drugs, and currently operating 
under the Council Decision 2005/387/JHA, provides Europe 
with an EU EWS. In 2017, it is expected that the new proposed 
legislation (Regulation of the European Parliament and the 
Council amending Regulation EC No 1920/2006) will replace 
the Council Decision of 2005. Whereas the 2005 legal 
instrument entailed tight deadlines for all the tasks covered 
therein, the schedules stipulated by the proposed new 
regulation are no more than half as long.
The EWS is implemented by the EMCDDA and its partners in 
the Member States (the Reitox network) in cooperation with 
Europol, and with the active contribution of the European 
Medicines Agency (EMA) and the EC. The strength of the EWS 
is derived in part from the fact that the events-based data 
reported through the system sit within, and benefit from, the 
broader framework of indicator-based data that the agency 
has established.
Over the past few years, the importance of this work has 
grown following a dramatic increase in the number, type and 
availability of NPS in Europe. There were 98 NPS detected for 
the first time in 2015 (the last year for which complete data 
were available at the time of drafting this document). Together 
with the NPS notified in 2014, these represent 40 % of the 
total number of NPS monitored by the EWS since 1997. 
Alongside information on the appearance of NPS on the 
market, a key function of the EWS is to identify signals of 
serious harms and respond as necessary. This requires 
monitoring each of the over 600 substances that have been 
reported so far. A growing number of reports of serious harms, 
often related to acute toxicity leading to hospitalisation and 
deaths, have been processed by the EWS in recent years. 
Since 2005, the EMCDDA has issued over 130 public health 
alerts, of which close to 75 % were in the last six years. Of 
great concern in this respect is that during the past two years 
a record number of eight risk assessments (RAs) were 
requested by the Council of the EU (more than one third of the 
total number of RAs ever conducted). However, currently there 
is no provision for the EMCDDA to commission experimental 
(in vitro or in vivo) studies, which would greatly enhance the 
risk assessments.
The number and type of NPS reported each year is critical to 
understanding the development and growth of the market. 
These numbers, however, fail to convey the enormous amount 
of work undertaken in real time by the EWS network at 
national and EU levels. Furthermore, all the signs appear to 
indicate that future information needs in this area will 
increase; consequently, the demands placed on the EMCDDA 
in this respect are likely to grow.
It is clear from recent developments that the early 
identification of and response to emerging threats will 
increasingly benefit from more proactive data collection 
systems. As a result, the EMCDDA is working to improve the 
ability of the EWS to detect signals relevant to public health 
from open source information (OSI) by developing and 
implementing OSI monitoring and analysis systems that can 
provide new data on areas such as the online drug markets, 
epidemiology and reports of serious adverse events.
The toxicovigilance component of the EWS is the mechanism 
that permits early detection of an emerging toxicological 
problem related to a new substance at both national and EU 
levels. This allows public health alerts to be issued to the EWS 
network and the substance to be placed under intensive 
monitoring. For the EMCDDA to meet the increased needs and 
demands arising from the phenomenon at both national and 
EU levels, identification, reporting and monitoring of serious 
adverse events need to be scaled up. To this end, work started 
in previous years will be enhanced during the 2017–19 period, 
when a framework for strengthening the toxicovigilance 
component of the EWS will be gradually put in place. The 
system will facilitate the identification and reporting of serious 
events as well as optimise the reported data in order to best 
analyse these signals. It will be strengthened by drawing on 
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data from the new systems being developed for monitoring 
OSI on serious adverse events (mentioned above). Ultimately, 
this will allow the Member States and the EU to respond 
earlier to emerging harms.
As part of its EWS, the agency will also gradually develop and 
implement a technical and procedural framework for risk 
communication.
Improving our understanding of the phenomenon requires our 
monitoring of new drug laws and policies, and health and 
social responses to NPS to be strengthened. Epidemiological 
surveillance of NPS and other emerging drug trends also 
needs to be developed and integrated into core monitoring 
procedures (see KA 3).
In addition, a new legislative framework on new psychoactive 
substances is expected to enter into force. The associated 
information exchange and risk assessment mechanism and 
related data collection tools and guidelines will need to be 
developed.
Reflecting the globalised nature of the NPS phenomenon, 
international cooperation with third countries will be 
strengthened (see also CCA C). Among other work, support 
will be provided to CC and PCC in establishing and developing 
an EWS at national level, as requested in Chapter 24 of the 
negotiation package for enlargement.
Furthermore, cooperation with the United Nations Office on 
Drugs and Crime (UNODC) and the WHO will be stepped up in 
2017–19 with a view to enhancing data sharing and exchange 
of experience in the field of NPS. This will contribute to 
a better understanding of the global phenomenon while 
avoiding double reporting by the Member States and will also 
ensure efficiency.
Emerging trends and threats
The dynamic nature of drug use requires an equally dynamic 
monitoring response. The detection and monitoring of new 
trends therefore remains one of our key tasks, of which the 
EWS is but one element. We will work, therefore, to strengthen 
the EMCDDA’s system for monitoring and understanding new 
and emerging trends in drug use and drug markets. 
Cooperation with key partners such as Europol, ECDC and 
EMA will be enhanced.
The EMCDDA will follow a three-tiered approach for reaching 
the goals of this new strategy: (1) strengthen existing rapid 
information assessment tools, (2) integrate new methods and 
tools into existing monitoring routines and (3) explore new 
data sources for the timely identification of emerging threats.
During the 2017–19 period, the EMCDDA will build on past 
successes and improve the existing rapid information 
assessment tools. A Rapid Information Assessment manual will 
be prepared in order to improve analysis and assessment in this 
area (including systematised trendspotter methodology). Using 
knowledge gained from previous trendspotter studies, the 
trendspotter methodology will be piloted, completed and 
published. Equally important is the close collaboration between 
the EMCDDA and ECDC on monitoring incoming information on 
the evolution and epidemiology of drug-related infectious 
diseases. Furthermore, existing expert networks will continue 
their role as alert platforms for early warnings in the field of 
drug-related harm and related responses (infections, deaths 
and other acute problems).
As emerging threats in the supply area are identified, rapid 
joint analyses and more detailed threat assessments will be 
conducted with Europol in order to enhance law enforcement 
responses.
The integration of new methods and tools into existing 
monitoring routines is of crucial importance here. One 
example is the need for rapid and efficient inclusion of new 
substances or new patterns of use in routine monitoring tools 
once their significance is established. This will be done based 
on an annual systematic review of new drugs and behaviours 
and an analysis of the implications for routine monitoring 
tools. In addition, new sensitive and timely monitoring tools 
need to be integrated into routine monitoring systems. 
Wastewater-based epidemiology, for example, has 
demonstrated its potential as an important complement to 
established monitoring tools and has moved from being an 
experimental technique to being a new method in the 
epidemiological toolkit. Another example will be the use of 
hospital emergencies data as a new sensitive monitoring tool, 
the European Drug Emergencies Network (Euro-DEN) project 
(see KA 3). A project for the integration of data from 
wastewater and hospital emergencies in local and city-level 
monitoring will be set up. In addition, the EMCDDA will 
continue its support for innovative methods such as pooled 
urine analysis and analysis of syringes to improve timely 
identification and reporting of new trends.
Equally important for this area is the exploration of new data 
sources for timely identification and reporting on emerging 
threats. One example here is the development of systematic 
tools for monitoring online drug markets and drug user forums. 
The EMCDDA will also investigate the potential of innovative 
online information collection methods such as crowdsourcing.
Through a combination of structured monitoring and analysis 
of the internet, the EMCDDA will provide a better 
understanding of the nature and scale of the online market 
and of new developments, at both consumer and supply 
levels, as well as early identification of new trends and threats.
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Identifying and responding to emerging trends in a timely 
fashion relies critically on event-based data. In recent years, 
the internet has become a vast source of such data. The 
EMCDDA will develop tools that allow OSI to be collected and 
analysed on a range of indicators from the internet on NPS 
use. This includes systems to monitor the online market, as 
well as other epidemiological indicators, and reports of serious 
adverse events.
The identification of new developments requires an 
appropriate dissemination approach. The EMCDDA will 
continue to issue alerts when these are required through the 
EU EWS network and other expert information networks and 
channels.
| 2.3  Key area 3: Situation, responses and trend analysis
Core monitoring activities provide the foundation for the 
EMCDDA’s work. Throughout the more than 20 years of drug 
monitoring in Europe, this foundation has become more solid, 
as the number of tools developed by the agency with support 
from its networks has grown and their usefulness for 
collecting reliable and comparable data from across the EU 
has increased. It is worth noting that at present the EMCDDA’s 
data on core monitoring accounts for most of the data 
available in Europe on the prevalence of drug use as well as on 
its health and social consequences.
The monitoring work is focused on two core dimensions: the 
drugs situation and the responses to tackle it. Together they 
address both the demand for and the supply of drugs. These 
two dimensions are interlinked and they feed multiarea and 
cross-indicator analyses. This integrated, holistic approach 
allows the agency to provide an accurate diagnosis of the 
drugs phenomenon at EU level, as well as — on the basis of 
the evidence drawn through scientific research and presented 
as best practice — the best possible assessment of the 
effectiveness of responses to the different forms of drug use 
and supply, and their consequences.
These dimensions are complemented by the rapid information 
collected and analysed as part of the early warning and threat 
assessment component (see KA 2). Together they form the 
basis of the comprehensive knowledge that the EMCDDA 
disseminates via state-of-the art outputs and high-quality 
services (see KA 1), as its critical contribution to informed and 
evidence-based action in drug policy and practice.
In terms of monitoring the demand side of the drugs situation, 
the agency relies on its well-established key epidemiological 
indicators (KIs), which include the prevalence and pattern of 
drug use in the general population (general population survey, 
GPS); the prevalence and patterns of high-risk drug use 
(problem drug use, PDU); the number and characteristics of 
drug users contacting drug services, in particular treatment 
services (treatment demand indicator, TDI); the number of 
drug-induced deaths and mortality among drug users (drug-
related deaths, DRD); and the infectious diseases related to 
drug use (drug-related infectious diseases, DRID). Although 
these indicators are now conceptually stable, some further 
development and methodological improvements will be 
needed in order to ensure they remain fit for purpose.
This work will be steered by the findings of the last triennial 
assessment exercise, which was carried out in 2015 in all 30 
countries reporting to the EMCDDA (the 28 EU Member 
States plus Norway and Turkey). Although the results of the 
assessment are generally positive and show that overall the 
European data set continues to progress, they do not provide 
grounds for complacency. In addition to specific problems 
related to the data available from some countries, the overall 
timeliness of reporting remains a general issue that needs 
addressing, especially given the increasingly dynamic nature 
of the contemporary drugs problem. The compatibility of data 
across countries is also a problem in some areas, particularly 
in the assessment of prevalence of PDU and in some other 
areas, such as parts of the data on DRD. Since the previous 
assessment was carried out (in 2012), worsening economic 
conditions appear to have become more evident in terms of 
their negative knock-on effect on data collection in some 
countries. Finally, there is a clear ongoing need to adjust 
guidelines and methods to reflect changing conditions.
To this end, measures to address the issues identified will be 
developed and implemented; work remains challenging, 
however, from both a resource and a technical perspective. 
The EMCDDA is committed to ensuring that the KIs remain fit 
for purpose, and at times this requires the introduction of new 
codes, methods and even data sources. With this in mind, 
a review of the medium-term and long-term strategy for the 
KIs within the overall framework of the EMCDDA’s data 
collection activities is being planned. Reflections in this area 
will be extended to include how some of the ongoing work to 
develop rapid assessment and reporting methodologies can 
complement the KI approaches and how significant blind 
spots in the current reporting system — such as the lack 
information on acute drug-related harms — can be addressed.
Details will be provided in the annual work programmes (see 
Section III, ‘EMCDDA work programme 2017’). Results will be 
monitored via annual assessments, and a new comprehensive 
triennial review is planned for 2018.
Furthermore, in 2017–19 the focus on increasing analysis and 
quality control will remain, while expanding the range of 
sources and methods. In parallel, it will be necessary to 
increase the quality and comparability of our information 
regarding the different types of responses that aim to prevent 
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use, reduce harms, or treat and help the recovery and social 
reintegration of drug users with problems. Monitoring polydrug 
use, namely the consumption of illicit drugs in combination 
with licit substances or medication, is an area that requires 
strengthening. Considerable policy concern exists in Europe 
and beyond in this area, especially with regard to the 
interaction between alcohol and drug use.
As a step towards developing this part of its mandate, the 
EMCDDA has significantly enhanced its collaboration with 
European School Survey Project on Alcohol and Other Drugs 
(ESPAD) activities. ESPAD provides useful and harmonised 
information on long-term patterns of substance use, including 
polydrug use, in many EU countries and neighbouring 
countries. The EMCDDA Management Board, the Swedish 
Government and the EC have acknowledged that the agency 
is an appropriate institutional home for the study; hence, they 
have stressed the need for ESPAD, while maintaining its 
individual entity, to be progressively anchored in the EMCDDA. 
Further to the formal request received from the Swedish 
Government in 2015, the EMCDDA, in close cooperation with 
the EC, will look for options to ensure that the other future 
ESPAD coordination tasks can be assumed fully by the 
agency. To this end, the EMCDDA provided the production 
support for the 2015 ESPAD report, expanding the website 
and supplementary materials, and has committed itself to 
supporting ESPAD through the next round of data collection in 
2019, with the subsequent report in 2020.
The monitoring of the misuse of medicines is a developmental 
area for the EMCDDA, with tasks defined in Regulation 
1920/2006 (the agency’s recast Regulation), Council Decision 
2005/387/JHA and Regulation 1235/2010. Work in this area 
will be linked and integrated with the other activities related to 
polydrug use, the work of the EU EWS and the monitoring of 
emerging trends (see KA 2). The aim of the EMCDDA will be to 
contribute to the protection of public health by reducing the 
risks to the citizens of the EU posed by the misuse of 
medicines. This will be achieved through fulfilment of the tasks 
defined in Regulation 1920/2006, Council Decision 
2005/387/JHA and Regulation 1235/2010 
(Pharmacovigilance) (see also KA 2).
In 2017–19, the EMCDDA will continue to provide technical 
support to the discussions held among the Member States 
within the framework of the HDG. The outcome of these 
discussions will inform the activities of the EMCDDA towards 
improving data collection in this area, in close cooperation 
with the Reitox partners. Using multi-indicator analysis and 
literature reviews, specific medicines will be identified as 
relevant topics that can also serve as case studies.
A complete picture of the drugs situation cannot be provided 
without appropriate monitoring of drug supply, as the demand 
and supply indicators together provide the building blocks 
necessary for describing the drugs situation and for tracking 
trends and developments.
Improving the measurement of drug markets and of the 
effectiveness of drug supply reduction responses requires 
enhanced supply indicators and data, for which timely 
investment will be required. In line with Action 16 of the EU 
action plan 2013–16, the EMCDDA will further develop and 
progressively implement KIs on drug supply and drug supply 
reduction as outlined in the 2013 Council conclusions on 
improving the monitoring of drug supply in the EU.
During 2017–19, work on the tools to improve the 
comparability and quality of data available will have reached 
maturity and the agency will now work towards the full 
implementation of the supply indicators (drug seizures, drug 
law offences, drug purity and tablet content, drug prices, 
dismantled drug production facilities, perceived availability of 
drugs in population surveys, and market size estimates); this 
will be complemented by an ongoing review and assessment 
of the relevance of these data sets/sub-indicators. 
A framework for monitoring drug supply reduction will be 
conceptualised. Moreover, the EMCDDA is planning to develop 
the areas of monitoring drug-related crime and drug 
precursors, progressively and in line with available resources. 
To this end, an important element of EU-level drug-monitoring 
efforts is the collection and analysis of data on drug precursor 
seizures and stopped shipments by the EC. Although this 
information is not yet systematically analysed alongside the 
data collected by the EMCDDA from other areas, collaboration 
is already well under way and such pooling of knowledge will 
be a priority for cooperation with the Commission in the 
period 2017–19.
Central to the work of the EMCDDA in the area of drug supply 
and drug supply reduction is the EMCDDA Reference Group 
on drug supply indicators. This group is composed of 
representatives from each Member State, who ensure the link 
to national expertise in this field. Key partners such as the EC, 
Europol and Eurojust are also represented, enhancing 
coordination at EU level. Ensuring continuity and stability 
while improving efficiency will be essential for the functioning 
of the Reference Group in 2017–19.
The health and social responses dimension of drug monitoring 
completes the picture of the phenomenon. Data related to the 
range and coverage of interventions are naturally linked to 
information about the situation and trends in drug use and 
drug-related harm. These data are integrated and analysed 
together and the results of these analyses support sound 
assessment of the effectiveness of responses. Ultimately, this 
provides the evidence-based information, which supports 
sound actions in both policy and practice.
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In this area, continuity will be ensured in implementing the 
existing tools and methodologies while regular assessments 
will be carried out to ensure that they remain efficient and 
relevant. In recent years, the completeness and internal 
consistency of the reported data and the level of comparability 
both between countries and over time have substantially 
improved; however, some important information gaps still 
exist and the level of data coverage is partial in some 
countries. Overall, a clearer picture of the drug treatment 
system is necessary to allow a better contextualisation of TDI 
data. Coverage issues exist in some countries and need 
addressing; this applies both to the number of centres 
reporting and in some cases where important types of 
treatment providers, such as general practitioners, are not 
covered. To this end, with a view to allow the national 
estimates of the total number of people in treatment to be 
improved, and ultimately the gaps in the coverage of the 
different treatment systems across the EU to be assessed, the 
analysis of the treatment facilities will continue in 2017–19. 
Particular attention will be given to primary care (general 
practitioners) and specialised treatment agencies, which, 
although representing a very important element of the 
treatment systems, often escape routine monitoring.
Knowledge on the total number in treatment and on the 
availability of interventions will be improved through the 
implementation of other instruments such as the European 
facility survey questionnaire (EFSQ) and the integration of the 
TDI Prevalence module. Based on needs, workshops with 
groups of countries will be run to support implementation. The 
results will allow collection of reliable information on the total 
treated population and, together with other tools, will help 
provide a complete national picture of the treatment provision.
Other measures aimed at supporting the treatment system-
based monitoring in the Member States will include support 
for implementing treatment prevalence and estimation 
methods; consolidation of treatment system mapping for each 
country; and developing monitoring of treatment outcome as 
a means to inform policy measures to increase effectiveness 
of interventions. Cross-indicator analysis of data on treatment 
provision (TDI) and treatment needs (PDU, DRD, emergency 
cases) will be used to better understand accessibility of 
treatment for major user groups.
In the area of drug-related infectious diseases and harm 
reduction, monitoring the prevalence of HIV and hepatitis 
B and C among PWID will be further enhanced. Data 
collection in this area will be sustained through measures 
aiming mainly to support the monitoring capacity in the 
Member States. This sustainable approach will include 
maintaining the monitoring of behavioural/risk data (injecting, 
sharing) as well as supporting the national experts in critically 
assessing the notification data reported for their country. 
Prevalence studies in PWID and drug users at risk of sexual 
transmission will also be promoted with Member States.
Furthermore, the EMCDDA will continue to contribute to 
European and international efforts in this area. Among other 
tasks, this will involve the co-organisation of the ‘Drug-related 
infectious diseases — Hepatitis 2017’ conference, jointly with 
ECDC.
Cooperation with other institutions will be pursued in the area 
of prison. This will include finalisation and dissemination of the 
data collection tools on drug use among prisoners and on drug 
services in prison with WHO, and of the first module of Prison 
guidance on communicable diseases, with ECDC.
Responding to EU needs, and to the extent that resources 
allow, the EMCDDA will continue to develop and/or refine its 
drug monitoring system. In 2017–19 the agency will review its 
approach to collecting information on effective interventions 
and services in drug demand reduction. This is to ensure that 
relevant information on EU minimum quality standards is 
included in its annual reporting exercise. This is in line with the 
Council conclusions on the implementation of the EU action 
plan on drugs 2013–16 regarding minimum quality standards in 
drug demand reduction in the European Union (see also KA 1).
One important developmental area is the responses to NPS. 
This phenomenon has rapidly increased in recent years and, 
even though a world-class EWS has been implemented to 
monitor the growing number of NPS identified and their risks 
to users (see KA 2), information on the responses to this 
dynamic phenomenon are still scarce. There is a significant 
need, therefore (confirmed by the outcome of the external 
consultation exercise which was conducted to inform this 
document), to develop this area, which has become 
increasingly important for policy and practice.
A methodological framework for monitoring health-related 
responses to NPS will be implemented, with a view to 
becoming part of the EMCDDA’s routine monitoring system.
The internet is a rapid and easy means of procuring 
information. In recent years, however, it has also become 
a convenient vehicle for the purchase and sale of drugs, which 
has motivated the EMCDDA to monitor it (see KA 2). The 
internet is also a way to seek and provide interventions on 
drug use. A methodological framework for monitoring internet-
based interventions will be implemented.
In 2017–19, the EMCDDA will continue to monitor national 
drug strategies, coordination mechanisms and policy 
evaluations. In addition, the EMCDDA will monitor the core 
aspects of drug legislation that define and penalise offences 
relating to drug use and supply, including national approaches 
to legislation on NPS. This activity will be improved by 
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combining more closely information from Reitox and other 
sources, verified by the Legal Correspondents network, with 
a view to moving towards more focused and rapidly updated 
online dissemination of current laws and trends. In line with 
recent events, there will be increased focus on collecting and 
disseminating legislation controlling cannabis and NPS, while 
the agency will remain responsive to requests received from 
stakeholders.
Where possible, the EMCDDA will also continue to design and 
promote tools for comparing legislation applicable in third 
countries or regions, with the aim of building on exchange of 
information and good practice.
Moreover, the agency will increase its cross-indicator analysis, 
which will allow a better understanding of how laws are 
implemented, combining these analyses with other data sets 
and innovative studies if required to fill information gaps.
| 2.4  Cross-cutting area A: Information collection and management
To fulfil its mandate, the EMCDDA has developed an 
integrated and detailed reporting package. The reporting 
system consists of a range of different data inputs. A major 
component of this package is the reporting of primarily 
numeric data through Standard Tables and primarily textual 
data through Structured Questionnaires. Both these types of 
data are collected through a set of standard instruments via 
Fonte.
Firstly, Fonte will be maintained and will continue to act as the 
principal data collection instrument and data repository for 
the EMCDDA during 2017–19. Secondly, new tools for 
constructing templates will be used with the aim of improving 
the interface for data input, primarily to aid the NFPs. Work 
will also progress on the cleaning of data in the database as 
well as on rationalising and harmonising variable names. This 
may involve further investment into correcting or developing 
parts of the underlying software to redress existing problems. 
Thirdly, in the longer term (up to 2019), forward planning will 
be undertaken to assess the future of Fonte and its supporting 
software. This will imply developing a map of the underlying 
data structure and processes, including a mapping of the 
various data inputs. This will support the preparation for the 
replacement of Fonte and the development of a framework for 
a new data collection, storage and extraction system.
Furthermore, during the 2013–15 period the national reports, 
the second major information input to the agency, were 
thoroughly reviewed and revised to improve their utility. 
Workbooks were piloted and introduced as a key reporting 
tool. These new tools provide information that is 
complementary to the data collected via Fonte. In addition, 
there is scope for reducing the burden of reporting by further 
coordinating the Structured Questionnaires and the 
Workbooks. During 2017–19, priority will be given to ensuring 
the stability of the Workbooks, defining and producing 
web-based outputs, and developing an online Workbooks 
submission platform to support reporting from the countries 
(subject to resources). The dialogue and feedback processes 
between the NFPs and the EMCDDA will be put in place. At 
a broader level, the coordination between the various types of 
input information ― quantitative, qualitative, rapid response, 
regular monitoring and ad hoc collection ― will be improved. 
In addition to harmonising the data reported in Fonte and the 
Workbooks, the possibility of incorporating additional and 
more rapid sources of information into the system will be 
investigated.
A key output from the data collection activities is the 
Statistical Bulletin (see also KA 1). This essential product 
provides access to the data on the drugs situation collected 
by the EMCDDA. In addition, key information is presented in 
a graphical format and short analyses are provided as 
appropriate. In 2017–19 the Statistical Bulletin will be further 
developed to improve the data visualisation and the country-
level methods. The possibility of including new data sets (e.g. 
on wastewater or hospital emergencies) will be explored. Links 
with other external data sources will be also developed.
An important component of the EMCDDA’s information 
collection work is the data collection mechanism within the 
EU EWS on NPS (see KA 2). The EDND plays a critical role in 
this mechanism, by providing round-the-clock access to the 
latest information on new substances including chemistry, 
pharmacology, toxicity, law enforcement seizures, 
epidemiology and legal status to the EWS network. Given the 
huge increase in both the amount and the types of data now 
being reported, the EDND needs significant investment. 
A core part of this work requires the development of a new 
infrastructure that will allow secure electronic submission of 
data through standard web-based structured forms and that 
will facilitate the central analysis of data and production of 
reports. Alongside being able to provide real-time information 
on a new drug (or a specific aspect of a new drug such as its 
detection in a particular ‘legal high’ product or reports of 
serious adverse events), the system should be able to provide 
an overview of the phenomenon as a whole to stakeholders. In 
addition, a new legal framework on NPS is expected to enter 
into force in 2017; the EDND will need to be aligned 
accordingly. Work will therefore continue in this three-year 
programming period to ensure that the EDND can meet the 
needs of the EU in the near future as well as the longer term.
PROGRAMMING DOCUMENT 2017–19
24 / 86 
Management of the Reitox network of national focal 
points
The European information network on drugs and drug 
addiction (Reitox) is the main data provider of the EMCDDA. 
This network of 30 NFPs allows the agency to collect and 
analyse information on drugs and drug addiction, as well as on 
policies and solutions applied, bringing together experience 
and expertise from different sectors — health, justice, law 
enforcement — and from all EU countries, Norway and Turkey.
The main priorities for the EMCDDA in its work with the Reitox 
network during 2017–19 will be to:
a) Support the NFPs in the implementation of the new 
reporting package described above. This will be done by 
providing feedback and quality reports (see CCA area B), 
through the Reitox Academy training programme 
(see KA 1), as well as by ongoing technical support.
b) Strengthen the institutional capacity of the NFPs, in order 
to enhance their performance, both as core data providers 
for the EMCDDA but also as reference points on drugs at 
national level. This will involve consolidation of the Reitox 
grant system in order to ensure quality deliverables along 
with financial transparency of the EU funds used to that 
end. Furthermore, an accreditation system for NFPs will be 
developed and implemented; work started in previous 
years will be carried out in line with the needs of the 
network, and with a view to enhancing their added value at 
both national and EU levels.
c) Enhance knowledge exchange among the Reitox 
community and between Reitox and other partners, with 
a view to further developing synergies and improving 
overall communication. This will be done mainly by means 
of the annual meetings and the online communication 
platform (forum).
Guided by the EMCDDA Strategy 2025, a new Reitox 
Development Framework, which will define the main priorities 
for the network and guide its future work, will be developed by 
the EMCDDA jointly with the NFPs. Once it has been adopted, 
the EMCDDA will support the NFPs in its implementation.
| 2.5 Cross-cutting area B: Quality assurance
Ongoing commitment to improving the scientific quality of our 
work is a prerequisite for fulfilling our role as a centre of 
excellence for the collection, analysis and dissemination of 
drug-related information. This is a process rather than an 
event. The pursuit of quality, and establishing systems and 
processes to ensure quality, are prominent features of the 
2017–19 strategy, and a range of initiatives will be undertaken.
The EMCDDA is an information-intensive organisation, which 
bases its core tasks on adding value to data through an 
information value chain. Data quality management at the 
EMCDDA follows this model. The approach encompasses the 
EMCDDA’s raw material (the data that are collected from 
different information sources) and the way it is collected, 
stored, analysed and transformed for use in different types of 
information products (paper-based publications, web pages, 
reports, articles, presentations, etc.) for the different target 
groups defined in the agency’s regulation.
The outcomes of an Internal Audit Service audit of data 
management at the EMCDDA in early 2017 will inform actions 
to ensure the continued quality of the data published by the 
EMCDDA. Measures to document and harmonise processes 
will continue in 2017–19.
The work towards implementing an overall data quality 
framework, including for non-statistical data, will continue in 
2017–19 and be integrated into the routine EMCDDA core 
data processes. The different elements of this framework will 
be developed under the relevant key and cross-cutting areas.
Two main aspects are particularly important for the data 
quality assurance CCA: developing and piloting indicators for 
the principles set out in the Internal statistical code of practice 
and ensuring that data flow core processes, including for 
non-statistical data/information, are further systematised/
standardised and documented.
Collaboration with Member States and international partners 
(including training activities covered under KA 1 and relevant 
activities under CCAs A and C) will focus, respectively, on 
consolidating the current reporting system and on complying 
with EMCDDA standards for data collection and monitoring.
The national quality report provided to NFPs as part of the 
mutual obligations set out in the Reitox grant agreement took 
into account the reorganisation of the national reporting 
package and its implementation for the first time in 2015–16. 
Quality feedback on the new national reporting package was 
piloted in 2016 and will be progressively adjusted and 
adapted, to better address the needs and potential challenges 
of national reporting.
The EMCDDA’s integrated communication approach privileges 
multidisciplinary work to ensure coordinated and efficient use 
of resources to produce pertinent and cost-effective results. 
A number of processes aimed at quality assurance in the 
definition and production of outputs support the overall 
framework set up in this area. This includes the development 
of a staff handbook for production of scientific output, the 
documentation of core output processes, including content 
and production workflows for scientific publications and 
website content. A long-term digital content roadmap will be 
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drafted, training will be offered and an overall web governance 
mechanism will be further developed.
As guardian of the EMCDDA’s scientific excellence, the 
Scientific Committee plays a key role in assuring and 
improving the quality of our work. Ongoing support will be 
provided by the agency in order to ensure that the 
Committee’s work and regular meetings are successful and 
efficient.
| 2.6 Cross-cutting area C: Cooperation with partners
This area presents the activities to be carried out by the 
EMCDDA in order to strengthen its ongoing cooperation with 
key partners, as well as to develop new partnerships with 
a view to maximising opportunities for synergies and 
enhancing the value of these synergies. This area reflects one 
of the key business principles of the EMCDDA and has the 
ultimate aim of increasing the quality (relevance, timeliness) 
and broadening the scope of services provided to our 
European and national stakeholders (see KA 1).
During its more than 20 years of existence, the EMCDDA has 
built strong, collaborative relations with an array of EU and 
global partners. As the EMCDDA’s objective is to provide 
information to the EU and its Member States, priority has been 
given to strengthening the partnership with EU institutions, 
with national policymakers in the Member States and with 
other EU agencies working in the drugs field. By further 
scaling up these partnerships, the EMCDDA’s proven technical 
and analytical capacity can deliver new opportunities for 
informed European policy and interventions.
The EMCDDA has been working increasingly closely with the 
European Parliament, the Council of the EU and the EC within 
the context of its mandate to provide technical support, 
information and analysis. In 2017–19 the agency will further 
develop its role of service provider to EU institutions, through 
contributions to EU policy documents, key drug-related events, 
other activities and initiatives, as requested and in line with 
the available resources (for details, see KA 1).
Another highlight will be to work towards enhancing 
cooperation with the EU Member States and in particular with 
key national policymaking bodies, such as national 
parliaments and governments. The ultimate aim here is to 
improve the quality and relevance of EMCDDA service 
provision (information and analysis) to the national authorities, 
in close collaboration with the NFPs.
In 2017–19 existing synergies with other EU agencies will be 
strengthened and new ones pursued, delivering greater value 
from the work of all agencies involved and providing the EC with 
an invaluable holistic analysis of the complex and interlinked 
issues in this area. In line with the EMCDDA’s vision to contribute 
to a more secure and healthier Europe, this will mainly concern 
other EU agencies working in the JHA area (particularly Europol, 
Eurojust and CEPOL) and in the health field (namely CHAFEA, 
EMA and the ECDC). The objective of the cooperation is to use 
the existing expertise and know-how of the agencies in order to 
provide operational and technical support to the Member States 
and the EU institutions, and deliver cross-agency and evidence-
based input to the policy- and decision-making processes at EU 
level. Concrete areas for cooperation are identified within each of 
the concerned substantive areas of the work programme (namely 
KAs 1, 2 and 3). In addition, the EMCDDA will explore options to 
identify areas of strategic and common interest (e.g. money 
flows and migration) for collaboration and joint outputs with 
other agencies, such as FRA and the European Agency for the 
Management of Operational Cooperation at the External Borders 
of the Member States of the European Union (Frontex).
The role of the EMCDDA within the JHA area will be 
strengthened, further to the chairing by the agency of the JHA 
network in 2017 (see details in Section III, ‘EMCDDA work 
programme 2017’).
To understand and forecast possible EU developments, it is 
necessary to put the European situation/responses/markets 
in a broader perspective. Therefore, in 2017–19 the EMCDDA 
will pay increased attention to monitoring international 
developments and trends, using a more integrated and 
focused approach.
Information and knowledge exchange with global partners 
(mainly the UN family — UNODC, WHO and the Joint United 
Nations Programme on HIV/AIDS, UNAIDS — but also other 
partners, such as the Pompidou Group) will be enhanced in 
line with, and guided by, the strategy for international 
cooperation adopted by the EMCDDA’s Management Board in 
2007. This cooperation will mainly involve providing data and 
sound analysis to the international reporting systems, and 
supporting the development of coherent information 
standards and data collection systems.
Furthermore, as a centre of excellence on drugs and a key 
partner worldwide, the EMCDDA will contribute with its 
know-how to important European and international events, 
publications and scientific initiatives in the drugs field (e.g. 
participating as keynote speaker in conferences, producing 
joint publications with partners, attending expert meetings 
and technical/advisory groups, organising external visits to 
the EMCDDA).
An essential part of the EMCDDA’s work in this area is 
cooperation with non-EU countries that have been identified 
as a priority for the EU, namely the CC and PCC and the 
countries covered by the ENP. Transferring the agency’s 
know-how to these countries, and in particular assisting them 
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in setting up their national drug observatories based on the 
successful EU model of the Reitox NFPs, is one of the tasks 
defined in the EMCDDA’s mandate. This task was highlighted 
and the work of the EMCDDA greatly valued by the EC in its 
formal Opinion on the recently adopted 2016–18 strategy and 
work programme, which is the basis for this SPD.
During the 2017–19 period, the agency will continue to 
support the EC in preparing CC and PCC for their accession to 
the EU. By making use of dedicated IPA funds, the EMCDDA 
will build on its previous work to develop the capacity of these 
countries in the field of drug monitoring. The agency will 
successfully complete the implementation of its fifth IPA 
project, which started in 2015, and it will develop a new 
project proposal (IPA 6) to run until 2019. Furthermore, 
following the finalisation in 2016 of the first project addressed 
to seven ENP beneficiary countries, the EMCDDA submitted 
to the EC a proposal to continue to provide technical 
assistance activities to ENP countries.
This cooperation will promote the EU balanced approach and 
will ultimately contribute to:
■■ sound EU drug policies with third countries, including those 
in the EU Enlargement and European Neighbourhood 
programmes; and
■■ enhanced capacity to address drug threats in EU priority 
countries.
Together with the expected outcomes presented in the other 
strategic action areas of this document, this will be a key 
dimension of the EMCDDA’s contribution to a more secure 
and healthier Europe.
Based on successful past experience, further input into EC 
regional programmes (e.g. the Cooperation Programme 
between Latin America, the Caribbean and the EU on Drugs 
Policies, COPOLAD II, and Central Asia Drug Action 
Programme, CADAP) will be provided on request and in line 
with our mandate, priorities and available resources. Data 
produced by these programmes will feed into the EMCDDA 
reporting and assessments on an ad hoc basis, depending on 
their quality and relevance.
Also subject to the availability of resources, new partnerships 
will be pursued. These will include sound information 
providers (organisations and networks) which could support 
the EMCDDA in providing a more comprehensive analysis of 
the drugs phenomenon. Participation in new networks and 
obtaining access to established complementary data sources 
in the agency’s developmental areas of work (crime, supply, 
medicines, alcohol) will be particularly beneficial. Further 
cooperation with scientific and civil society networks will also 
be sought.
In addition, as recommended by the EC in its formal Opinion 
on the 2016–18 strategy and work programme, the EMCDDA 
will explore opportunities for cooperation with the Committee 
of the Regions and with local authorities, keeping the 
respective NFPs informed, as appropriate. This will allow the 
agency to gain further insight into regional approaches to drug 
problems (see also KA 1). On the technical side, work already 
started in 2015 with the release of a well-received publication 
on drug policies at city level. In 2017, a pilot project aimed at 
integrating data from wastewater and hospital emergencies in 
local and city-level monitoring will be implemented (see KA 2). 
This technical cooperation could be taken forward at 
institutional level, by creating/facilitating partnerships with/
among cities confronted with drug problems with a view to 
enhancing exchange of knowledge and expertise and 
supporting a sustainable approach to tackling drugs.
| 2.7 Corporate area Governance
The period 2017–19 marks the first EMCDDA SPD three-year 
cycle. This will also be the first multiannual planning exercise 
to be implemented under the new EMCDDA long-term 
strategy to 2025 (‘the strategy’). Hence, it is expected to bring 
some important changes for the agency, which will carry out 
its work under a new strategic direction.
The strategy to 2025 was developed throughout 2016, the first 
year under the leadership of the new EMCDDA Director, Alexis 
Goosdeel, for adoption by the Management Board in 
December 2016.
The effective implementation of the new strategy will require 
the setting up of a new organisational structure, which will 
improve how the agency allocates the available resources to 
enable it to better meet the needs of a modern organisation 
that needs to keep pace with the developments in the drugs 
phenomenon in Europe. This new organisational structure will 
enter into force from 1 January 2017.
On the basis of the available resources, and supported by the 
results of a competency-mapping exercise, a staff 
development programme will be designed and gradually 
implemented. This programme is aimed at strengthening 
potential staff weaknesses and filling possible skill gaps 
detected. Strengthening the managerial capacity at middle-
management level will be of particular relevance and will 
constitute a priority for the new Director. Management 
training, together with appropriate internal communication 
measures and other supplementary actions intended to highly 
motivate the staff and increase their performance, will 
contribute to ensuring that the EMCDDA has the capacity to 
reach its long-term objectives, within the challenging context 
of an increasingly dynamic drugs situation and the resource 
constraints expected.
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In addition, the commitment to efficiency will be stepped up. 
The process to rationalise work processes and tools initiated 
in previous years will be continued and strengthened with 
a view to maximising value from the investments made. 
Further efficiency gains will be pursued by searching for new 
synergies for corporate services with our partners. This will 
build on the successful model already established with our 
neighbouring agency the European Maritime Safety Agency 
(EMSA), acknowledged by the EC as an example to be 
followed. Last, but not least, the EMCDDA will seek to find 
additional resources with a view to making full use of its 
potential to provide services to the EU and its Member States. 
The agency’s values and business principles will underpin this 
work.
One crucial element for scaling up corporate performance is 
the existence of a reliable planning, performance 
measurement and reporting system. This function will play the 
fundamental role of ensuring that the core elements of the 
new strategy will be implemented at operational level by fully 
aligning the programming documents to the new vision, 
mission, values and long-term goals. Documents such as the 
SPDs will serve as operational action plans for the strategy, 
allowing its concrete implementation and monitoring of 
results.
This is already partially reflected in this first SPD 2017–19; 
however, given the fact that the adoption of the new strategy 
by the EMCDDA Management Board took place in December 
2016, at the same time as the adoption of the SPD 2017–19 
and of the preliminary draft SPD 2018–20, there will be 
a transition period during which the programming documents 
will be gradually aligned with the Strategy 2025.
Further developing a sound performance management 
system will be another priority for the Governance area. The 
important steps made in previous years will be intensified in 
the period 2017–19. This will involve improvements to the 
quality of the KPIs and to the monitoring and evaluation (M&E) 
plan, which supports their measurement, and the 
development of the new management information system 
(MIS), among other actions. These actions will be 
complemented by the necessary enhancement of the 
agency’s staff project management skills, including risk 
identification and management. It is expected that these 
coordinated measures will lead to improved timeliness and 
reliability of corporate performance information and analysis, 
with the ultimate purpose of supporting sound management 
decision-making for the agency.
Finally, the EMCDDA will continue to strengthen its internal 
control measures in line with the internal standards for 
effective management and control adopted by the 
Management Board in 2010.
The recommendations arising from the audits performed at 
the EMCDDA will be closely followed up on and implemented 
in line with the action plans adopted by the Management 
Board.
| 2.8 Corporate area Administration and ICT
Administration
In 2017–19 the EMCDDA administration function will continue 
to make a significant contribution to the overall organisational 
performance of the agency. The purpose of this function is to 
ensure that the implementation of activities planned across the 
different areas of this multiannual programming document is 
supported by effective and efficient management of available 
resources. At the same time, the administration function has 
the critical role of providing those involved in the EMCDDA’s 
governance and executive management with appropriate 
information and instruments to support sound decisions. The 
better integration between operational and resource planning 
now facilitated by the SPD exercise will facilitate this.
At the heart of the EMCDDA’s activities are its human 
resources. The agency employs some 100 staff from 16 EU 
countries with wide-ranging and highly qualified professional 
backgrounds. Ensuring that appropriate processes and tools 
are in place to allow efficient management of these resources 
is therefore a key objective and will encompass the following 
priorities:
a) Ensure the smooth implementation of the relevant 
management processes (e.g. rules of employment, 
individual rights and obligations, recruitment and 
personnel planning, work-related entitlements).
b) Implement effective measures for professional 
development of the staff, with a focus on enhancing 
managerial skills at middle-management level. In particular, 
these measures will be designed to support the 
implementation of the new EMCDDA long-term strategy 
(see also corporate area Governance).
c) Streamline and optimise the human resources (HR) 
management processes. Depending on the resources 
available, this will involve maintaining and further 
developing appropriate ICT solutions.
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As far as the management of financial resources is concerned, 
the objective will be to ensure effective and timely planning, 
monitoring and execution of the EMCDDA budget, in line with 
the organisational priorities and the existing constraints, and 
pursuant to activity-based management (ABM) and activity-
based budgeting (ABB) principles. A key target will be to 
maintain the excellent level of performance achieved in the 
budget execution in previous years, and improve it where still 
possible. Efficiency of all related processes will be pursued, 
namely by making increased use of digital solutions.
Safety at work is paramount for staff wellbeing, and hence 
organisational performance. In 2017–19 the agency will 
implement further measures to ensure a safe work 
environment. Furthermore, efficient use of the EMCDDA 
infrastructure will continue to be a priority, with special 
attention paid to controlling utilities-related costs over the 
next three years. In line with the policy in place at the 
EMCDDA, this will be complemented by environmentally 
friendly measures, including promoting the use of renewable 
energy.
Information and communication technology (ICT)
ICT programmes and services are planned to support the 
agency’s core developmental objectives and to guarantee the 
smooth operation of all up-and-running services. In line with 
the overall EMCDDA strategic development framework for 
2017–19, the priorities in the ICT area will be to:
a) Implement and support core business and corporate 
projects and processes: this component will support the 
core work processes of the agency, including data 
collection and analysis, development and dissemination of 
EMCDDA outputs, and corporate processes, including 
business planning and monitoring and other corporate 
support practices and tools.
b) Provide a continuously stable environment that supports 
existing basic and advanced services: ongoing service and 
infrastructure management which ensures business 
continuity and allows the EMCDDA to operate in a stable 
and protected ICT environment.
Applying best practice in management, including project 
management, and technology will be a transversal priority that 
will cut across the entire work carried out in this area.
In setting up annual priorities, work will be guided by the 
internal ICT Steering Committee, which fulfils the role of 
a governance mechanism for this important area.
| 3.  Human and financial resources outlook for 2017–19
| 3.1 Overview of the past and current situation
Significant growth of some of the existing tasks can be 
expected in the three-year period concerned, particularly in 
the area of monitoring NPS (see KA 2). New tasks might be 
added, due to the formal request addressed by the Swedish 
Government to the EMCDDA in 2015 to fully assume the 
coordination of ESPAD (see KA 3).
Nevertheless, the EMCDDA has complied with the requested 
reduction of its staff as per its Establishment Plan, cutting one 
post from those authorised in the Establishment Plan 2016 
(80 posts authorised in 2015, 79 posts in 2016). Pursuant to 
the decision of the EU budget authority, the posts authorised 
in the EMCDDA’s Establishment Plan 2017 should be further 
reduced by two posts (i.e. from 79 to 77).
The EMCDDA has redeployed resources to adapt to the 
growing demand for additional tasks, although they have not 
been formalised in its founding regulation. This has been done 
to try to maximise the existing limited resources to provide the 
best output possible.
For further information on the allocation of human resources, 
please refer in particular to Table 1 in Annex II and to Table 1 
in Annex III.
| 3.2 Resources programming for 2017–19
3.2.1 Financial resources
The outlook for the budget/financial resources over the period 
in question reflects, as a reference, the scenario resulting from 
the EC Communication to the European Parliament and the 
Council on the programming of human and financial resources 
for decentralised agencies for 2014–2020 (COM(2013) 519 of 
10/07/2013). This is without prejudice to the possible needs 
for supplementary resources, as required to cope effectively 
with additional and new tasks (see below).
In this context, on 29 August 2016 the Commission adopted 
a proposal for a regulation which amends the founding 
regulation of the EMCDDA by introducing among its tasks the 
EWS and risk assessment on NPS. The proposal provides for 
the EMCDDA to receive the necessary financial and human 
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resources and in this context it envisages supplementary 
funding to the EMCDDA of about EUR 1 million over the 
2017–20 period.
More detailed data can be found in the tables in Annex II.
3.2.2 Human resources
New tasks
An important development has been the scaling up of the 
support provided by the EMCDDA to the ESPAD group. This is 
the world’s largest cross-national research project on 
adolescent substance use; it covers more than 40 European 
countries and provides a valuable source of longitudinal data 
on drug and alcohol trends. Following an agreement endorsed 
by the EMCDDA Management Board in December 2011, the 
agency has been hosting ESPAD coordination since January 
2013 and a joint EMCDDA–ESPAD work programme was 
developed in 2014.
In 2015, however, the Swedish Government addressed 
a formal request to the EMCDDA to fully assume the 
coordination of the project. Although the EMCDDA 
Management Board and the EC have acknowledged that the 
agency is an appropriate institutional home for the study, the 
EMCDDA does not currently have the financial means to 
ensure that. In 2016, the agency could allocate resources only 
for the necessary coordination activities, for hosting the 
website and the database and for the publication of the 2015 
ESPAD Report. The needs of ESPAD go far beyond that, 
however, particularly as far as the sustainability of the study is 
concerned; to this end, additional resources, both human and 
financial, are required in order to ensure coordination of the 
forthcoming ESPAD cycle, culminating in the 2019 data 
collection round and the production of the subsequent 2020 
ESPAD report (see KA 3). Furthermore, there is a need to 
develop further analysis of both new and historical data, which 
is not yet fully exploited.
Growth of existing tasks and additional tasks
The most dynamic and rapidly growing area of work for the 
EMCDDA is monitoring and responding to new psychoactive 
substances (see KA 2 for details and most recent figures). 
Most of this work is focused on the development, 
management and coordination of the EU EWS and risk 
assessments — legal tasks which the EMCDDA has been 
responsible for since 1997. These two major activities, along 
with EU-level control measures, represent the three pillars 
(Council Decision 2005/387/JHA) which underpin Europe’s 
response to these new substances, allowing the EU and the 
Member States to rapidly identify, understand, monitor, and 
react to the public health and social harms that they can 
cause.
The workload in this area has increased dramatically in the 
past few years due to the massive increase in the number and 
availability of new psychoactive substances appearing on the 
market. This has led to an increase in data being reported to 
the EMCDDA through the EU EWS and identified from OSI. 
This includes large increases in reports of seizures by law 
enforcement, and in acute poisonings, deaths and chronic 
harms reported by health agencies. As part of the EU EWS 
signal management system, these reports have to be collated, 
validated, assessed and prioritised in a timely manner, in order 
to produce a recommendation for action with respect to early 
warning activities, such as public health alerts and Joint 
Reports, as well as risk assessment.
It is important to note that preparation for a risk assessment of 
a new psychoactive substance has important financial and 
human resource implications, especially given the tight legal 
deadline of 12 weeks in which to complete this work. Given 
that the number of new substances requiring risk assessment 
is likely to continue to increase in the next few years, this may 
have implications in the near future, in particular where a lack 
of adequate resources would affect the EMCDDA’s capacity to 
fully meet the abovementioned operational needs and 
obligations.
The EMCDDA is also likely to face additional pressure once the 
new legislative framework on NPS that replaces Council 
Decision 2005/387/JHA comes into force, particularly given 
the expected shorter deadlines and additional work required 
for risk assessments. To this end, it is expected that the new 
proposed legislation (Regulation of the European Parliament 
and of the Council amending Regulation (EC) No 1920/2006 
as regards information exchange, early warning system and 
risk assessment procedure on new psychoactive substances 
(COM/2016/0547 final — 2016/0261 (COD)) will enter into 
force, thus replacing Council Decision 2005/387/JHA. The 
2005 legal instrument entails well-defined and tight deadlines 
for all the tasks covered therein. The legal deadlines stipulated 
by the proposed new regulation, however, are no more than 
half the length, e.g. two weeks for collecting data from the 
Reitox NFPs, five weeks for drafting the initial report and six 
weeks for preparing a requested risk assessment. In addition, 
the new regulation foresees the inclusion of new tasks, 
additional information and new working procedures in the 
operation of the EWS and RA.
Significant resources are also required to ensure the 
replacement of the ageing EDND — Europe’s information hub 
on new substances (see CCA A) — with a next-generation 
information system that can meet the growing needs of the EU.
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Last but not least, with the new Director taking up his post in 
2016, the EMCDDA Management Board approved in 
December 2015 a temporary reorganisation. The Director 
wishes the agency to further develop the quality and efficiency 
of the services and information it delivers to its main 
stakeholders and partners, in order to be recognised as the 
‘EU’s leading provider of evidence for decision-making and 
action on drugs’.
To this end, he presented for adoption to the Management 
Board in December 2016 a long-term strategy for EMCDDA 
activities and operations up until 2025 — EMCDDA Strategy 
2025. The strategy will be based on an analysis of the 
information needs of two key groups of customers to be 
treated on an equal footing by the agency — the EU 
institutions and the national policymakers — while exploring 
how to better address the needs of professionals working in 
the field.
Together with the EMCDDA Strategy 2025, he presented 
a new organisational structure for the agency that will support 
the implementation of the strategy and ensure delivery of the 
expected results. To this end, the new organisational chart has 
been prepared with the objective of maximising the use of the 
agency’s human and financial resources, while allowing 
economies of scale where possible.
Before the new EMCDDA strategy and organisational 
structure are adopted by the Management Board, and with 
a view to ensuring continuity of services while anticipating 
some potential changes, the Director Elect temporarily 
merged the former ‘Governance’ unit with the ‘Reitox and 
international cooperation’ unit under a new ‘Reitox and 
external partners’ unit with effect from 1 January 2016. The 
aim was to group under the same umbrella the activities 
related to relations between the EMCDDA and its external 
partners: the Reitox network, the EU institutions and agencies, 
international organisations and partner countries.
To support the Director in drafting and implementing the 
strategy, and in monitoring and reporting on the execution of 
the three-year and annual work programmes, including the key 
performance indicators, financial analysis and budgetary 
monitoring, the Director Elect created a small office, the 
‘Executive office’. This small team now coordinates and 
monitors the implementation of the agency’s strategy in close 
cooperation with middle management, and reports directly to 
the Director.
The final organisational structure was defined in the second 
half of 2016 taking due account of the contribution of key 
stakeholders to the drafting of the EMCDDA Strategy 2025.
Efficiency gains
As far as efficiency gains are concerned, and based on the 
EMCDDA’s past and present performance in the use of 
assigned resources, the EMCDDA is committed to constantly 
improving the effectiveness and efficiency of its activities and 
to maximising the use of its resources.
In this context the EMCDDA worked to further rationalise and 
reduce the running costs of its premises, namely by means of 
measures aimed at reducing energy consumption in order to 
offset the impact entailed by the extension of staff working 
time pursuant to the entry into force of the revised Staff 
regulations (e.g. installation of solar shading on glass areas; 
A/C switches in windows; intelligent lighting system; 
optimisation of heating and cooling cycles of EMCDDA 
premises). These measures have resulted in a reduction in 
consumption of about 10 % compared with previous years (at 
the end of 2015), which has entailed savings of about 
EUR 16 000 in utilities-related costs.
Furthermore, the optimisation of costs related to services 
(namely for security, maintenance and cleaning of shared 
premises) through joint tenders with EMSA allowed 
substantial efficiency gains and savings of about EUR 70 000 
(in 2014).
The cooperation and synergies with EMSA have been 
intensified beyond those resulting from the implementation of 
the agreement in force between the EMCDDA and EMSA to 
share the use of common areas in the compound where their 
headquarters are seated (namely canteen, underground 
parking and conference facilities). Further cooperation and 
synergies have been developed, in a common effort to 
proactively exploit the opportunities provided by the 
geographical proximity of the two agencies, while 
safeguarding the autonomous legal personality and capacity 
assigned to each agency by the EU legislator. These 
developments concern in particular the joint procurement of 
shared services to increase critical mass and get better 
conditions (e.g. for canteen and cafeteria, travel agency, 
interim staff and medical services), the joint organisation of 
training activities of common interest for the staff of both 
agencies, and the sharing of some services/bodies, such as 
the EMCDDA medical officer and the invalidity and disciplinary 
committees.
Further EMCDDA–EMSA synergies have been put in place in 
the ICT area, namely to share infrastructures and costs for 
telecommunications and internet-based services. This has 
brought efficiency gains and savings of around EUR 35 000.
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Negative priorities/decrease of existing tasks
Starting in its 2014 work programme, the EMCDDA has 
introduced a complex prioritisation exercise, which is carried 
out annually in the context of the planning exercise. This is 
based on the classification of activities in the work programme 
across three priority levels, from level 1 (L1), the highest 
priority (‘must do’), to level 3 (L3), the lowest priority (see 
Section III.1, ‘Executive summary’). The work programme also 
sets out different targets for these different levels, as follows: 
100 % for L1 results, 80 % for L2 results and 50 % for L3 
results.
Conclusion on changes in resources compared with the 
Commission Communication 2014–2020
The EMCDDA considers that it has fully met the goals set in 
the Commission Communication 2014–2020 (in line with the 
Budget circular ‘Establishing the Draft Budget for 2017’, 
BUDG A01/JB/D(2015)6341893).
The EMCDDA will do its best to deal with the growth of 
existing tasks and needs described above by maximising the 
use of available resources and by giving priority, as much as 
possible, to internal redeployment. Any possible request for 
supplementary resources will target needs that cannot be met 
through redeployment of existing resources.
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SECTION III
Work programme 2017
| 1. Executive summary
This is the first annual work programme from the EMCDDA’s 
SPD for 2017–19. This section mirrors the multiannual 
programme 2017–19; for each area of work, specific objectives 
which contribute to the achievement of the strategic 
multiannual objectives are set up; in line with the SPD template, 
expected outcomes/results, outputs and KPIs are defined to 
reflect and track progress in the attainment of these objectives.
The financial resources required for this work programme will 
be provided by the EMCDDA budget for 2017. In accordance 
with the relevant provisions the EMCDDA budget becomes 
definitive when adopted by the Management Board and after 
final adoption of the general budget of the EU, in which the 
amount of the agency’s subsidy will be fixed. For planning 
purposes, the 2017 work programme has been drafted based 
on the parameters of the 2017 EMCDDA draft budget, as 
adopted by the Management Board in December 2016. This 
budget foresees an amount of EUR 15 135 600 for the EU 
2017 subsidy to the EMCDDA.
The 2017 work programme applies the prioritisation approach 
based on three levels (L1, L2 and L3) that was first introduced 
in 2014 and was further refined for the 2016 work programme. 
The definitions for these priority levels are presented below:
■■ L1: These are ‘must do’ tasks which are time bound and 
critical for the agency to fulfil its institutional obligations. 
These tasks cannot be scaled down, removed from the 
work programme or postponed to future years without 
compromising the core performance of the agency.
■■ L2: These tasks are necessary to achieve the key 
commitments and fulfil the strategic objectives set out in 
the 2016–18 work programme. In the event of resources 
constraints generated by external or internal factors, 
however, these tasks could potentially be scaled down or 
delayed without affecting the ability of the agency to 
deliver its L1 results in the current work programme.
■■ L3: These are mostly developmental tasks, or new analyses, 
which are necessary for the agency to maintain an up-to date 
understanding of the European drugs situation in the 
medium term; however, in the event of resources constraints, 
they could potentially be scaled down or postponed without 
a significant impact on the ability of the agency to deliver its 
L1 and L2 results in the current work programme. Some L3 
tasks also refer to desirable and valuable activities such as 
joint initiatives with third parties; these appear viable within 
the current planning framework, but could be postponed or 
cancelled if resources prove to be insufficient.
The target for the EMCDDA is to achieve 100 % of the L1 
expected outputs/results, at least 80 % of the L2 expected 
outputs/results and a minimum of 50 % of the L3 expected 
outputs/results (see KPI GOV.2.1).
| 2. Activities
| 2.1  Key area 1: Communicating evidence and knowledge exchange
In 2017, the EMCDDA will publish two key comprehensive 
analyses, the annual EDR package and the first triennial 
EDRR.
The EMCDDA will publish the annual EDR package. The 2017 
EDR will include the now established Trends and 
Developments report and the repository of data for the regular 
monitoring of illicit drugs, the Statistical Bulletin. 30 Country 
Drug Reports will be produced for the first time in 2017, to 
provide individual country information which forms the 
national companion to the Trends and Developments report. 
This new country product will be primarily a graphic-rich online 
output. Developed in collaboration with the NFPs, it will 
enhance the country-level information provided by the 
EMCDDA and contribute to the development of the EMCDDA 
website.
The first EDRR will provide an overview of responses to drug 
use and drug-related problems across the EU and their 
effectiveness, as well as implications for action based on 
identified examples of best practice. The multidisciplinary 
report will have a public health and intervention focus; hence 
it will be designed to complement the EDMR. It will cover key 
drug response topics (e.g. prevention, treatment, harm 
reduction, responses in prison); it will also explore new areas 
and look ahead to the new challenges in the responses field, 
such as responses to NPS. Potential contributions from 
partners will also be considered.
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In addition to the major outputs described above, in 2017, in 
line with policy requests and needs, the EMCDDA may 
produce other smaller and focused strategic analyses based 
on emerging topics and geographical developments. Threat 
assessment reports and alerts, designed as rapid and focused 
products that provide immediate dissemination of critical 
information relevant to safeguarding public health and safety, 
will also be prepared. These will include (as appropriate) joint 
analyses (with Europol and/or the ECDC), an update on latest 
developments in infectious diseases and health risks through 
drug use, a trendspotting case study/report and outputs 
related to the implementation of the applicable legal 
framework on NPS (see KA 2).
In addition, the agency will produce thematic outputs on 
topical developments and emerging issues, and updates, in all 
areas (online or printed). Examples include overviews on 
internet-based interventions to drug use and harms; prison 
and drugs; prevention approaches; patterns in polydrug use; 
policy developments; and gender-oriented interventions 
(possibly in collaboration with partner agencies). In the field of 
drug supply reduction, in 2017 a report will be published on 
European specialist drug law enforcement, which will be the 
second analysis of its type (the first having been published in 
2013). Furthermore, there will be a new joint EMCDDA–
Europol publication on darknet and drugs.
Social and multimedia channels will be increasingly used for 
giving information on EMCDDA activities and results. As well 
as these, for the more sensitive areas of our work, restricted-
circulation alerts and analyses will be produced for certain 
customer groups.
In terms of services, the main EMCDDA institutional 
customers are its key stakeholders and partners: EU Member 
States and the institutions (European Parliament, the Council 
of the EU and the EC), as well as relevant EU agencies, and 
other international partners.
At EU level, in 2017 the agency will continue to support sound 
policymaking through its high-quality technical input. 
Concerning the EC, this will mainly involve providing support 
to DG HOME and DG SANTÉ in the field covered by the 
agency’s mandate. Highlights here include the contribution to 
the implementation of the new EU AP for 2017–20 (as 
required). The EMCDDA will continue to support the Policy 
Cycle on Organised Crime and provide expertise on the 
European Multidisciplinary Platform against Criminal Threats 
(EMPACT) drug priority areas as well as highlighting overlaps 
with other key areas such as migration and firearms.
The EMCDDA will continue to contribute to the work of the 
Council’s working groups, such as the Horizontal Working 
Party on Drugs (HDG). Furthermore, the agency will fulfil the 
obligations arising from the EU Agenda on Security 2015–20.
Collaboration with local authorities will be strengthened. As 
a first step, the agency will seek to identify major cities in the 
EU facing different drug problems/conceptual problems 
(sharing best practices), with a view to initiating dialogue and 
improving knowledge exchange. Contingent on resources, 
a meeting on city-level policies will be organised and follow-up 
ensured as appropriate; as a next step, a draft concept paper 
will be prepared. Strengthening local capacity through 
facilitating knowledge exchange will ensure a sustainable 
approach to tackling drug issues at city level in the future (see 
also KA 2).
Another area where the EMCDDA has extensive expertise is in 
relations with third countries, especially those which are 
a priority for the EU, namely the CC, PCC and neighbouring 
countries (see CCA C). To this end, the agency will continue to 
provide its technical support to the EC as far as relations with 
these countries are concerned. This will include the successful 
completion of the technical assistance project funded by the 
EC through IPA 5. Further to the successful completion of the 
first ENP project for seven beneficiary countries in 2016, the 
agency has submitted to the EC a proposal for a project to 
continue providing technical assistance activities to ENP 
countries. The EMCDDA project entitled Inter-LINK aims to 
strengthen the capacity of these countries by creating an 
analysis and response platform to tackle the dynamic links 
between drugs, security and health threats. Furthermore, the 
agency will continue to support the EC (as requested) in the 
implementation of EU drug-related regional programmes, such 
as CADAP and COPOLAD II.
Enhancing knowledge exchange will be an ongoing task in 
2017. Among other work, it will involve the further 
dissemination of best practice, in line with needs and available 
resources, and the delivery of capacity building and training 
activities to our different audiences.
Identifying best practice and effectiveness of interventions 
across the EU and beyond is a key area for the EMCDDA, the 
main dissemination channel of which is the BPP. In 2017, 
existing modules will be updated regularly and new modules 
will be added as appropriate (e.g. in the areas of drug testing 
in schools and law enforcement interventions in communities, 
schools and nightlife settings).
The EU’s approach to drug monitoring and best practice 
dissemination will continue to be effected through translating 
key EMCDDA methodological documents for non-EU 
countries. Another effective means of disseminating best 
practice is through training activities. These will include 
courses for professionals, including Reitox Academies in EU 
Member States and third countries, and training activities 
carried out in cooperation with other partners, such as 
institutional partners, e.g. academia or CEPOL. To this end, an 
important task will be the contribution to the capacity-building 
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activities contained in the 2017 EMPACT Operational Action 
Plans.
Furthermore, a European training module for prevention 
providers developed in 2016 by a partnership involving the 
European Drug Prevention Quality Standards (EDPQS) 
project, the UNODC, the Colombo Plan for Cooperative 
Economic and Social Development in Asia and the Pacific and 
the EMCDDA will be piloted in 2017 in nine countries, where 
training of trainers will be implemented.
In 2017, the EMCDDA will continue to disseminate its findings 
via a range of direct communication channels. This includes 
attendance at key events, such as conferences, technical 
meetings, professional networking events, on-demand 
external visits, etc.
Strategic objective:
Serve as European central reference point for drug-related information and analysis, and through doing so provide policy and practice with better 
evidence for decision-making and action
Specific objective 1.1:
Inform policy and practice by providing timely and high-quality data, strategic and situational analyses and threat assessments
Expected outcomes:
Better and more informed policy and practice through the provision of timely and high-quality data, strategic and situational analyses and threat 
assessments (L1)
Outputs/results:
Comprehensive annual situation assessment of trends and developments in drug use in Europe:
2017 EDR package:
■■ Trends and Developments Report published (L1)
■■ Statistical Bulletin published online (L1)
30 Country Drug Reports 2017 published (L2)
State-of-the-art strategic analyses on established and emerging challenges:
■■ First edition of the EDRR published, integrating findings from topic overviews (L1)
■■ Focused strategic analyses (short and policy-oriented, topics defined by need) (L2)
Threat assessment reports (event generated):
■■ EMCDDA–Europol Joint Report(s) on NPS (L1)
■■ Risk Assessment Report(s) on NPS (L1)
■■ Joint threat assessments and alerts (e.g. with Europol, ECDC) (L2)
■■ Trendspotting case study (L2)
Topic overviews and updates on important established or emerging issues (online or printed), e.g.:
■■ Prison and drugs (L2)
■■ Misuse of benzodiazepines among high-risk drug users (L2)
■■ Methods to estimate the costs of drug treatment (L2)
■■ National drug strategies (L2)
■■ Prevention systems: drug specific and generic (L3)
■■ Specialised drug law enforcement (L3)
■■ Patterns of polydrug use (including alcohol and misuse of medicines) (L3)
EMCDDA–Europol Annual Report on the implementation of Council Decision 2005/387/JHA (or applicable legal framework) on NPS (L1)
Other joint publications (subject to agreement):
■■ EMCDDA–Europol joint publication on darknet and drugs (L2)
■■ Gender-sensitive interventions (with United Nations Interregional Crime and Justice Research Institute and/or UNODC) (L3)
■■ Cooperation with ECDC on guidance (drug-related communicable diseases in prison) (L3)
Scientific articles in high-impact journals (L2)
Country overviews for CC, PCC, ENP partner countries and other third countries depending upon availability of information and of resources (L2)
KPIs Targets 2017
KPI 1.1.1. Timely production of major EMCDDA outputs Launched as planned:
■■ 2017 EDR package
■■ First edition EDRR
KPI 1.1.2. Efficiency in delivering key outputs Key milestones defined and used for monitoring and follow-up actions 
(as appropriate)
KPI 1.1.3. Publishing of scientific articles in peer-reviewed journals Impact score 20 or higher (impact score = the journal impact factor × 
the number of scientific articles published in 2017)
KPI 1.1.4. Use of the EMCDDA’s key online resources Targets for accessing key resources set up based on 2016 baseline 
data, and met
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Specific objective 1.2:
Provide support for relevant European and national-level policy and technical activities and meetings (knowledge exchange, institutional support, 
technical backstopping) (request and resource dependent)
Expected outcomes:
EU institutions-related activities supported by the EMCDDA within the context of its mandate and available resources, including:
■■ Implementation of the 2017–20 EU drug AP (L1)
■■ European Agenda on Security 2015–20 (L1)
■■ Support for the EU Policy Cycle on Organised Crime, in particular through appropriate tasks with the Operational Action Plans on drug priorities 
and the development of multiannual strategic plans, as well as through contribution to the SOCTA (L2)
■■ Activities with third countries (L2)
■■ Other policy initiatives within areas relevant to the EMCDDA (e.g. infectious diseases including HIV/AIDS prevention, alcohol and behavioural 
addictions, misuse of medicines etc.) (L2)
■■ Support for EU-funded research including input to the Annual dialogue on research of the HDG and the dissemination of findings (L2)
■■ Data exchange and technical cooperation with the UN System and appropriate technical backstopping to support the EU in external dialogues 
with international bodies and third countries (L2)
EU Member States supported by the EMCDDA within the context of its mandate and available resources (L1)
Outputs/results:
■■ Input to EU institutions-related activities (e.g. reports, briefings, analyses) (L1/L2 — depending on the policy area — see Outcomes above)
■■ Input to Member State-related activities (e.g. information requests and technical input to national initiatives) (L1)
■■ Presentations at and/or input to key drug-related events (L2)
KPI Targets 2017
KPI 1.2.1. Responsiveness of the EMCDDA to the needs of key 
institutional stakeholders (EU institutions and Member States)
a) List of institutional meetings established and minimum 90 % of 
events attended
b) 100 % of the requests for input/advice from key institutional 
stakeholders assessed and responded to within three weeks
c) 100 % of the requests to visit the EMCDDA received from EU 
institutions and national authorities from EU Member States fulfilled
Specific objective 1.3:
Identify, promote and monitor evidence-based responses and best practice
Expected outcomes:
Better and more informed policy and practice on effectiveness of interventions in drug demand reduction within the EU (L1)
Outputs/results:
■■ BPP kept up to date and enhanced with new modules introduced (as appropriate) (L1)
■■ Appropriate follow-up to Council conclusions on minimum quality standards in drug demand reduction in the EU endorsed in September 2015 
(L2)
KPI Target 2017
KPI 1.3.1. Increase in the coverage of evidence provided by the BPP BPP regularly updated in all the required areas and new modules 
introduced as appropriate
Specific objective 1.4:
Provide training and support capacity-building activities in the Member States and priority third countries (needs based and resource dependent)
Expected outcomes:
■■ Increased capacity for drug monitoring in the Member States and priority third countries through high-quality training provided by the EMCDDA 
(L2)
Outputs/results:
■■ Reitox Academies and workshops with EU countries and third countries (within the framework of the technical assistance projects) (L2)
■■ European training module for prevention providers piloted in 9 countries (in cooperation with EDPQS, UNODC and Colombo Plan) (L3)
■■ Input on request to activities with partners (e.g. with CEPOL, WHO, Pompidou Group) (L3)
KPI Target 2017
KPI 1.4.1. Level of satisfaction with the training provided by the 
EMCDDA via Reitox Academies (average score calculated based on all 
the training evaluation reports)
Minimum 80 % satisfaction rate
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Specific objective 1.5:
Promote better understanding of and response to the European drugs problem through engagement with policymakers and practitioners, 
scientists and civil society
Expected outcomes:
Better and more informed audience through direct communication (e.g. presentations at scientific and technical events, visits to the EMCDDA, 
social media, public enquiries) (L2)
Outputs/results:
■■ Presentations at scientific and technical events (L2)
■■ Lisbon Addictions 2017, the major European-focused scientific conference in this area, including satellite events, successfully organised with 
support from the EMCDDA (L2)
■■ European Drug Summer school organised in collaboration with the University Institute of Lisbon (L2)
■■ Increased use of social and multimedia communication channels for immediacy and wider reach (compared with 2016) (L2)
■■ Efficient public enquiry service (according to European Ombudsman guidelines) in the context of resource availability and operational priorities 
(L2)
■■ Tailored information provided to visitors to the EMCDDA (L3)
KPIs Targets 2017
KPI 1.5.1. Contribution to major scientific and practice drug events EMCDDA presentations delivered at minimum 70 % of the relevant 
events
KPI 1.5.2. Responsiveness to public requests 100 % of the public enquiries received are answered in line with the 
European Ombudsman guidelines
KPI 1.5.3. Audience reached through social and multimedia channels 
and products
a) Increased reach of multimedia products (e.g. videos) (compared with 
2016)
b) Increased social media reach (compared with 2016)
Specific objective 1.6:
Communicate successfully with media
Expected outcomes:
Well-paced news products resulting in news coverage of the EMCDDA’s activities and results (L2)
Outputs/results:
■■ Responses to media enquiries (written and oral) (L2)
■■ Articles in media citing the work of the agency for key product launches (L2)
KPI Target 2017
KPI 1.6.1. Responsiveness to media requests 100 % of media enquiries received responded to within 2 working days
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
3 904 752.55 23
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| 2.2 Key area 2: Early warning and threat assessment
Responding to NPS ― EU Early Warning System and 
risk assessment
In 2017 the EMCDDA, together with its partners in the 
Member States (the Reitox network of EWS correspondents), 
Europol and the EMA, will carry on ensuring continuous and 
robust implementation of the EWS as provided for by Council 
Decision 2005/387/JHA or by the new legislative framework 
that is expected to replace it. Key outputs of the system will 
remain rapid notifications and public health alerts on NPS, the 
exchange of forensic and toxicological analytical data, 
longer-term monitoring and analysis of health and social risks, 
monitoring and analysis of illicit and ‘legal highs’ markets, and 
a report on legal developments.
Depending on the entry into force of the new legal framework, 
the reporting and monitoring tools and instruments necessary 
for implementing the information exchange mechanism — 
including the Reporting Forms, the EWS progress and final 
reports, and the Joint Report questionnaires — will need to be 
automated, interlinked and aligned. This will involve close 
cooperation with Europol. As a result of having structured data 
available, new trends analyses will be undertaken to inform 
the community and, in particular, international organisations. 
Adaptation to the new legislative instrument will also entail 
adaptation of the risk assessment operating guidelines.
A key task will be to have an implemented and fully operational 
EMCDDA EDND, which is the main working tool of the EWS 
(see CCA A).
In 2017, a new framework to strengthen the toxicovigilance 
component of the EWS will be implemented. This allows both 
public health alerts and non-urgent information to be issued 
to the EWS network and specific substances to be placed 
under intensive monitoring. In some cases this may also lead 
to formal action through a Joint Report, and, where necessary 
a risk assessment. For the EMCDDA to meet the increased 
needs and demands arising from the phenomenon, at both 
national and EU levels, the identification, reporting and 
monitoring of serious adverse events will continue to be 
strengthened. This entails full implementation of the 
Reporting Forms on suspected adverse events.
In addition, building on the activities started in 2016, during 
2017 the EMCDDA will pilot OSI monitoring and analysis 
systems relevant to proactive early detection of new trends 
and threats of public health relevance, including NPS markets, 
serious adverse events reported through the media, drug user 
forums, social media, and the scientific and medical literature.
Where requested, a risk assessment on a new psychoactive 
substance will be carried out under the auspices of the 
EMCDDA’s Scientific Committee. This activity always carries 
resource implications and risks associated with the lack of such 
resources. This concern is becoming more relevant than ever 
with the growing amount of information and evidence gathered 
not only about the increased number of substances monitored, 
but also about the increased number of reported health harms.
A risk communication system to transmit public health-related 
information on NPS by the EMCDDA to the EU EWS Network 
and, where appropriate, to the public, will be piloted in 2017.
Further activities will be undertaken to improve the 
understanding and visibility of EU actions in the field of NPS. 
The web pages related to the EMCDDA’s action on new drugs 
will be kept updated to provide customised information to the 
growing number of diverse stakeholders and the general public.
Provisions of Article 28c of the pharmacovigilance (PhV) 
legislation will continue to be implemented in close 
cooperation with the EMA, and the information exchange and 
cooperation between the two agencies will be further 
strengthened.
The multiannual strategic plan of the COSI Policy cycle on 
organised crime 2014–17 identifies as a priority the 
production and trafficking of synthetic drugs (including NPS). 
In line with this plan, in 2017 the coordination between the 
EWS and the forensic and toxicological laboratory networks 
will be strengthened to increase sharing of information on 
NPS. A technical and procedural framework for sharing 
forensic data will be developed.
Where possible, active participation of the EMCDDA in 
EU-funded projects on NPS will ensure timely access to 
project results.
The mainstreaming of NPS work within the overall reporting 
and analysis framework of the EMCDDA will continue in 2017. 
A priority here will be to follow up on epidemiological 
information on the use of NPS and developments in the 
responses area, including legal responses (see KA 3). Some 
ongoing technical work will also be required in order to adjust 
current reporting tools to the demands of reporting on NPS 
topics.
The activities linked to the proposed new legislation that will 
replace Council Decision 2005/387/JHA are subject to the 
publication/adoption of the proposed new legislative 
framework. Furthermore, some activities are conditional on 
the EMCDDA’s legal obligations under the Council Decision, 
for example requirements to undertake Joint Reports and 
requests for risk assessments, the number of which cannot be 
foreseen.
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Emerging trends and threats
In 2017, the EMCDDA’s system for monitoring and 
understanding new and emerging trends in drug use and drug 
markets will be further developed, building on activities 
started in 2016. A Rapid Information Assessment manual will 
be drafted in order to improve analysis and assessment in this 
area (including systematised trendspotter methodology).
The trendspotter studies are one example of the EMCDDA’s 
threat assessment tools. Equally important are the EMCDDA’s 
joint risk assessments on emerging threats, including its close 
collaboration with Europol and with the ECDC on the monitoring 
of all incoming information on the evolution and epidemiology of 
drug-related infectious diseases and outbreaks.
In 2017, the EMCDDA will further develop the mechanisms for 
early warnings/threat assessments in the fields of drug use, 
harm reduction and responses. One example of these expert 
networks for rapid information collection and exchange is the 
trendspotter forum, which will be fully operational in 2017.
The EMCDDA will continue key activities for better integrating 
new methods and tools within existing monitoring routines. 
New substances and new patterns will be systematically 
reviewed with the purpose of rapidly and efficiently including 
them in routine monitoring tools once their significance is 
established. The EMCDDA will continue its successful 
collaboration with the Sewage Biomarker Analysis for 
Community Health Assessment (SCORE) group with the 
objective of strengthening the existing epidemiological toolkit 
by integrating wastewater analysis into routine monitoring tools.
Equally important is the exploration of new data sources for 
timely identification and reporting on emerging threats. One 
example here is the development of systematic tools for 
monitoring online drug markets and drug user websites. 
Through a combination of structured monitoring and analysis 
of the internet, the EMCDDA will provide a better 
understanding of the nature and scale of the online market 
and of new developments, at both consumer and supply 
levels, as well as providing early identification of new trends 
and threats.
Strategic objective:
Support a rapid EU response to new threats by providing EU institutions and Member States with prompt and scientifically sound information for 
action on NPS and emerging drug trends
Responding to NPS ― EU Early Warning System and Risk assessment
Specific objective 2.1:
Implement the provisions of the legislative framework on EWS and Risk Assessment in place in 2017
Expected outcomes:
■■ Operational EWS and information exchange mechanism:
• NPS appearing on the EU market are detected, notified in a timely manner and systematically monitored, and action is taken as necessary 
(e.g. public health alerts are issued) (L1)
• NPS trends are identified and analysed (L1)
• EWS network is operational and supported by the EMCDDA (L1)
■■ Scientific evidence on the health and social risks posed by the use of NPS provided to the Council and the Commission, on the basis of which 
further action on measures to control these substances at EU level may be taken (EU-level risk assessment procedure is implemented, as 
required) (L1)
■■ Strengthened capacity to identify emerging toxicological problems associated with the use of NPS (toxicovigilance) (L2)
■■ Signal identification and prioritisation: risk communication, including formal notifications, public health alerts, advisories and briefings (L2)
■■ Strengthened proactive approach to the early detection and response to emerging threats through the development of OSI monitoring and 
analysis capacity (L2)
■■ Improved knowledge of the NPS market (L2)
Outputs/results:
■■ EMCDDA–Europol Annual Report on the implementation of Council Decision 2005/387/JHA (or applicable legal framework) on NPS (L1)
■■ Joint Reports prepared as appropriate (L1)
■■ Risk Assessment Reports prepared as appropriate (L1)
■■ Annual meeting of the EWS network (L1)
■■ Guidelines, procedures, processes and tools progressively adapted to the new legislative framework and implemented (as required) (L1)
■■ EU EWS publication series (updates and issues in focus) (L2)
■■ Technical support to national early warning systems, forensic and toxicological networks (L2)
■■ Expert meetings in the area of NPS (if required) (L2)
■■ Framework documents (risk communication, toxicovigilance and open source monitoring) developed (L3)
■■ 5th International Conference on Novel Psychoactive Substances (L3)
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KPIs Targets 2017
KPI 2.1.1. Timely and high-quality implementation of the EWS and risk 
assessment mechanism on NPS, in line with the deadlines and quality 
criteria defined by Council Decision 2005/387/JHA (or applicable legal 
framework) and the applicable Standard Operating Procedures
a) Formal notifications on NPS and public health-related warnings 
issued to the EWS network
b) Annual implementation reports submitted to the EP, the Council and 
the EC, and published
c) Formal reports (EMCDDA–Europol Joint Reports on NPS, and Risk 
Assessment Reports) submitted to stakeholders (as appropriate)
KPI 2.1.2. Contribution of the EMCDDA to policy decisions with impact 
on the public health of EU citizens
Decisions concerning the control of NPS made by the Council of the EU 
in 2017 informed by the evidence provided by the EMCDDA
Specific objective 2.2:
Implement the provisions of Article 28c of the EU PhV legislation
Expected outcomes:
Effective information exchange with EMA and the EU PhV system (L1) including timely identification and transmission of signals of public health 
relevance in response to NPS which are medicines (L1)
Outputs/results:
Formal notifications and public health-related risk communications (L1)
KPI Target 2017
KPI 2.2.1. Timely and quality implementation of the provisions of Article 
28c of the EU PhV legislation
Timely issue of formal notifications and public health-related risk 
communications on NPS which are medicines
Specific objective 2.3:
Support the use of EU data and analysis on NPS in activities at international level (in line with reporting obligations and existing Memoranda of 
Understanding, MoUs), and support third countries in building national EWS (contingent upon resources)
Expected outcomes:
■■ Synergies at international level and reduced reporting burden on the EU Member States (L3)
■■ Enhanced capacity of third countries (mainly CC and PCC) to design and operate an EWS at national level and to meet EU standards and 
requirements when applicable (L3)
Outputs/results:
■■ Data exchange with international bodies (e.g. UNODC, WHO Geneva) to support prioritisation, scheduling discussions and information exchange 
activities (L2)
■■ Technical support for third countries (L3)
KPI Targets 2017
2.3.1. Timely and quality contribution to the WHO and UNODC expert 
meetings and fora
a) WHO Geneva: data on serious adverse events and seizures made 
available to the WHO’s Expert Committee on Drug Dependence annual 
risk assessment meeting
b) UNODC Global Synthetics Monitoring: Analyses, Reporting and 
Trends Programme:
• List of newly notified NPS transmitted twice a year
• Aggregated data on NPS seizures transmitted once a year
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Emerging trends and threats
Specific objective 2.4:
Timely identification of emerging threats through the use of rapid information assessment methods and systems
Expected outcomes:
Emerging trends and threats captured and reported in a timely matter:
■■ Rapid and in-depth assessment of new threats as required (trendspotter study) (L2)
■■ Targeted and joint risk assessments on emerging threats (as required; e.g. with ECDC, Europol) (L2)
■■ Improved rapid information collection and exchange in the field of drug use, harm and responses implemented (L3)
Outputs/results:
■■ Trendspotter forum, including online key informants, up and running (L3)
■■ Trendspotter studies prepared as required (L2)
■■ Rapid information assessment manual prepared (systematised trendspotter methodology) (L2)
■■ Joint risk assessments on emerging threats prepared as required (L2)
■■ Expert network platform for rapid information collection and exchange in place (L3)
KPI Target 2017
KPI 2.4.1. Timely identification and reporting of emerging trends and 
threats
Rapid assessment and communication of new threats (when triggered)
Specific objective 2.5:
Develop and further systematise new methods and tools for timely and sensitive identification and reporting of new threats
Expected outcomes:
■■ Findings from wastewater analysis incorporated into EMCDDA reporting in collaboration with the SCORE group (L2)
■■ New patterns of use and new analytical methods better incorporated into routine data collection methods and tools (L2)
■■ Report from the pilot project ‘European Web Survey on Drugs: patterns of use’ (L2)
■■ Development of OSI monitoring and analysis systems for monitoring online markets and drug user forums (L3)
■■ New online information collection methods for identification and monitoring of new trends and developments explored (L3)
Outputs/results:
■■ Findings from the 2016 wastewater monitoring campaign published (if available) (L2)
■■ Pilot exercise for the integration of data from wastewater and hospital emergencies in local and city-level monitoring (L3)
■■ Expert meeting(s) on new monitoring methods (need and resource dependent) (L3)
KPI Target 2017
KPI 2.5.1. Availability of new methods and tools for rapid monitoring Roadmap for improving sensitivity of reporting tools for new threats and 
developments implemented
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
1 340 468.69 8
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| 2.3  Key area 3: Situation, responses and trend analysis
Ongoing monitoring and analytical work will be carried out 
throughout the year and this will feed into the key outputs 
produced by the agency in 2017 (presented under KA 1).
The EMCDDA has a distinctive, holistic and multidisciplinary 
approach to monitoring the drugs phenomenon. This includes 
the monitoring of drug demand (use in its different patterns) 
and of the harms associated with aspects of use, supply and 
availability, and also the monitoring of the measures taken to 
decrease demand and associated harms, as well as to reduce 
drug supply.
A comprehensive triennial review of the implementation of the 
EMCDDA epidemiological indicators (KIs) in the 30 reporting 
countries was conducted in 2015. The overall level of 
implementation was relatively high, although specific 
problems with data availability exist in some countries. In 
some areas, problems still exist with respect to comparability, 
which can limit the data’s utility and result in considerable 
uncertainty, particularly when constructing numeric estimates 
at the European level. The timeliness of data remains a general 
problem, and one that is becoming more significant within the 
context of an increasingly dynamic situation.
These issues were discussed in 2016 with the networks of 
nominated national experts and focal points. Continuous 
support will be provided for all KIs in order to extend the data 
collection template to emerging areas (for GPS); increase the 
number of countries submitting individual estimates and 
improve comparability across countries, including the 
estimation of cannabis PDU; better integrate TDI data within 
an overall concept of treatment systems and capacity within 
Member States in order to address coverage issues still 
existing in some countries; support, where possible, the 
efforts of the national experts and focal points to address 
systematic under-reporting in some countries (DRD); and 
improve the availability and quality of estimates on prevalence 
of, incidence of and burden of disease resulting from HIV, 
hepatitis B virus and hepatitis C virus infection among 
problem drug users at national level (DRID).
As before, the knowledge base provided by the KIs will be 
supported by the EMCDDA’s Reitox NFPs and other networks 
of experts that contribute their national expertise to the 
European drug information and analysis system of the agency. 
Interaction with these networks is ongoing, through regular 
collaboration, including annual expert meetings organised by 
the agency at its premises in Lisbon. Defined quality criteria 
will be observed (see CCA B) to ensure that maximum value is 
obtained from these meetings. Rapid communication outputs 
will be produced to disseminate results. Furthermore, based 
on the successful approach initiated in recent years, the 
agency will continue to explore ways to organise the annual 
expert meetings in conjunction with other major drug events 
(e.g. DRID expert meeting close to the ‘Hepatitis 2017’ 
conference, see below; to be confirmed). This will facilitate 
exchange of expertise while increasing efficiency.
In 2017, the EMCDDA will have the opportunity to join efforts 
with traditional EU and international partners to organise two 
major events for the area:
■■ ‘Drug-related infectious diseases — Hepatitis 2017’ joint 
event with ECDC. The event will bring together for the first 
time international experts from the EMCDDA DRID expert 
network and the ECDC hepatitis network.
■■ ‘EMCDDA/WHO Health in Prisons Programme (HIPP)’ 
conference. The conference will be held at the EMCDDA 
and will focus on drug addiction, with EMCDDA 
contributions addressing the data collection package and 
the joint ECDC–EMCDDA prison guidance.
Smaller technical meetings on established or developmental 
topics will take place (based on needs and resources).
Following the publication of the ESPAD study report in 2016, 
the EMCDDA will work closely with ESPAD principal 
investigators to exploit the current survey results and to 
coordinate the activities necessary in 2017 for the next round 
of ESPAD planned for 2019. The EMCDDA will continue to 
support the development of ESPAD’s web presence. Activities 
envisaged in 2017 will include an initial review of the survey 
instruments and the establishment of a protocol for the new 
round of the study.
In the area of responses, further steps will be made towards 
improving our understanding of the coverage of treatment 
services across the EU. As part of the treatment data 
collection strategy, this will include an analysis of primary care 
(general practitioner) facilities and specialised treatment 
agencies, and implementation of the EFSQ, whose findings 
will be presented in a report.
In the prison area, the results of the pilot survey completed in 
2016 will be disseminated and the use of the tool will be 
promoted among further countries. The second part of the 
data collection package, namely an adaptation of the EFSQ for 
prison health services, will be developed. Work on the joint 
prison guidance with ECDC will continue in 2017, including at 
a meeting of the expert panel to be hosted by the EMCDDA.
Depending on the most effective way of reaching our 
audiences, all these findings will be either integrated in the 
first EDRR (see KA 1) or presented as stand-alone outputs 
(online or printed).
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The internet provides a convenient means for obtaining 
services. A mapping of e-health and m-health (mobile health) 
applications for social and health responses to drugs will be 
carried out, and a methodological framework for monitoring 
internet-based interventions will be developed in 2017, 
allowing collection of more systematic information on this 
rapidly developing area.
Another rapidly expanding area which requires the 
development of a systematic monitoring approach is NPS. 
Effort was invested in 2016 to improve monitoring; in 2017, 
a review and fine-tuning of the data collected will be carried 
out.
In the area of drug supply, full implementation of the reporting 
instruments on drug seizures and drug law offences is 
planned. A review of the data on drug purity, potency and 
tablet content as well as on drug prices, which were collected 
through the pilot exercises implemented in 2016, will be 
carried out, which will allow these instruments to be fine-
tuned for full implementation in 2017.
The developmental work on the reporting instruments for drug 
availability will be finalised, and the draft instrument will be 
subject to consultation with and endorsement by the 
Reference Group and subsequent adoption by the Reitox focal 
points. The data collection on drug production facilities 
(synthetic drug production sites, cannabis cultivation and 
cocaine secondary extraction labs) will be reviewed and any 
process improvements will be implemented in consultation 
with Europol. The results of the conceptualisation exercise in 
the area of drug-related crime will also lead to actions in this 
area in 2017.
To support the EC and Europol, the EMCDDA will further 
enhance the joint analysis of existing data on drug precursors 
and will continue to include data on precursor seizures and 
stopped shipments in the agency’s main publications such as 
the EDR. The EMCDDA will propose the establishment of 
a trilateral annual technical meeting to discuss the collection 
and exchange of data and to improve analysis and monitoring 
practices. Depending on the results of the 2016 pilot project 
on market size estimation, a proposal for a targeted web-
based survey might be presented to the NFPs with the 
objective of broadening participation in the methodology 
within the following five years.
The recommendations arising from the review of the EMCDDA 
European Reference Group on drug supply indicators, 
completed in 2016, will be implemented and the annual 
meeting of the group convened.
Ongoing monitoring of drug laws will be carried out in 2017 
with a focus on emerging issues (e.g. cannabis, NPS, etc.).
The European Legal Database on Drugs (ELDD) will be 
maintained and the annual meeting of the Legal 
Correspondents will be organised, as a way of further 
improving the sharing of knowledge and expertise among 
Member States.
In the area of monitoring the misuse of medicines in the 
context of polydrug use, progress will be achieved in 
cooperation with our Reitox partners, in line with the outcome 
of the discussions held among the Member States within the 
framework of the HDG and where necessary in consultation 
with EMA. Any follow-up work suggested in the review of 
benzodiazepines prepared in 2016 will be initiated. 
Furthermore, work will focus on a study examining the 
emerging concerns related to misuse of the prescribed opioid 
tramadol within the context of polydrug use. This will result in 
a technical report (for publication in 2018) and an expert 
meeting organised to discuss the findings of the study and 
methodological aspects related to monitoring and analysis of 
misuse of medicines. The collaboration between the EMCDDA 
and EMA may result in a joint publication on tramadol 
(depending on the agreement between the two agencies), and 
will inform future EMCDDA work in the area of misuse of 
medicines.
Monitoring emergency rooms data will also be developed. This 
will mainly involve the consolidation and enlargement of the 
sentinel network Euro-DEN; making best use of the data 
provided by the Workbooks; and carrying out cross-indicator 
analyses with DRD.
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Strategic objective:
Provide a holistic picture of the drugs phenomenon, through an integrated and coherent core monitoring system
Specific objective 3.1:
Perform state-of-the-art monitoring necessary for European-level assessment of the drugs situation (core trends and developments in use, 
consequences and responses)
Expected outcomes:
■■ Data interrogation, taking into account relevant research and source material, to conduct situational and strategic analysis necessary for 
European-level assessment of the drugs situation (core trends and developments in use, consequences and responses) (L1)
■■ Improved understanding of country-level data (contextual factors, methodological issues, configuration of responses) (L2)
■■ Implementation of monitoring tools optimised (L2)
■■ Maximised value obtained from expert meetings, through greater focus on surveillance, cross-indicator analysis and rationalisation of 
methodological and tool development activities (L2)
■■ Knowledge exchange and improved data quality through the maintenance of expert networks (L2)
■■ Sustainability of the ESPAD study ensured; better understanding of and availability of data on long-term drug trends among European school 
students (L2)
■■ Improvements to quality, granularity and comparability of drug supply data (L2)
■■ Increasingly relevant description of drug laws and national and international policies, including information on evaluations and impact (L2)
■■ Data from third countries better integrated into the EMCDDA’s analyses (L3)
Outputs/results:
■■ Quality monitoring and analytical work to inform key outputs (see KA 1) (L1)
■■ Results of Workbooks data collection and projects completed in 2016 disseminated (L2)
■■ Multi-indicator analysis to allow cross-checking of findings and more sensitive detection of trends (L2)
■■ Consolidated European Model Questionnaire (EMQ), including new modules, where required (L2)
■■ Incremental progress in implementing the reporting instruments on drug supply and supply reduction (L2):
• Drug seizures and drug law offences fully implemented
• Drug purity, potency and tablet content, and drug prices reporting instruments reviewed and fine-tuned
• Drug production facilities dismantled (contingent upon the data provided by Europol) — synthetic drugs sites, cocaine secondary extraction 
labs and cannabis cultivation sites: analysis of the data collected by Europol through European Reporting on Illicit Synthetic Substances 
Production Sites and European Reporting Instrument for Cocaine Extraction Sites (contingent upon the data provided by Europol), pilot 
implementation of cannabis monitoring tool
■■ Results of the EMCDDA Reference Group on drug supply review implemented (L2)
■■ ESPAD website maintained, analysis of existing data undertaken, coordination activities (including meeting), list of preparatory activities 
necessary to support new data collection round developed and agreed (L2)
■■ Report on mapping of existing studies on Nightlife Settings. (L3)Expert meetings on established and developmental topics (resource dependent) 
(L3)
■■ Joint events and/or outputs with EU and international partners (e.g. ECDC, WHO) (resource dependent) (L3)
■■ EFSQ module for prison available for the Member States and IPA partner countries (L3)
■■ Analysis of coverage provided by national drug treatment systems, with a focus on primary care and specialised treatment agencies (L3)
■■ TDI Prevalence module in treatment coverage further developed and integrated (L3)
KPIs Targets 2017
KPI 3.1.1. Relevance and consistency of reporting tools and instruments Efficient follow-up of the review of the key epidemiological indicators 
(KIs) with the EMCDDA reporting countries (28 Member States, Norway 
and Turkey)
KPI 3.1.2. Level of progress in the implementation of supply indicators Indicators on drug seizures and drug law offences fully implemented; 
indicators on drug purity, potency and tablet content, and drug prices 
ready for full implementation from 2018
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Specific objective 3.2:
Develop new tools and processes for drug demand and supply: situation and responses/interventions to ensure that monitoring capacity remains 
fit for purpose (developmental areas)
Expected outcomes:
■■ Improved reporting in the areas of:
• Health-related responses to NPS (L2)
• Internet market (L2)
• Crime and supply reduction (L3)
• Polydrug use (including misuse of medicines, alcohol) (L3)
Outputs/results:
■■ Methodological framework for monitoring internet-based interventions implemented (L2)
■■ Methodological framework for monitoring responses to NPS implemented (L2)
■■ Expert meetings on developmental topics (resource dependent) (L3)
■■ Conceptual framework for monitoring implementation of minimum quality standards (L3)
■■ Concepts on drug crime and supply reduction areas explored for potential routine monitoring (conditional upon resources) (L3)
■■ Proposal for a targeted web-based survey presented to the NFPs (contingent on outcome of 2016 pilot exercise) (L3)
■■ Framework for monitoring misuse of medicines in the context of polydrug use implemented (contingent on the outcome of the discussions 
within the HDG) (L3)
KPI Target 2017
KPI 3.2.1. Availability of new methods and tools to monitor drug areas 
where information is currently insufficient (e.g. health-related responses 
to NPS, internet)
New frameworks for drug monitoring implemented as required in the 
areas of responses to NPS, internet-based interventions and misuse of 
medicines (in the context of polydrug use)
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
2 626 675.89 16.9
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| 2.4  Cross-cutting area A: Information collection and management
The annual information collection exercise
A major component of the EMCDDA’s reporting system is the 
national reporting package developed and implemented in close 
collaboration with the NFPs. This reporting package incorporates 
data delivered through a set of standard instruments (the 
Standard Tables and the Structured Questionnaires) reported via 
Fonte, the main online data collection system of the agency, and 
a structured commentary on the drugs situation (the 
Workbooks), reported via the Reitox Extranet.
In 2017, Fonte will continue to act as the principal data 
collection instrument and data repository for the EMCDDA, 
but efforts will be made to improve data collection and 
management. A map of the underlying structure and 
processes will start to be developed, with a view to preparing 
the ground for the later replacement of Fonte and a new data 
collection, storage and extraction system.
The reporting package was thoroughly revised to strengthen 
its overall coherence and efficiency; the Workbooks were 
introduced and piloted as a key reporting tool in 2015 and they 
were reviewed in 2016. In 2017, a review of the Workbook 
questions will be initiated, and the Workbooks and the 
structured questionnaires coordinated. This may extend into 
2018, and an assessment of the Workbook review process will 
be implemented. The work on establishing the nature and form 
of a web-based output which commenced in 2016 will be 
continued.
Another key task in this area will be to further develop and 
maintain a fully operational EMCDDA EDND, which is the main 
working tool of the EU EWS (see KA 2). The technological 
redevelopment of the EDND is being undertaken in different 
phases in order to include advanced technical functionalities 
and to allow secure electronic submission of information by 
relevant expert users at national level. By the end of 2017, it is 
expected that both the event-based data which are routinely 
collected by the EMCDDA from the EWS network, the bi-annual 
progress reports and the final reports, and the Joint Report 
questionnaires will be submitted to the EMCDDA and validated 
by the agency through the secure electronic system. This 
system will allow implementation of an audit trail for the data 
along the entire submission chain; it will therefore minimise the 
risks of errors and will lead to significant improvements in the 
quality of data. At the same time, automatic data manipulation 
will support rationalisation of work procedures and processes, 
with an obvious decrease of the burden both at the level of the 
national data providers and at the level of the EMCDDA.
Ultimately, the more efficient and quality-assured data 
collection and management processes will result in better 
identification and prioritisation of the signals with a public 
health impact, more rapid and reliable information transmitted 
to decision-makers, and ultimately better health for EU citizens.
Management of the Reitox network of national focal 
points
The activities in 2017 will follow the main priorities for the 
EMCDDA in its work with the Reitox network which were set 
up in the three-year work programme, namely to (a) support 
the NFPs in the implementation of the new reporting package; 
(b) strengthen the institutional capacity of the NFPs, to 
enhance their performance; and (c) enhance knowledge 
exchange among the Reitox community and between Reitox 
and other partners, with a view to further developing synergies 
and improving overall communication. An important outcome 
in 2017 will be the adoption of a new Reitox Development 
Framework, defining the main priorities for the network and 
guiding its future work. This will be developed by the EMCDDA 
jointly with the NFPs in line with the EMCDDA Strategy 2025.
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Strategic objective:
Maintain the EMCDDA data collection and reporting system and ensure its validity, consistency, reliability and timeliness, including through the 
efficient management of, and support to, the Reitox network of NFPs
The annual information collection exercise
Specific objective A.1:
Maintain and develop the computing tools to support the collection of data and information
Expected outcomes:
Systems for data collection operational (L1)
Outputs/results:
Fonte reporting system and Data warehouse maintained and further developed, including work on cleaning of the data and new tools for 
constructing templates (L1)
KPI Targets 2017
KPI A.1.1. Efficiency of the data flow processes a) Collection of data provided by the NFPs into Fonte completed using 
current templates
b) Transfer of data from Fonte to the Data warehouse completed
c) Extraction of data to populate the Statistical Bulletin on the EMCDDA 
web page complete
Specific objective A.2:
Maintain and develop the collection of data and information
Expected outcomes:
■■ National reporting package consolidated and operational (L1)
■■ Effective management of data received from the NFPs and support for its incorporation into the outputs of the EMCDDA (L1)
Outputs/results:
■■ Processing of the data into outputs (tables, graphs and infographics) to support EMCDDA publications and populate the main repository of 
monitoring data, the Statistical Bulletin (L1)
■■ Workbook data collection evaluated and adapted for next submission (L1)
■■ Web-based output from the Workbook input, including the Country Drug Reports (L2)
■■ Structured Questionnaires and Standard Tables reviewed and updated in line with the information demands of the agency (L2)
■■ Progressive review of Workbook questions initiated(L2)
■■ Assessment of the Workbook review process (L2)
■■ Analysis of the data collection needs of the agency in the medium term (L2)
KPI Targets 2017
KPI A.2.1. Effective revision of the data collection instruments a) Consultations between EMCDDA and NFPs on the revision of the 
data collection instruments concluded
b) Agreed changes implemented within the Fonte templates by April 
2017, and within the Workbook templates by December 2017
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Specific objective A.3:
Further develop and operationalise the EDND as the core monitoring tool of the EWS
Expected outcomes:
■■ Strengthened capacity to identify and prioritise signals of harm of public health relevance to EU citizens (L1)
■■ Improved quality, integrity and management of the data (L1)
■■ Functionality aligned to the requirements of the new legislative framework on NPS (L1)
Outputs/results:
■■ EDND maintained and regularly updated (L1)
■■ EWS progress and final reports (L2)
KPI Targets 2017
KPI A.3.1. Functionality level of the EDND in line with the phased 
implementation of the project
a) Secure electronic submission and validation of the data through the 
system piloted, including:
• Event-based data
• Biannual and annual national reports
• Joint Report questionnaires
b) Access to core data through the information system of the database 
given to relevant stakeholders (in line with the applicable policy for 
access levels)
Management of the Reitox network of national focal points
Specific objective A.4:
Support the NFPs in the implementation of the new reporting package and enhance knowledge exchange among the Reitox community and 
between Reitox and other partners
Expected outcomes:
■■ Improved reporting capacity of the Reitox NFPs (L1)
■■ Reitox NFPs benefiting from knowledge exchange activities coordinated by the EMCDDA (L2)
Outputs/results:
■■ Data provided to the EMCDDA’s annual reporting exercise (L1)
■■ Biannual meetings of the HFPs (L1)
■■ Reitox Network Development Framework (L2)
■■ NFPs provided with technical assistance (e.g. Reitox Academies, see KA 1), quality feedback (see CCA B) and institutional support (where 
required) (L2)
■■ Technical meetings (as appropriate) (L2)
KPIs Targets 2017
KPI A.4.1. Implementation of the national reporting packages in the 
countries
a) Reminders to ensure the deliveries of the national reporting packages 
sent to the NFPs by the end of November 2017
b) Annotated summary of the NFPs deliveries prepared for internal use
KPI A.4.2. Good quality organisation of the HFP meetings Biannual meetings of the HFPs organised in line with the established 
quality standards (i.e. all meeting documents made available to the 
NFPs 2 weeks prior to the meetings, and conclusions disseminated 
within 4 weeks after the closing of the meetings)
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Specific objective A.5:
Strengthen the operational and budgetary capacity of the NFPs to implement the grant agreements
Expected outcomes:
■■ High level of performance in the implementation of the grant agreements (L2)
■■ On-site grant agreement audits performed as needed and in line with resources (L2)
■■ EMCDDA support to NFPs’ sustainability, via meetings with national stakeholders and other initiatives, on demand and as appropriate (L2)
Outputs/results:
■■ 2017 grant deliverables (financial and narrative reports) provided in line with the applicable rules and regulations (L2)
■■ Grant agreement audit reports (2 or 3 reports, depending on budget availability) prepared further to the audit missions carried out in selected 
countries, and made available to the European Court of Auditors (upon request) (L2)
■■ Conclusions of support meetings with national stakeholders available (L2)
■■ Reitox accreditation tools and processes developed (L3)
KPIs Targets 2017
KPI A.5.1. Execution rate (commitments) of the grant agreements 
budget
95 % of the available funding is committed for NFP grants
KPI A.5.2. Timeliness of processing of the payment requests 85 % of the balance payment requests, submitted complete and on 
time, are successfully checked and paid by 30 June of year N+1
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
5 145 469.30 10
PROGRAMMING DOCUMENT 2017–19
49 / 86 
| 2.5 Cross-cutting area B: Quality assurance
In 2017, the EMCDDA will continue to follow up on ways to 
improve the high quality of our analysis and outputs across all 
key areas of work. Efforts will focus on implementing the 
feedback from the quality aspects of the reporting system 
(see also CCA A)
Work on the overall data quality framework and on the 
indicators for the Internal statistics code of practice will 
continue. The documentation around data/information flows 
and processes will be improved and key meetings will 
continue to be organised in line with the EMCDDA quality 
standards to help maximise the analytical value of expert 
networks. Ongoing cooperation with non-EU countries will 
continue to focus on working towards fuller compliance with 
EMCDDA standards for data collection and monitoring.
In 2017, measures for quality assurance in content production 
will be further developed. This concerns in particular the 
documentation of core processes and generation of online 
content using the new content management tool, Drupal, and 
its integrated approval processes. The roadmap with main 
milestones for the implementation of this new content 
management tool will continue to be developed. The core 
content coordination and scientific writing tasks will continue, 
providing supported for the drafting and development of key 
EMCDDA publications. A new handbook for EMCDDA staff 
focusing on drafting scientific publications will be piloted and 
revised in 2017. This will include guidance on publication 
planning, quality assurance processes and peer review.
The EMCDDA Scientific Committee will start a new mandate 
(2017–19). The members of the Scientific Committee will 
adopt a formal opinion on the EMCDDA SPD 2018–20 and will 
continue to provide input on the agency’s main projects and 
scientific publications, in line with the guiding principles for 
the review of selected EMCDDA publications. They will also 
continue to engage actively in the EMCDDA Scientific Award 
and contribute to the HDG’s annual dialogue on research.
Strategic objective:
Ensure that the EMCDDA’s tools, processes and outputs remain of high quality and fit for purpose through a process of continuous improvement 
and evaluation of efforts
Specific objective B.1:
Implement quality assurance mechanisms for EMCDDA core processes and outputs
Expected outcomes:
Core activities are coordinated, resources are efficiently used, objectives are achieved and quality control of outputs is maintained (L1)
Outputs/results:
■■ Internal scientific coordination meeting organised and communication tools maintained (L2)
■■ Improved coordination and planning of outputs (Products Database updated) (L2)
KPI Target 2017
KPI B.1.1. Implementation of quality mechanisms to support the 
scientific activities
Quality standards and guidelines in place for key scientific processes 
and outputs
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Specific objective B.2:
Coordinate, prepare and organise the meetings of the Scientific Committee, follow up on the conclusions and recommendations and provide 
support to its work
Expected outcomes:
Further enhancement of the scientific quality of the EMCDDA’s work through the provision of support and guidance by the Scientific Committee 
(L1)
Outputs/results:
■■ Provision of scientific input/advice (in the form of peer review, formal opinions, input to protocols, projects, products, etc.) by the Scientific 
Committee members (L1)
■■ Agenda and minutes of Scientific Committee available on the public website; feedback on recommendations and follow-up provided at relevant 
meetings (L2)
KPIs Targets 2017
KPI B.2.1. Responsiveness of the Scientific Committee to the Director’s 
and Management Board’s requests
Minimum 70 % of the requests met, out of the total number of requests 
received by the Scientific Committee members from the Director and 
the Management Board
KPI B.2.2. Effectiveness of the Director in providing support to the 
Scientific Committee in performing its tasks
Meetings of the Scientific Committee organised in line with the 
established quality standards (i.e. 100 % of the supporting documents 
uploaded on the Scientific Committee extranet at least 2 weeks before 
the meetings (except for documents related to events occurring within 
this timeframe), and draft minutes of the meetings sent to the Chair 
within maximum 2 weeks of the close of the meetings)
Specific objective B.3:
Implement and review data/information quality assurance mechanisms for input, processing and output
Expected outcomes:
Data/information quality assurance monitoring and review mechanisms are in place for all steps of the EMCDDA data/information lifecycle and 
underpinned by a data/information quality assurance framework (L2)
Outputs/results:
■■ Guiding principles for the review of selected EMCDDA publications maintained and updated when necessary (L1)
■■ Information/data quality management framework available (L2)
■■ Quality standards for Workbooks available (L2)
■■ Quality feedback on Workbooks provided to Reitox NFPs (L2)
■■ Documentation of data processing and analysis methods and of data flows available (L2)
■■ Reports from key meetings contributing to enhancing the quality of data/information analysis made available to the relevant audience(s) (L2)
■■ Up-to-date documentation for content production and sign-off (including online) available (L2)
■■ Web publishing quality standards in place and documented (L2)
■■ Indicators for data quality management framework available (L2)
KPIs Targets 2017
KPI B.3.1. Provision of quality assurance feedback for the reporting 
system
Quality feedback reports provided to Reitox NFPs on their contributions 
under the reporting system
KPI B.3.2. Level of progress in the implementation of the quality 
assurance framework
Measures to address recommendations from the 2017 audit’s follow-up 
action plan implemented (as applicable)
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
1 366 859.44 7.9
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| 2.6 Cross-cutting area C: Cooperation with partners
In line with its strategic priorities, in 2017 the EMCDDA will 
enhance information and knowledge exchange with its 
European and global partners. Priority will be given to the 
activities concerning the provision of technical support to EU 
institutions and the EU Member States (for details, see KA 1). 
Actions in this area will be informed by the outcome of the 
strategic exercise carried out in 2016 with the objective of 
better identifying and efficiently addressing the needs of 
these two key groups of customers.
Other EU agencies, in particular those from the JHA cluster, as 
well as the ECDC and EMA, are key partners. In 2017, the 
successful collaboration developed in previous years will be 
continued and further developed. This will result in joint 
outputs, knowledge exchange through technical meetings and 
training initiatives, and input to other joint activities. Initiatives 
with the JHA cluster partners (especially with Europol, 
Eurojust and CEPOL) will be carried out, with the main 
objective being to support the implementation of the EU 
Agenda on Security 2015–20 and the priorities set up in the 
2014–17 policy cycle of the COSI. Europol and EMA are also 
key partners in the implementation of the EWS on NPS (see 
KA 2).
From 1 January to 31 December 2017, the EMCDDA will chair 
the JHA network, which is composed of nine EU agencies (1). 
The network was established in 2006 to foster bilateral and 
multilateral cooperation between these JHA agencies, and to 
explore and develop synergies in areas of common interest 
such as strategic and operational work, training and external 
relations. Chairing the network will involve, among other tasks, 
organising the JHA agencies’ directors’ meeting, routine 
network meetings and other sub meetings and seminars 
according to the plans and priorities established by the 
network; preparing joint statements or common papers, when 
necessary; and presenting the work of the network to COSI 
and the Committee on Civil Liberties, Justice and Home 
Affairs (LIBE).
(1) The European Union Agency for Law Enforcement Training (CEPOL), the 
European Asylum Support Office (EASO), the European Institute for Gender 
Equality (EIGE), Eurojust, Europol, FRA, the European Border and Coast Guard 
Agency – replacing Frontex as from 6 October 2016 — the European Agency for 
the Operational Management of Large-Scale IT Systems in the Area of Freedom, 
Security and Justice (eu-LISA) and the EMCDDA.
Other joint initiatives (subject to agreement and resources) 
will be the co-organisation of an international event on 
hepatitis with ECDC (see KA 3) and developing joint guidance 
on prison with ECDC.
The EMCDDA will also continue to contribute actively to the 
discussion on issues of common interest to the agencies, 
within the framework of the EU agencies’ network. One of the 
highlights during the year will be the hosting by the EMCDDA 
of the 10th meeting of the EU Agencies Network for Scientific 
Advice (EU-ANSA). Cross-agency and evidence-based input to 
the policy- and decision-making processes at EU level will be 
provided within the framework of the JHA agencies’ network.
Regarding our global partners, cooperation will be 
strengthened with international organisations, in particular 
those belonging to the UN family (UNODC, WHO, UNAIDS), as 
well as the Inter-American Drug Abuse Control Commission 
(part of the Organization of American States), and the 
Pompidou Group of the Council of Europe, with a view to 
maximising synergies and avoiding duplication of effort. 
Cooperation with the World Customs Organization and 
Interpol will be pursued in the area of drug supply and supply 
reduction.
In terms of cooperation with third countries, the priority will be 
the successful completion of the IPA 5 technical assistance 
project, which started in 2015, followed by a closing 
conference. A new project proposal (IPA 6) will be submitted 
to the EC with a view to continuing activities in this area. 
Further to the finalisation in 2016 of the first ENP technical 
assistance project, the agency has submitted to the EC an 
EMCDDA project for funding a second ENP project entitled 
‘Inter-LINK — Strengthening the capacity of ENP partner 
countries by creating an analysis and response platform to 
tackle the dynamic links between drugs, security and health 
threats’.
A detailed implementation plan for the IPA 5 project is 
presented in Annex XIII.
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Strategic objective:
Enhance the EMCDDA’s strategic understanding of the drugs phenomenon, by maintaining and further developing our strong partnership with key 
players at European and global levels, as well as by continuing our successful knowledge exchange with EU priority third countries and regional 
programmes. Ultimately, this will result in high-quality services (information and analysis) provided to EU and Member States stakeholders (see KA 
1).
Specific objective C.1:
Maintain and strengthen information and knowledge exchange with partners at European and global levels and support international monitoring 
and reporting systems and standards
Expected outcomes:
■■ Enhanced capacity for strategic analysis and threat assessment through better capturing the global and multidisciplinary aspects of the drugs 
phenomenon (L2)
■■ EMCDDA’s contribution to improved quality and comparability of international data (L2)
■■ Successful chairmanship of the JHA network, contributing to improved work coordination among the members of the network and increased 
visibility of the work of the network among key stakeholders (L2)
Outputs/results:
■■ High-quality input to partners’ work, and joint outputs produced (as appropriate) (L2)
■■ Contribution to expert meetings and technical/advisory groups (L2)
■■ Contribution of EMCDDA data sets or expertise to other relevant regional/global reporting activities (L2)
■■ 10th meeting of EU-ANSA successfully organised (L2)
■■ Validation of European data sets for international partners (L3)
KPI Target 2017
KPI C.1. Efficient implementation of MoUs and other working 
arrangements with key partners
Priority interventions for joint annual work implemented and objectives 
achieved
Specific objective C.2:
Assist EU priority countries (CC, PCC, ENP countries) in developing their drug-monitoring systems, especially for the establishment and 
development of national drug observatories and core data collection processes
Expected outcomes:
■■ Enhanced capacity to address drug threats in EU priority third countries (L2)
■■ High-quality national data fed into EMCDDA’s analysis and reporting, contributing to sound EU policies with third countries (L2)
Outputs/results:
■■ IPA 5 project implemented in line with the defined implementation plan (see Annex XIII) and the applicable KPI (KPI C.2) (L2)
■■ IPA 5 final report (L2)
■■ IPA 6 project proposal (L2)
■■ Annual Reitox week (L2)
■■ IPA 5 closing conference (L2)
■■ Training and capacity building activities (see KA 1) (L2)
■■ Methodological tools (guidelines, questionnaires, protocols) translated into national languages (L3)
■■ Contribution to third countries’ sub-committee meetings (on request) (L3)
KPI Targets 2017
KPI C.2. Efficient implementation of the IPA 5 project a) Minimum 80 % of the project’s expected results achieved (in line with 
the commitments expressed by the partner countries)
b) Minimum 85 % of the total budget committed
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
722 068.26 3.9
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| 2.7 Corporate area Governance
In line with the elements described in detail in the strategic 
overview provided under Section II, the priorities for the 
Governance area in 2017 will be as follows:
a) To continue to support the Management Board in its 
governance function by ensuring ongoing assistance and 
providing timely high-quality documents for the meetings 
organised during the year.
b) To implement the new EMCDDA long-term strategy, until 
2025. Among other tasks, this will involve the implementation 
of a new organisational structure and appropriate work 
processes. The activity will commence in 2016, when a new 
organigram will be developed in line with the outcome of the 
strategic thinking exercise and submitted for adoption to the 
Management Board. The first year of implementation of the 
new structure will be 2017. During the same year, much effort 
will have to be made to ensure a smooth and successful 
transition. Also in 2017, informed by the results of 
a competency-mapping exercise, a staff development 
programme will commence and will be gradually implemented 
over the following years in line with available budgetary 
resources.
Furthermore, for 2017, the new long-term strategy 2025 
features the launch of an innovative project: a foresight 
exercise on the drugs situation with the horizon of 2030. This 
project will aim at identifying possible scenarios for the 
development of the drugs phenomenon in the EU by 2030. 
Building on the knowledge base that has been developed over 
the last 25 years and combining the data and analysis 
resulting from long-term monitoring with more recent work on 
emerging trends and risk assessments, this exercise will 
develop possible scenarios and explore the likely 
consequences for demand and for supply reduction. To 
achieve this, the EMCDDA will work in close cooperation with 
its Scientific Committee, bringing together the expertise of the 
Reitox network of NFPs and other networks of national 
experts, and the expertise from its international partners.
c) To ensure efficient implementation of the first EMCDDA 
SPD for 2017–19 and timely delivery of the next SPDs for 
2018–20, and for 2019–20 (preliminary draft), in alignment, 
as much as possible, with the new long-term strategy. The 
objective is to design the future SPDs as operational action 
plans of the strategy. Their implementation will be supported 
by detailed annual management plans (starting with 2017).
d) To pursue the development of the performance 
management system, ensuring that it provides the agency’s 
Director and middle management with sound performance 
information and analysis. In 2017, this will include refining the 
annual KPIs and developing the M&E plan, and progressing in 
the development of the MIS (in line with available resources). 
To prepare for the full implementation of the MIS, the training 
programme on project management which started in 2016 will 
be rolled out, targeting staff with relevant responsibilities 
across all units.
Strategic objective:
The EMCDDA functions as a modern, efficient and forward-looking EU administration, which is committed to providing high-quality services to its 
stakeholders and to the EU citizens in general; in achieving this, the agency will be guided by good governance, steered by sound management and 
leadership and operated by a highly motivated and well-performing workforce.
Specific objective GOV.1:
Support the EMCDDA’s Management Board in fulfilling its governance role
Expected outcomes:
Sound strategic decisions at the level of the Management Board, informed by effective preparatory work carried out by the EMCDDA (L1)
Outputs/results:
■■ Management Board, Executive Committee and Budget Committee meetings duly organised and decisions adopted (L1)
■■ Supporting documents prepared for relevant items on the agenda (L2)
KPI Target 2017
KPI GOV.1. Effectiveness of the Director in providing support to the 
Management Board for performing its tasks
Management Board meetings organised in line with the established 
quality standards (i.e. 100 % of the supporting documents uploaded on 
the Management Board extranet at least 2 weeks before the meetings 
(except for documents related to events occurring within this 
timeframe), and draft minutes sent to the Chair within a maximum of 20 
working days from the close of the meetings
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Specific objective GOV.2:
Implement efficient management and leadership of the EMCDDA
Expected outcomes:
■■ Good performance by the EMCDDA in implementing its long-term strategy and its work programmes (L1)
■■ New organisational structure and adjusted work processes in place (L2)
■■ Staff sharing ownership and engaged with the new strategy (L2)
Outputs/results:
■■ Director’s decisions (L1)
■■ Management meetings documented by minutes which are made available to the staff (L2)
■■ Training for middle management (L2)
■■ Staff kept informed through regular communications and via the Staff Committee (L2)
KPI Targets 2017
KPI GOV.2.1. Degree of implementation of the 2017 work programme 100 % of the expected outputs/results listed as L1, 80 % of the 
expected outputs/results listed as L2 and 50 % of the expected 
outputs/results listed as L3 achieved
KPI GOV.2.2. Degree of implementation of internal audit 
recommendations
100 % of the internal audit recommendations (‘critical’ and ‘very 
important’) implemented within the deadline set out in the follow-up 
action plan endorsed by the Management Board
KPI GOV.2.3. Internal communication between Director and staff as an 
effective means to enhance transparency and address staff concerns
a) Three meetings held yearly between the Director and the staff 
committee
b) Two general assemblies of staff convoked by the Director to inform 
staff of developments of general interest
Specific objective GOV.3:
Support sound organisational performance management through state-of-the-art corporate planning, performance measurement and reporting
Expected outcomes:
■■ Programming documents gradually aligned with the EMCDDA long-term strategy and adopted by the Management Board (L1)
■■ Management provided with timely, relevant and reliable corporate performance information (L2)
Outputs/results:
■■ Final draft SPD for 2018–20 submitted to the Management Board (L1)
■■ Preliminary draft SPD for 2019–21 submitted to the Management Board (L1)
■■ General Report of Activities 2016 presented to key stakeholders and published in line with the recast regulation (L1)
■■ Mid-year monitoring report (L2)
■■ Sound KPIs in place for all the areas (L2)
■■ MIS:
• Implementation of the first pilot phase (L2)
• Project management training programme rolled out (L3)
KPIs Targets 2017
KPI GOV.3.1. Timely delivery of the documents supporting the strategic 
planning and programming cycle (SPDs and General Report of 
Activities) (as required by the recast EMCDDA founding regulation)
All documents delivered within deadline
KPI GOV.3.2. Degree of implementation of the performance 
measurement system
a) Annual M&E plan developed and implemented
b) MIS project implemented in line with the agreed project plan
Resources necessary for the implementation of the activities 
in this area
Budget (EUR) Human resources (FTE)
700 870.42 8.8
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| 2.8 Corporate area Administration and ICT
Administration
In line with the strategic priorities for 2017–19 presented in 
Section I, in 2017 the objective for this area will be to ensure 
that implementation of the activities planned across the 
different areas of the annual work programme are supported by 
effective and efficient management of the available resources.
Concerning HR management, this will encompass the sound 
management of existing processes, as required by the 
applicable Staff regulations and their implementing rules. To 
the extent possible, these processes will be further optimised 
through developing digital solutions. Another priority will be 
the organisation of appropriate training for the agency’s staff, 
to support the effective implementation of the new EMCDDA 
long-term strategy and in line with available resources. In this 
context, special attention will be given to enhancing 
managerial capacity at middle-management level. To this end, 
other measures to support smooth implementation of the new 
organisational structure which will enter into effect after its 
adoption by the Management Board in December 2016.
The priorities in the financial resources management area are 
effective and timely planning, monitoring and execution of the 
EMCDDA budget, and optimising all the related processes. These 
will be complemented by the efficient use of material resources.
Ensuring safety at work will continue to be a key objective for 
this important support area.
Information and communication technology
The ICT programmes and services will be developed and 
delivered in line with the triennial objectives, which are to 
implement and support core business and corporate projects 
and processes and to provide a continuously stable environment 
which supports existing basic and advanced services.
Concerning the support to core business areas, the following 
activities will be given priority in 2017:
■■ the maintenance and development of the established 
EMCDDA’s online data collection platforms, namely Fonte and 
the EDND (see also CCA A), and the Drugs data warehouse;
■■ technical support related to implementation of the tools 
related to the new reporting system (the Workbooks).
Support will be also provided to the corporate areas, particularly 
to the planning and performance monitoring activities, as well 
as to the HR and financial management processes.
To ensure the most effective allocation of the limited 
resources in this area, the ICT Steering Committee will 
exercise the role of further refining these priorities and 
deciding on the intensity of work to be devoted to each 
activity, depending on the most critical organisational needs.
Strategic objective:
Ensure sound allocation and management of financial and human resources and assets, and the management of the ICT infrastructure and 
services, through further rationalising and automating relevant processes, enhancing efficiency and synergies, and developing the quality of 
services and support
Specific objective ADM.1:
Maximise efficiency and effectiveness of HR management
Expected outcomes:
■■ Resources of the HR function properly managed, in compliance with the rules set out in the Staff regulations and their implementing provisions, 
and in line with organisational needs (L1)
■■ Ongoing professional development of staff, through training and managerial support (L2)
■■ Integrated and efficient electronic system for the management of staff (i.e. rights, entitlements, working time, etc.) (L2)
Outputs/results:
■■ Staff training, in line with the approved 2017 training plan (L2)
■■ Existing digital tools (HR database, E-recruitment, working time management) maintained and improved (as appropriate) (L2)
KPIs Targets 2017
KPI ADM.1.1. Occupation rate (implementation of the establishment 
plan)
94 % of the establishment plan posts (officials, temporary agents) filled 
at the end of the year (in line with resources)
KPI ADM.1.2. Staff turnover Maximum 4 % of staff leaving EMCDDA during the year, out of the total 
number of staff (officials, temporary agents, contract agents)
KPI ADM.1.3. Average number of training days per staff member Minimum of 3 days
KPI ADM.1.4. Average time of recruitment processes Maximum of 4 months from the expiry date of the vacancy notice to 
appointment decision
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Specific objective ADM.2:
Ensure efficiency in financial and budget management and accounting
Expected outcomes:
■■ Sound management of the EMCDDA’s financial resources, in compliance with applicable rules and procedures (L1)
■■ EMCDDA 2018 draft budget and 2019 preliminary draft budget adopted by the Management Board (L1)
■■ Internal processes (procurement, payments, missions, meetings, contracts management) optimised, including through enhanced use of 
electronic tools and workflows (L2)
■■ High level of budget execution (commitment and payment appropriations), in line with annual targets (L2)
■■ Effective follow-up on the recommendations from external audits performed at the EMCDDA (L2)
Outputs/results:
■■ 2017 procurement plan successfully implemented (L2)
■■ Efficiency of the contracting and payment process, with special attention to the actual execution of payments due before the end of legal 
deadlines (L2)
■■ EMCDDA 2017 draft budget and 2018 preliminary draft budget finalised and submitted on time for internal approval and for adoption by the 
Management Board (L1)
■■ Follow-up action plan to recommendations from external audits developed and implemented (L2)
■■ Timely publication of the report on the EMCDDA’s annual accounts for 2016 (L2)
■■ Meeting-related expenditure electronic workflow procedures developed (L3)
KPIs Targets 2017
KPI ADM.2.1. Budget execution rate — commitment appropriations 
(without assigned appropriations)
Minimum 95 % of the total commitment appropriations
KPI ADM.2.2. Cancellation rate of payment appropriations Maximum 5 % cancelled payment appropriations (the basis for 
calculation is available payment appropriations for the year and 
payment appropriations, carried forward from Title 1 and Title 2 of the 
2016 budget)
Specific objective ADM.3:
Ensure a healthy working environment and further optimise the use of the available facilities, equipment and infrastructure
Expected outcomes:
Safe and environmentally friendly workplace, which prevents work accidents, promotes use of renewable energy and avoids waste of resources 
(L2)
Outputs/results:
■■ Health and safety risks identified (L2)
■■ Security risk assessment delivered (L2)
■■ Measures to ensure efficient use of utilities (L2)
■■ Environmental report delivered (L2)
■■ Contribution to the Greening network (L3)
KPIs Targets 2017
KPI ADM.3.1 Number of accidents at workplace No accidents
KPI ADM.3.2 Efficiency in using available facilities, equipment and 
infrastructure
No increase in utility costs (compared with 2016)
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Specific objective ICT.1:
Implement and support core business and corporate projects and processes
Expected outcomes:
Core business and corporate projects and processes rely on efficient ICT services which help maximise corporate results (L2)
Outputs/results:
■■ Infrastructure for the annual drugs data collection and analysis (Fonte, Data warehouse, EDND) functional and further developed (see also CCA 
A) (L1)
■■ Web system functional and further developed (migration of special contents, plan, upgrade of Drupal architecture) (L2)
■■ Tools and processes developed to support efficient corporate planning and monitoring, and management of resources:
• MIS: software customised (L2)
• Elements of HR management system reviewed, leave-management system up and running (L2)
• E-recruitment upgrade planned in the context of the development of the HR management system, as adequate (L3)
KPI Target 2017
KPI ICT.1. Project management and implementation accountability 
(compliance with the EMCDDA’s adopted ICT project management 
standard)
100 % compliance for the L1 and L2 priority projects
Specific objective ICT.2:
Provide a continuously stable environment which supports existing basic and advanced services
Expected outcomes:
Optimal level of operability of the ICT systems (L2)
Outputs/results:
■■ Business continuity plan implemented (L1)
■■ Services implemented in line with the adopted ICT Service catalogue (L2)
KPI Targets 2017
KPI ICT.2. Availability of the ICT systems a) Office supporting infrastructure availability: system availability 
superior to 95 %, office hours (maximum of 103 hours of accumulated 
down time over the year)
b) Corporate supporting infrastructure availability (websites, web 
applications, Fonte, databases, email, security): system runs on a 24/7 
basis with an overall annual target of minimum 99 % availability 
(maximum of 88 hours of annual accumulated down time)
Resources necessary for the implementation of the activities  
in this area
Budget (EUR) Human resources (FTE)
5 376 742.89 32.5
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ANNEXES
|  ANNEX I Estimated budget allocation for the implementation of the EMCDDA 2017 work programme
The amounts indicated in the table below are based on the 
parameters of the 2017 EMCDDA draft budget, as expected to 
be adopted by the EMCDDA Management Board in December 
2016. This budget reflects the expected result of the EU 2017 
budget procedure, which should provide EUR 15 135 600 for 
the EU’s 2017 subsidy to the EMCDDA. Should this amount 
not be confirmed, adjustments will be required to the activities 
proposed.
According to the aforementioned draft budget, in 2017 the 
EMCDDA budget should rely on the following revenues:
■■ EUR 15 135 600 to be provided by the EU subsidy to the 
EMCDDA;
■■ EUR 400 564 to be provided by Norway for its participation 
in the EMCDDA activities.
■■ EUR 271 000 to be provided by Turkey for its participation 
in the EMCDDA activities, pursuant to the agreement in 
force between the EU and Turkey which defines the terms 
of this participation.
In this context, the tables below present the estimated 
allocation of the expected EMCDDA’s 2017 budget 
appropriations for the implementation of the EMCDDA’s 2017 
work programme.
A. Key areas (KAs)
WP action areas
Main actors for 
implementation/
cost objects
Allocated human resources 
(fte/year: full time equivalent per year)
Allocated budget resources — non-assigned 
appropriations (EUR)
O TA CA SNE
Total 
HR






KA 1: Communicating 
evidence and knowledge 
exchange
EPI, IBS, SAT, SDI, 
COM, RTX
1.75 16.75 4.5 0 23 2 400 531.78 1 504 220.78 3 904 752.55
KA 2: Early warning and 
threat assessment
SAT, EPI, IBS, SDI, 
COM
0 5 3 0 8 956 229.41 384 238.75 1 340 468.16
KA 3: Situation, responses 
and trend analysis
EPI, IBS, SAT, SDI, 
COM
1 11.15 3.75 1 16.9 1 570 737.82 1 055 938.07 2 626 675.89
Total 2.75 32.9 11.25 1 47.9 4 927 499.01 2 944 397.59 7 871 896.60
CA, contract agent; COM, Communication unit; EPI, Prevalence, data management and content coordination unit; IBS, Consequences, responses and best practices 
unit; O, official; RTX, Reitox; SAT, Supply reduction and new drugs unit; SDI, Scientific division; SNE, seconded national expert; TA, temporary agent; WP, work 
programme.
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B. Cross-cutting areas (CCA)
WP action areas
Main actors for 
implementation/
cost objects
Allocated human resources 
(fte/year: full time equivalent per year)
Allocated budget resources — non-assigned 
appropriations (EUR)
O TA CA SNE
Total 
HR
For direct cost 
of operations (1)
For indirect cost 
of operations (2)
Total budget
CCA A: Information 
collection and 
management
EPI, SAT, RTX 0.5 3.25 6.25 0 10 3 902 911.24 1 242 558.06 5 145 469.30
CCA B: Quality assurance SDI, EPI, COM, 
RTX
1.25 5 1.65 0 7.9 845 493.77 521 365.67 1 366 859.44
CCA C: Cooperation with 
partners
RTX, DIR/EXO 1.3 1.85 0.75 0 3.9 426 379.97 295 688.29 722 068.26
Total 3.05 10.1 8.65 0 21.8 5 174 784.98 2 059 612.02 7 234 397.00
CCA, Cross-cutting area; COM, Communication unit; DIR/EXO Directorate/Executive office; EPI, Prevalence, data management and content coordination unit; SAT, 
Supply reduction and new drugs unit; SDI, Scientific division; SNE, seconded national expert; TA, temporary agent; WP, work programme.
C. Corporate area Governance
WP action area
Main actors for 
implementation/
cost objects
Allocated human resources 
(fte/year: full time equivalent per year)
Allocated budget resources — non-assigned 
appropriations (EUR)
O TA CA SNE
Total 
HR
For direct cost of 
operations (1)
For indirect cost 
of operations (2)
Total budget
Governance DIR/EXO 1.2 5 2.6 0 8.8 328 137.14 372 733.28 700 870.42
Total 1.2 5 2.6 0 8.8 328 137.14 372 733.28 700 870.42
CA, contract agent; SNE, seconded national expert; TA, temporary agent; WP, work programme.
D. Support to operations — corporate area Administration and ICT 
(Overhead included in Tables A, B and C in the column presenting indirect cost of operations)
Action areas




Main actors for implementation/cost objects
Administration and resources/
assets management
ICT (equipment and services)
Allocated human resources  
(fte/year: full time equivalent per year)
O 3 0 3
TA 11 8 19
CA 8 2.5 10.5
SNE 0 0 0
Total 22 10.5 32.5
Allocated budget resources for direct cost of supporting 
activities to be distributed to operations (2) (see the 
column ‘For indirect cost of operations’ above) — non-
assigned appropriations (EUR)
4 144 325.38 1 232 417.51 5 376 742.89
CA, contract agent; SNE, seconded national expert; TA, temporary agent.
Notes:
(1) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(2) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/
WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion of the human resources 
assigned for the implementation of these activities.
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Summary of total allocations
Operations
Allocated human resources 
(fte/year: full time equivalent per year) Allocated budget resources — 
non-assigned appropriations 
(EUR)O TA CA SNE
Total 
HR
For direct cost of operations (Tables A+B+C) 7 48 22.5 1 78.5 10 430 421.13
For indirect cost of operations (i.e. direct costs of support 
activities — Table D)
3 19 10.5 0 32.5 5 376 742.89
TOTAL 10 67 33 1 111 15 807 164.02
CA, contract agent; SNE, seconded national expert; TA, temporary agent.
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N (2016) N+1 (2017)
Commitment appropriations Payment appropriations Commitment appropriations Payment appropriations
Title 1 9 321 199 9 321 199 10 128 023.17 10 128 023.17
Title 2 1 724 289 1 724 289 1 226 547.66 1 226 547.66
Title 3 4 348 475 4 348 475 4 452 593.19 4 452 593.19















9 159 160 9 321 199 10 128 023.17 10 465 237.30 10 565 237.30
11 Salaries and allowances 9 024 996 9 204 199 10 000 423.17 10 337 637.30 10 427 637.30
- of which establishment plan posts 7 814 694 8 013 195 8 479 795.72 8 674 895.72 8 724 895.72
- of which external personnel 1 210 302 1 191 004 1 520 627.46 1 662 741.58 1 702 741.58
12 Expenditure relating to Staff recruitment 37 028 27 000 11 000.00 11 000.00 11 000.00
13 Mission expenses
14 Socio-medical infrastructure
15 Training 65 736 90 000 100 000.00 100 000.00 100 000.00
16 External Services 31 400 0 16 600.00 16 600.00 16 600.00
17 Receptions and events
Title 2
Infrastructure and operating expenditure
4 855 783 1 724 109 1 226 547.66 1 252 194.36 1 292 194.36
20 Rental of buildings and associated 
costs (3)
4 018 350 949 132 578 674.58 600 193.26 640 193.26
21 Information and communication 
technology
575 683 458 571 408 475.00 409 475.00 409 475.00
22 Movable property and associated costs 134 713 119 960 104 972.48 109 360.00 109 360.00
23 Current administrative expenditure 100 005 148 953 97 250.00 95 805.50 95 805.50
24 Postage/telecommunications 4 982 10 400 8 000.00 8 080.00 8 080.00
25 Meeting expenses
26 Running costs in connection with 
operational activities
27 Information and publishing
28 Studies
Other infrastructure and operational 
activities
22 050 37 093 29 175.60 29 280.60 29 280.60
Title 3
Operational expenditure
4 138 265 4 348 475 4 452 593.19 4 414 903.54 4 473 293.37
Information and publishing 558 832 701 625 587 150.00 552 460.35 592 150.00
Studies 469 222 421 504 672 423.72 672 423.72 681 123.72
RTX grants 2 069 945 2 228 537 2 228 537.26 2 228 537.26 2 228 537.26
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Mission expenses 249 748 289 559 260 000.00 260 000.00 260 000.00
Meeting expenses 505 274 701 250 698 482.21 695 482.21 705 482.39
Receptions and events 1 490 6 000 6 000.00 6 000.00 6 000.00
Expenditure related to IPA and ENP projects, 
total
283 754
Expenditure related to IPA projects 95 904
Expenditure related to ENP projects 187 850
TOTAL EXPENDITURE 18 153 208 15 393 783 15 807 164.02 16 132 335.20 16 290 725.03















9 096 519 9 321 199 10 128 023.17 10 465 237.30 10 565 237.30
11 Salaries and allowances 9 022 497 9 204 199 10 000 423.17 10 337 637.30 10 427 637.30
- of which establishment plan posts 7 812 195 8 013 195 8 479 795.72 8 674 895.72 8 724 895.72
- of which external personnel 1 210 302 1 191 004 1 520 627.46 1 662 741.58 1 702 741.58
12 Expenditure relating to staff 
recruitment
24 865 27 000 11 000.00 11 000.00 11 000.00
13 Mission expenses
14 Socio-medical infrastructure
15 Training 48 337 90 000 100 000.00 100 000.00 100 000.00
16 External services 820 0 16 600.00 16 600.00 16 600.00
17 Receptions and events
Title 2
Infrastructure and operating 
expenditure
4 449 295 1 724 109 1 226 547.66 1 252 194.36 1 292 194.36
20 Rental of buildings and associated 
costs (3)
3 919 418 949 132 578 674.58 600 193.26 640 193.26
21 Information and communication 
technology
346 851 458 571 408 475.00 409 475.00 409 475.00
22 Movable property and associated 
costs
76 306 119 960 104 972.48 109 360.00 109 360.00
23 Current administrative expenditure 89 574 148 953 97 250.00 95 805.50 95 805.50
24 Postage/Telecommunications 4 761 10 400 8 000.00 8 080.00 8 080.00
25 Meeting expenses
26 Running costs in connection with 
operational activities
27 Information and publishing
Other infrastructure and operational 
activities




4 074 891 4 348 475 4 452 593.19 4 414 903.54 4 473 293.37
Information and publishing 662 725 701 625 587 150.00 552 460.35 592 150.00
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Studies 387 108 421 504 672 423.72 672 423.72 681 123.72
RTX grants 2 095 889 2 228 537 2 228 537.26 2 228 537.26 2 228 537.26
Mission expenses 256 991 289 559 260 000.00 260 000.00 260 000.00
Meeting expenses 470 877 701 250 698 482.21 695 482.21 705 482.39
Receptions and events 7 396 6 000 6 000.00 6 000.00 6 000.00
Expenditure related to IPA and ENP 
projects, total
193 905
Expenditure related to IPA projects 83 513
Expenditure related to ENP projects 110 392
TOTAL EXPENDITURE 17 620 705 15 393 963 15 807 164.02 16 132 335.20 16 290 725.03




N (2016) N+1 (2017)
Revenues estimated by the agency Budget forecast
EU contribution 14 794 000 15 135 600
Other revenue 599 963 671 564.02


















1 Revenue from fees and 
charges
(including balancing reserve from 
previous year’s surplus)
2 EU contribution 14 794 000 14 794 000 15 081 600 15 445 600.00 15 596 600.00
- of which assigned revenues 
deriving from previous years’ 
surpluses
151 000 69 000 54 000
3 Third countries contribution
(incl. EEA/EFTA and candidate 
countries)
544 006 599 963 671 564.02 686 735.20 694 125.03
- of which EEA/EFTA
(excl. Switzerland)
394 006 389 963 400 564.02 410 184.71 414 870.91
- of which candidate countries 150 000 210 000 271 000 276 550.49 279 254.12
4 Other contributions
5 Administrative operations 2 581 837 
(4)
- of which interest generated by 
funds paid by the Commission by 






















6 Revenues from services 
rendered against payment
7 Correction of budgetary 
imbalances
TOTAL REVENUES 17 919 843 15 393 963 15 807 164.02 16 132 335.20 16 290 725.03
(4) Includes Income from sale of EMCDDA building (EUR 2 500 000), internal assigned revenue (EUR 19 278.58), interest generated by funds paid to EMCDDA 
(EUR 20 944.90) and misc. revenue (EUR 41 614).
TABLE 3
Budget outturn and cancellation of appropriations
Budget outturn N–4* N–3* N–2*
Revenue actually received (+) 16 335 613 15 690 681 18 632 222
Payments made (–) –15 904 033 –14 994 984 –17 626 446
Carry-over of appropriations (–) –502 221 –893 022 –1 180 476
Cancellation of appropriations carried over (+) 29 846 8 622 38 712
Adjustment for carry-over of assigned revenue appropriations from previous year (+) 198 497 262 589 188 102
Exchange rate differences (+/-) –1 680 –1 272 4 976
Pro-rata Norway (2014, 2015, 2016) and Turkey (2015) –4 936 –2 253 –2 654
Adjustment for negative balance from previous year (–)
Total 151 386 70 360 54 436
*N – the year covered by the programming document drafted in N-1
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|  ANNEX III Human resources outlook and staff evolution
TABLE 1




















Officials AD 7 8 6 7 6 6 6 6
AST 5 5 4 5 3 4 4 4
AST/
SC
0 0 0 0 0 0 0 0
TA AD 42 44 42 45 42 45 45 45
AST 22 23 22 22 22 22 22 22
AST/
SC
0 0 0 0 0 0 0 0
Total 76 80 74 79 73 77 77 77
CA GF IV 0 2 2 2 3 7 7 7
CA GF III 8 9 8 9 9 10 10 10
CA GF II 13 13 12 13 13 13 13 13
CA GF I 3 3 3 3 3 3 3 3
Total CA 24 27 25 27 28 33 33 33
SNE 1 1 1 1 0 1 1 1
Structural 
service providers
0 0 0 0 0 0 0
TOTAL 101 108 100 107 101 111 111 111
External staff for 
occasional 
replacement
(5) Offer letters are counted as posts filled in.
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TABLE 2





plan in EU 
Budget 2015























Officials TA Officials TA Officials TA Officials TA Officials TA Officials TA Officials TA Officials TA
AD 16
AD 15 1 1 1 1 1 1
AD 14 1 1 1 1 1
AD 13 1 2 1 3 1 2 1 2 1 2 1 2
AD 12 4 10 3 6 +1 4 11 4 11 4 11 4 11
AD 11 3 10 5 2 10 –1 +1 1 11 1 11 1 11
AD 10 15 3 –2 13 13 13 13
AD 9 5 1 3 7 6 6 6




Total AD 8 44 6 42 7 45 6 45 6 45 6 45
AST 11 1 1 1 1 1
AST 10 2 1 +1 3 3 3 3
AST 9 1 8 3 –1 1 7 1 7 1 7 1 7
AST 8 2 7 1 1 2 7 2 7 2 7 2 7
AST 7 1 6 1 2 –1 1 5 5 5 5
AST 6 4














0 0 0 0 0 0 0 0
TOTAL 13 67 10 64 12 67 10 67 10 67 10 67
(5) Offer letters are counted as filled posts.
(6) Article 38 of the Framework Financial Regulation was applied following a screening exercise.
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|  ANNEX IV Human resources policies
A. Recruitment policy
The selection procedures applied by the EMCDDA comply 
with the relevant EU provisions, namely Article 12 of the 
Conditions of employment of other servants (CEOS) for the 
recruitment of temporary and contract agents and the 
principles and standards laid down for officials in Annex III of 
the Staff regulations.
The key phases of the selection procedure for the recruitment of 
temporary and contract agents can be summarised as follows:
■■ A vacancy notice is published on the EMCDDA website, on 
the European Personnel Selection Office (EPSO) website, 
a communication is sent to all other EU institutions and 
agencies, to all focal points of the Reitox network and to all 
members of the EMCDDA Management Board and 
Scientific Committee and, where appropriate, 
advertisements are placed in the local and specialised 
press and on web pages.
■■ The vacancy notice sets out eligibility and selection criteria, 
indicating type and duration of contract and recruitment 
grade.
■■ A Selection Committee is appointed, usually composed of 
five members. The Selection Committee includes 
a representative from the EMCDDA Staff Committee and 
takes into account gender balance and broad geographical 
representation. External members are invited in cases 
where specific expertise is required to carry out the 
selection process appropriately. The names of the 
Selection Committee members are now published in the 
vacancy notice in full respect of Regulation 45/2001 as 
required by the European Ombudsman.
■■ Applicants are first screened on the basis of their 
application file (application form, CV and the further 
supporting documents required) to identify the candidates 
who best match the published requirements.
■■ Selected candidates are interviewed on the basis of 
pre-defined questions that are presented to all candidates 
interviewed. The procedure includes a compulsory written 
test. The interview and test cover assessment of the 
specific competences and technical qualifications required 
for the selection process concerned; knowledge of 
European institutions and particularly of the EMCDDA’s 
activities; and general skills and language abilities of the 
candidate.
■■ The Selection Committee drafts a list of the most suitable 
candidates together with a possible proposal to the 
authority authorised to conclude contracts (AHCC) and/or 
to establish a reserve list for recruitment purposes.
■■ A reserve list may be established by the AHCC, who can, 
prior to this, choose to have a further interview with 
candidates.
■■ The result of the selection process is communicated to the 
selected candidates.
■■ All steps of the procedure and all decisions made are 
reported and documented.
The procedures described above comply with the 
implementing rules on the recruitment and use of temporary 
and contract agents adopted by the EMCDDA with the 
agreement of the EC pursuant to Article 110 of the Staff 
regulations.
When recruiting officials, the EMCDDA complies with the 
relevant provisions of the Staff regulations, namely with Article 
29 and Annex III. The EMCDDA organised two internal 
competitions in 1999 and 2002. These competitions were 
carried out in cooperation with the EC.
Other EMCDDA vacant posts for officials have been filled 
through interinstitutional transfer processes according to the 
applicable provisions of the Staff regulations.
The EMCDDA envisages that it will continue to draw on the 
assistance that EPSO can provide in this field, including using 
its reserve lists, as required. This has already been the case for 
hiring officials and contract agents.
Grade and function group corresponding to the tasks 
and level of the post
In line with the relevant provisions of the Staff regulations and 
CEOS and within the limits set by the budget adopted and the 
establishment plan, the EMCDDA applies by analogy the rules 
applied by the EC for the grading of officials, temporary agents 
and contract agents. The EMCDDA, as a basic rule, recruits 
temporary agents at grades ranging from AST 1 to AST 4 for 
function group AST and from AD 5 to AD 8 for function group 
AD.
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Recruitment at grades AD 9 to AD 11, and in exceptional 
cases at AD 12, is limited to filling middle management 
positions or to particular cases where a higher grade is 
essential to ensure a recruitment of high quality. In the latter 
case, the grade must be justified by the high level of expertise 
required, the specific conditions of the labour market 
concerned and/or by the fact that a lower grade would not be 
attractive for the target population of potential candidates.
Duration of employment
Upon recruitment, EMCDDA temporary and contract agents 
engaged to address long-term or permanent tasks are offered 
a contract of five years. In accordance with Articles 8 and 85 
of the CEOS, this contract may be renewed for further five 
years. In case of second renewal, agents are engaged for an 
indefinite period.
EMCDDA temporary and contract agents on short-term 
employment recruited to address time-bound tasks or 
temporary needs are engaged for the period required to fulfil 
the tasks concerned. In principle, the contract may be 
renewed just once for a definite period.
The EMCDDA Director is employed as a temporary agent for 
a five-year term, this term being renewable. This is in 
accordance with the relevant provisions of the EMCDDA 
founding regulation.
Profile of staff, and type and duration of employment 
required to fulfil the agency’s mission and tasks
For the majority of its activities, the EMCDDA requires 
scientifically and/or technically qualified staff with highly 
specialised knowledge and extensive experience – particularly 
in those fields linked to its core activities. Specialisation is 
inherent to the agency. The EU skill base of available and 
competent staff is limited. In some areas of activity only one 
staff member is involved in running the service. Furthermore, 
given the ground-breaking nature of many of its activities, the 
agency needs to cultivate a workforce that combines sector 
knowledge and insight in its specialised field of expertise 
(drugs and drug addiction) with a track record of innovation, 
cooperation and knowledge transfer. Staff therefore need to be 
prepared to nurture agency-wide skills, and must possess the 
professional latitude and flexibility to work ‘horizontally’ on 
other projects that might benefit from their area of expertise.
The EMCDDA’s staff policy must therefore rise to the challenges 
faced by all ‘centres of excellence’: to attract strong talent, to 
build on strong previous work, to retain valued expertise and, 
ultimately, to ensure business continuity. A key aspect in 
meeting these challenges is that the agency must have at its 
disposal the means to offer staff appropriate job security and 
career prospects, with a long-term or permanent outlook.
(a) Officials and temporary agents on long-term 
employment (long-term staff)
The EMCDDA employs officials and temporary agents on 
long-term employment to carry out its scientific, technical and 
administrative tasks of a permanent or long-term nature. 
These tasks can be summarised as follows:
■■ tasks directly relating to the implementation of the 
EMCDDA’s core activities as defined by its founding 
regulation;
■■ tasks relating to the management and functioning of the 
EMCDDA, aimed at providing technical and administrative 
support to its core business.
Temporary agents on long-term employment are offered 
a five-year contract at the time they are contracted. In 
accordance with Articles 8 and 85 of the CEOS, this contract 
may be renewed for a further five years. In the case of second 
renewal, agents are engaged for an indefinite period.
The use of officials is necessary for a number of reasons:
■■ Retaining proven talent and enhancing career 
opportunities for EMCDDA temporary staff.
■■ Sourcing skills from other EU bodies: enabling the 
possibility for transfers of officials from other EU 
institutions and bodies, in order to fill posts of a sensitive 
character or requiring specific professional expertise which 
is available in these institutions and bodies. In particular, 
the option of an official is important for sourcing the 
scientific, technical and administrative skills common to all 
EU institutions and bodies; it is also useful to attract 
suitably qualified candidates who are on reserve lists 
following successful completion of competitions at other 
EU institutions.
■■ Expertise exchange to other EU bodies: that is, the 
possibility to offer options for external mobility, by way of 
secondment or transfer. This option takes into account the 
limited possibilities provided for temporary agents in the 
context of their current fixed-term contracts, while 
providing incentives to younger staff who are given the 
chance to plan their career in the wider context of all EU 
institutions and bodies.
■■ Maximising resources: to profit from the specific 
experience and knowledge acquired for executing highly 
specialised tasks.
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All posts for officials and temporary agents authorised in the 
EMCDDA’s current establishment plan are posts of 
a permanent or long-term nature (long-term employments), 
with the post of the Director being a specific case.
(b) Temporary agents on short-term employment (short-
term staff)
The EMCDDA may also employ temporary agents on short-
term employment to fulfil specific scientific, technical and 
administrative operating needs of a limited duration. The 
duration of the contract is determined by the limited duration 
of the tasks. In principle, the contract may be renewed just 
once for a definite period:
■■ to ensure the delivery of time-bound tasks, that is, for the 
execution of technical assistance projects financed by 
specific appropriations provided by Community 
programmes (for example the Programme of Community 
aid to the countries of Central and Eastern Europe, PHARE; 
the Programme of Community assistance to the countries 
of South-Eastern Europe, CARDS; IPA);
■■ to ensure the temporary replacement of staff in cases of 
medium- or long-term absences;
■■ to cope with temporary peaks in workload;
■■ to fulfil highly specific temporary operational needs 
requiring highly specific and high-level technical or 
scientific expertise.
(c) Contract agents on long-term employment (long-term 
staff)
The EMCDDA employs contract agents on long-term 
employment for its scientific, technical and administrative 
tasks of a permanent or long-term nature. In accordance with 
the function groups (FGs) and grades defined by Article 80 of 
the CEOS, the EMCDDA’s contract staff are typically assigned 
to tasks aimed at providing administrative, linguistic, scientific 
and drafting support to the work of officials or temporary 
agents within FGs I, II and III. The use of contract staff in FG IV 
is limited to those situations where it is necessary to recruit 
very specific and high-level technical or scientific expertise.
Currently the tasks that EMCDDA contract staff are requested 
to carry out under the supervision of officials or temporary 
staff entail a lower level of responsibility. Some restrictions on 
contract staff have been established with regard to:
■■ functions and tasks relating to the execution of the 
EMCDDA budget, where a large measure of discretion 
implying strategic choices is involved;
■■ functions relating to the representation of the EMCDDA in 
institutional relations with its partners, such as EU 
institutions, national authorities and international 
organisations, in accordance with the regulation 
establishing the EMCDDA.
Contract agents on long-term employment are offered 
a five-year contract upon recruitment. In accordance with 
Articles 8 and 85 of the CEOS, this contract may be renewed 
for further five years. In the case of second renewal, agents 
are engaged for an indefinite period.
At the time of writing, all EMCDDA contract agent positions 
have been identified as long-term employment.
(d) Contract agents on short-term employment (short-term 
staff)
The EMCDDA may also employ contract agents on short-term 
employment to cope with specific scientific, technical and 
administrative operating needs of a limited duration, similar to 
the conditions assigned to temporary agents on short-term 
employment. In principle, the contract may be renewed just 
once for a definite period.
Some restrictions apply to the use of the contract agents on 
short-term employment and the nature of their duties as 
detailed above.
(e) Seconded national experts
The objective the EMCDDA follows with the recruitment of 
seconded national experts (SNEs) is to benefit from the high 
level of their professional knowledge and experience, in 
particular in areas where such expertise is not readily 
available.
The complete legal framework for recruitment of SNEs at 
EMCDDA is to be found in the Decision of the Management 
Board of the EMCDDA on the adoption of rules on the 
secondment of national experts at the EMCDDA (DEC/
MB/10/02) of 5 May 2010 (which adopts by analogy the EC 
Decision of 12 November 2008, laying down rules on the 
secondment to the Commission of national experts and 
national experts in professional training). SNEs are recruited 
following a similar procedure to the one used for the 
recruitment of temporary staff and the guidelines of such 
a procedure are publicly published on the EMCDDA job 
vacancies web page.
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B. Appraisal of performance and reclassifications/
promotions
Since 1998, the EMCDDA has carried out annual exercises for 
staff appraisal, promotion of officials, assignment of temporary 
agents to a post corresponding to a higher grade, and 
classification of contract agents in the next higher grade. The 
rules and procedures applied by the EMCDDA comply with the 
relevant provisions of the Staff regulations and the CEOS.
In this context, the EMCDDA applies tools and processes for 
its so-called long-term staff that reflect those applied by the 
EC. This means:
■■ For staff appraisal: an annual exercise focusing on the staff 
member’s performance. This includes dialogue between 
the actors involved, the possibility of appeal and definition 
of the staff member’s training needs.
■■ For promotion of officials, for assignment of temporary 
agents to a post corresponding to a higher grade and for 
classification of contract agents in the next higher grade: 
a merit-based annual exercise with two years in the current 
grade as a minimum condition for eligibility. This includes 
a focus on the comparative assessment of the merits of 
eligible staff, mainly taking into account the result of the 
appraisal exercise.
The EMCDDA’s rules and procedures in this field were revised 
in 2009, by decision of the EMCDDA Management Board and 
with the agreement of the EC, on the basis of common model 
decisions resulting from preparatory works carried out by the 
agencies and the EC. After the entry into force on 1 January 
2014 of the latest reform of the Staff regulations/CEOS, the 
EMCDDA revised the appraisal of performance rules and 
procedures on the basis of common model decisions 
prepared by the standing working party set up for this purpose 
by the EC’s relevant services and the network of the EU 
decentralised agencies. The EMCDDA Management Board 
adopted the rules that follow the model worked out by the 
standing working party that has been adopted by ex-ante 
agreement by the EC.
Taking into account the current policy at the EMCDDA for staff 
promotion and assignment to a higher grade (reclassification), 
the EMCDDA estimates a promotion and reclassification rate 
which is in line with Annex IB and Annex XIII of the Staff 
regulations. Regarding the legal framework for promotions and 
reclassification, the standing working party is finalising the 
work for proposing a model to all agencies. The EMCDDA will 
follow the ex-ante adoption of the rules by the EC as soon as 
the communication is received. The entry into force of the 
rules mentioned will also be 2016. In Tables 1 and 2 below, the 
actual figures on promotion/reclassification are presented for 
full information.
TABLE 1
Reclassification of temporary staff/promotion of officials
Category 
and grade
Staff in activity 
at 01.01.2014





Average no. of 








AD 13 2 1 1 8
AD 12 5 8
AD 11 4 2 6.5
AD 10 5
AD 9 1 1 1 3.92
AD 8 1 5 5 3.55
AD 7 11 2 3.71
AD 6 5
AD 5
Total AD 7 42 1 11
AST 11
AST 10 1
AST 9 2 1 6
AST 8 1 1 1 1 5
AST 7 2 3
AST 6 2 2 5














0 0 0 0
TOTAL 12 64 3 16
(*) Number of staff reclassified/promoted at the new grade.
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TABLE 2























CA III 12 1
11
10 4 1 5
9 3
8
CA II 7 5
6 3 3 7.5
5 4
4 1




(*) Number of staff reclassified at the new grade.
C. Mobility policy
(i) Mobility within the EMCDDA
So far, mobility of staff members within the EMCDDA has 
been achieved using the following:
■■ internal publication of calls for expression of interest;
■■ external publications of calls for selection which also 
welcome applications from internal candidates;
■■ redeployment or reassignment of staff in the interest of the 
service;
■■ mutual exchange of staff between different units, where 
there is agreement between the heads of unit concerned.
(ii) Mobility among EU agencies
Most of the EMCDDA’s staff is composed of temporary agents, 
as is the case with the staff of most other EU agencies. 
Inter-agency mobility has to date been achieved via the 
recruitment of staff previously employed at other agencies by 
applying the standard selection procedures used for all 
candidates. So far, the EMCDDA has recruited seven 
temporary agents who were previously engaged by other EU 
agencies. Seven of the EMCDDA’s former temporary agents 
have been engaged by other EU agencies.
From 2014 and with the entry into force of the new Staff 
regulations, the legal framework has changed. Because of the 
introduction of a new category of temporary agents (based on 
Article 2f of the Conditions of Employment of Other Servants 
of the EU (CEOS) and the introduction of Article 55 CEOS), the 
continuity of career for temporary agents is ensured. The 
EMCDDA has already recruited the first temporary agent from 
another agency using the abovementioned articles.
(iii) Mobility between the EMCDDA and the EU institutions
So far, mobility of staff members between the EMCDDA and 
the EU institutions has been achieved through:
■■ transfer of officials from the institutions to the EMCDDA 
(seven officials from the EC and one from the Council were 
concerned so far);
■■ transfer of officials from the EMCDDA to the EU institutions 
(six officials to the EC and one official to the Committee of 
the Regions);
■■ engagement as temporary agents of officials on 
secondment from EU institutions who have been 
successful in an EMCDDA selection process for temporary 
agents (12 officials from the EC; two officials from the 
European Parliament).
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D. Gender and geographical balance
The gender balance among EMCDDA overall staff in 2015 was 
once again slightly in favour of women. The illustration below 
provides a visual representation of the number of female and 
male staff per contract type (officials/temporary agents/
contract agents) with an indication of the function group (AD/
AST). The same information is provided regarding seconded 
national experts.
Gender balance at 31 December 2015




Sub-total 4 6 10
Temporary agents
AD 21 21 42
AST 10 12 22
Sub-total 31 33 64
Contract agents CA IV 2 2
CA III 5 3 8
CA II 11 1 12
CA I 3 3
Sub-total 18 7 25
SNE 1 1
Sub-total 0 1 1
TOTAL 53 47 100
SNE, seconded national expert.






AD AST AD AST CA I CA II CA III CA IV
Belgian 1 3 3 2 9 9
British 8 1 1 10 10
Bulgarian 3 3 3
Dutch 1 1 1
French 4 1 1 6 6
German 1 5 2 8 8
Greek 1 1 2 2
Irish 3 1 4 4
Italian 1 4 1 3 9 9
Latvian 1 1 1
Luxembourgish 1 1 2 2
Polish 1 1 1 3 3
Portuguese 1 3 5 9 3 8 4 1 34 34
Romanian 1 1 1
Spanish 2 2 2 6 6
Swedish 1 1 1
Total 6 4 42 22 1 3 12 8 2 100
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E. Schooling
There is no European or accredited school that can be 
attended free of charge in the area where the EMCDDA has its 
seat, and education is available only in English, French, 
German, Spanish and Portuguese on a private basis, which is 
more expensive than the cost staff members can cover with 
the double education allowance set out under Annex VII of the 
Staff regulations. Because of this, staff members of the 
EMCDDA are penalised by not being able to give their children 
an education in their mother tongue.
It is evident that the staff of the EMCDDA are not treated 
equally to other EU personnel when one considers that (i) the 
staff members of EU institutions, including some agencies, 
enjoy free access to European Schools (school fees and 
transport included), where available, on condition that they 
have a contract of at least one year; (ii) the average annual 
costs covered by the EU budget per pupil attending 
a European School is approximately EUR 11 840 (2) while the 
maximum reimbursement for education allowance laid down 
by the Staff regulations for covering the costs of attendance of 
a pupil per year at any school, where no European School is 
available, is approximately EUR 5 953; and (iii) European 
Schools provide multilingual tuition in all languages of the 
EU-15 and most of the EU-27 and offer the European 
Baccalaureate, recognised in all Member States.
Given that the EMCDDA is called upon to recruit officials and 
temporary staff of the highest ability, efficiency and integrity 
from the broadest possible geographical basis among 
nationals of Member States, as laid down in Article 27 of the 
Staff regulations and Articles 12 and 82 of the Conditions of 
employment for temporary officials and contract staff, 
a measure is needed to match the unequal working conditions 
(2) Annual Report of the Secretary-General to the Board of Governors of the European 
Schools — Presented to the Board of Governors of the European Schools at its meeting 8, 9 
and 10 April 2014, in Sofia. Ref.: 2014-01-D-23-fr-2.
to which the staff of the EMCDDA are subject compared with 
other staff working for the European Union in a location where 
European Schools exist. Local solutions based on existing 
best practice should have been found for the schooling of 
staff children — solutions that reconcile the work and private 
life of EMCDDA staff by facilitating the schooling of their 
children.
While awaiting a more structural solution resulting from the 
work performed by the management of the European Schools 
and in line with the ‘Guidelines on staff policy in the European 
regulatory Agencies’ as adopted by the EC on 16 December 
2005 (C(2005)5304), since the school year 2009/10 the 
EMCDDA has negotiated and concluded agreements with 
educational establishments in the area of Lisbon to provide 
schooling services for the children of its staff and ensure the 
direct payment of the eligible costs for educational services as 
described in the Staff regulations.
A staff member who benefits from this system does not 
receive the education allowance provided for in Article 3 of 
Annex VII to the Staff regulations, and the relevant rights/
entitlements are suspended for the period where he/she 
benefits from the system. The payment of expenses incurred 
by EMCDDA staff for the abovementioned eligible education 
costs is limited to a maximum ceiling of EUR 11 076 per child, 
per annum, which is, as mentioned above, the annual average 
cost covered by the EU budget per pupil attending a European 
School. The ceiling mentioned shall be revised annually 
pursuant to the relevant information provided by the Annual 
Report of the Secretary-General to the Board of Governors of 
the European Schools.
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|  ANNEX V Buildings
| 5.1 Current building(s)
Name, location and type of building Other comment
Information to be 
provided per building:
Cais do Sodré, Lisbon, office building, 
rented
Pursuant to an agreement with the Portuguese State, in 2009 an area of 
673.25 square metres (located in the so-called Relogio building of the EMCDDA 
premises) was sublet to the Portuguese State for the use of the Jacques Delors 
European Information Centre (JDEIC since 2009). This sublease covered the period 
between May 2009 and March 2012, when the CIEJD left the areas it had occupied 
pursuant to the decision taken by the relevant Portuguese authorities.
Since 2012, some private and public entities have expressed an interest in the 
sublease but they were not able to present any offer.
Finally in early 2016 the company Bensaude S.A. presented an offer for this sublease 
which would allow the EMCDDA to sublet the areas previously used by the CIEJD 
and neutralise the budget impact entailed by the departure of the latter. On this 
basis the EMCDDA and Bensaude concluded the contract for the sublease of these 
areas. The date of effect of this contract is 1 May 2016 and it will have an initial 
duration of five years, which may be extended for further period of five years.
Surface area (in 
square metres)
6 520 + 90 parking spaces planned, 
currently 61 rented
A supplementary area has been foreseen by the landlord.
Of which office space 5 846
Of which non-office 
space
674
Annual rent EUR 272 085.96 Pursuant to the agreement reached in 2015 with the landlord for the payment of the 
rent for the lease of the current premises in the next years, the annual amount of this 
rent was adjusted as follows:
EUR 272 085.96 for 2017 
EUR 305 421.96 for 2018 
EUR 589 689.96 for 2019 
EUR 955 889.96 for 2020 
EUR 1 072 089.96 from 2021 until the end of the 25-year lease contract in force.
Type and duration of 
rental contract
Rental for 25 years with option to buy
Host country grant or 
support
The host country supported the 
installation by providing the office 
furniture for the headquarters
Present value of the 
building
N.A.
| 5.2 Building project in the planning phase
Currently no new building projects are foreseen. The EMCDDA 
sold its former Santa Apolonia premises in 2015. In May 2016, 
the so-called Relogio building of the current EMCDDA premises 
was sublet and occupied by the company Bensaude S.A.
| 5.3  Building projects submitted to the European Parliament and the Council
The EMCDDA submitted all concrete offers received for the 
rental or sale of the Santa Apolonia premises. One offer from 
a public organisation was received and presented to the EP at 
the end of 2014. The offer was for sale of the building for 
a value of EUR 2.5 million. The budget authority approved the 
operation, which was concluded in January 2015. In line with 
the project approved by the EU budget authority for the lease 
of the current EMCDDA headquarters, the proceeds of this 
operation were used to reschedule the payment of rent due 
according to the contract in force for the 25-year lease of 
these headquarters.
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|  ANNEX VI Privileges and immunities
Agency privileges
Privileges granted to staff
Protocol of privileges and immunities/diplomatic status Education/day care (*)
The Portuguese Government granted the 
EMCDDA diplomatic status by means of 
the conclusion of a seat agreement on 26 
June 1996 (Protocol between the 
Portuguese Government and the 
EMCDDA regarding the functioning of the 
agency in Portugal and the installation of 
its headquarters in Lisbon). Through this 
agreement, which entered into force in 
May 1998, the Portuguese Government 
applies the Protocol on the Privileges and 
Immunities of the European Communities 
to the EMCDDA, exempting the agency 
from payment of all national, regional or 
municipal rates and taxes as regards the 
fixed assets it owns or rents, as well as 
from customs duties and from any other 
taxes, prohibitions or restrictions on goods 
of any kind which it imports or exports in 
the exercise of its official business (VAT, 
etc.).
The Protocol on the Privileges and Immunities of the 
European Communities is applicable to EMCDDA staff. 
The protocol concluded between the Portuguese 
Government and the EMCDDA regarding the functioning 
of the agency in Portugal and the installation of its 
headquarters in Lisbon grants the EMCDDA staff the 
privileges and immunities, exemptions and facilities 
recognised by the Portuguese State to members of 
a comparable category of the diplomatic corps in 
Portugal. As a consequence, EMCDDA staff members are 
entitled to purchase furniture and/or household aids VAT 
free. This exemption does not cover expenditure for food 
supplies and beverages, property works, including 
materials, water, gas, electricity, food and beverages 
services, hotels or similar services, or fixed-line telephone 
services. Limited exemption is granted from the payment 
of the Portuguese tax and VAT on the purchase and 
registration of vehicles.
There is no European or accredited school 
that can be attended free of charge in the 
area where the EMCDDA has its seat. As 
per the MoU signed in 2004 by the 
Portuguese Government, the EMCDDA and 
EMSA concerning the common premises of 
the two agencies in Lisbon, the Portuguese 
Government committed itself to do its 
utmost (jointly with EMSA and EMCDDA) to 
find the best possible solution for providing 
schooling for the children of EMSA and 
EMCDDA staff. In this context it agreed to 
pursue either the establishment of 
a European School in Lisbon or the 
signature of partial agreements between 
the European School Board and the main 
international schools in the Lisbon area. 
However, difficulties have been 
encountered in the implementation of this 
solution.
VAT, value-added tax.
(*) See also Annex IV, Section E — Schooling
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|  ANNEX VII Evaluations
In line with Article 23 of the EMCDDA founding regulation 
recast, the European Commission shall initiate an external 
evaluation of the agency every six years and forward the 
evaluation report to the European Parliament, the Council and 
the Management Board of the EMCDDA.
The last external evaluation of the agency was completed in 
June 2012. The main findings of this evaluation can be 
summarised as follows:
■■ As stated in the overall conclusions and recommendations, 
the EMCDDA has performed well during the 2007–12 
period in its mission of providing the EU and Member 
States with factual, objective, reliable and comparable 
information at the European level on drugs and drug 
addiction and their consequences. This overall conclusion 
is supported by the evidence from a number of different 
sources including the survey work.
■■ In relation to the various tasks set out in the EMCDDA’s 
2006 recast regulation, the evaluation findings are 
generally positive. Firstly, in relation to its role of providing 
‘factual, objective, reliable and comparable information at 
the European level concerning drugs and drugs addiction, 
and their consequences’, the EMCDDA has performed 
strongly. In addition to the demand side, progress was 
made on improving the understanding of the supply side of 
the drugs problem.
■■ The EMCDDA also performed well in relation to the second 
task defined for it in the 2006 regulation, namely to ‘collect, 
register and analyse information on emerging trends’. 
During the period under review, the upward trend in NPS 
being detected has accelerated but the EMCDDA has kept 
pace with developments through its EWS and related 
activities, providing useful information to the Commission 
and Member States that has been used to shape policy 
responses. Feedback from the research on the EMCDDA’s 
performance in relation to the third task set out in the 
recast regulation, ‘identifying best practices in Member 
States and facilitating and exchange of such practices 
between them’, is not as positive as for the other tasks. The 
EMCDDA’s fourth task (‘to promote cooperation with other 
European and international bodies and with third 
countries’) has been successfully carried out.
The result of the aforementioned evaluation can be found at 
the following web link: http://www.emcdda.europa.eu/html.
cfm/index184823EN.html
The final report contains 15 recommendations and the agency 
prepared an action plan to implement them. This action plan 
was adopted by the Management Board at its meeting of 5–6 
July 2012.
With a view to monitoring the implementation of the follow-up 
action plan, an annual internal assessment exercise was put in 
place and the results were presented in the General Report of 
Activities for 2013 and 2014 (available at: http://www.
emcdda.europa.eu/publications-database?f[0]=field_series_
type%253Aname%3AGeneral%20report%20of%20activities).
Furthermore, in order to measure the progress achieved, a KPI 
was set up in the 2014 work programme, namely KPI 10.1.6: 
Degree of implementation of the follow-up action plan to the 
third external evaluation of the EMCDDA, adopted by the 
Management Board in July 2012.
At the end of 2014, this KPI shows a good level of 
implementation (100 %) for all the actions resulting from the 
15 recommendations which have been under the control of 
the EMCDDA. The EMCDDA therefore concluded that all these 
recommendations could be closed. In this regard, a decision 
was adopted by the Management Board at its 51st meeting, 
which took place in September 2015.
The agency maintains, however, its commitment to ensuring 
that its future activities are aligned with these 
recommendations. This commitment is fully reflected in the 
EMCDDA’s 2016–18 strategy and work programme, which 
was adopted by the Management Board at its 52nd meeting, 
in December 2015, as well as in this SPD for 2017–19.
In line with the information available at the time of the drafting 
of this SPD, the fourth external evaluation of the EMCDDA will 
be carried out by the EC during 2018. The exercise will 
evaluate the success of the implementation of the new 
three-year strategy and work programme for 2016–18, as well 
as of the previous strategy and work programme for 2013–15.
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|  ANNEX VIII Risks 2017
Risk factors identified for delivery of the 2017 work programme Likelihood of risk and respective impact on the 2017 work programme
External risks with a direct link to specific fields of the annual work programme
1. Insufficient funding of the 2017 EMCDDA budget The amount of the EU subsidy decreased some EUR 756 000 from 2013 to 2014 
and has remained unchanged since then. This situation, if it continues, 
represents per se a medium- to high-level risk, as it encompasses an erosion in 
real terms of the nominal value of the EMCDDA budget and affects the capacity 
of the latter to effectively cope with the increasing operational needs and the 
resulting pressure on the agency’s resources (see risks 2 to 5, below).
2. Lack of adequate resources for NFPs in the Member States, 
which may affect their capacity to comply with reporting 
obligations towards the EMCDDA. This risk could be compounded 
by insufficient funding of information collection in Member States 
(see 3, immediately below)
All core monitoring activities could be affected, with the following main 
consequences: (a) lessened capability to identify new drug threats and 
developments; (b) undermining of established and valid time series data; and (c) 
reduced ability to properly report to the EMCDDA’s key partners.
The EMCDDA’s own budget constraints have led to a decrease in its grants to 
the NFPs. A review of the present national reporting package has been carried 
out and should continue, involving regular reviews of core data needs, timely 
feedback to the NFPs on their performance and compliance with reporting 
obligations towards the EMCDDA.
The budgetary situation in certain Member States has also led to cuts in funding 
of the respective NFPs; this risk can therefore be assessed as medium to high.
In particular, budget revisions performed by the national authorities during the 
last trimester may trigger corresponding reductions of the co-financing provided 
to the NFPs by the EMCDDA; this has obvious negative consequences for the 
NFPs in question; it may, however, also negatively affect the EMCDDA, which, at 
that late stage of the implementation of its work programme and execution of its 
budget, has limited options to rapidly reallocate the funds and spend them 
before the end of the year.
3. Reduction of the reporting capacity of Member States, due to 
either lacking or reduced availability of core data with adequate 
quality levels
The timeliness and comprehensiveness of reporting by Member States on new 
threats and drug developments have been affected; reporting on matters 
relating to the introduction of NPS has been missing or delayed.
Some comparative data has been unavailable, which has not allowed useful 
analysis at European level.
The impact of this risk can be considered as medium to high and should in 
principle be confined to some Member States. Closer attention to reporting 
biases and statistical approaches adopted across the Member States ought to 
be paid, in order to ensure the credibility of data received.
4. Supplementary specific requests from EU institutions to 
provide technical support for the implementation of EC 
programmes and actions, particularly regarding implementation 
of Council Decision 2005/387/JHA on NPS
Supporting drug policy and technical cooperation (with EU institutions) could be 
affected. The same applies regarding the undertaking of prompt action aimed at 
addressing issues arising from harmful NPS.
In view of the high number of NPS appearing over a short time period, 
monitoring through the EWS and risk assessments has placed 
a disproportionate burden on the work programme. Legal obligations regarding 
performance of risk assessments along the lines established in Council 
Decision 2005/387/JHA need to be complied with.
Similar concerns also exist for requests related to new activities in the field of 
Home Affairs. For this reason the risk level is within the medium to high range.
5. Supplementary requests from Member States and third parties 
to provide expertise in specific domains
Supporting drug policy and technical cooperation (with EU institutions) could be 
affected.
It has been increasingly difficult to deal with the level of requests. Any increase 
in demand for this type of expertise would need additional scientific resources 
dedicated to it and to be considered in view of other priorities of the work 
programme; in this respect, there are serious concerns over the work overload 
being created in response to the number of requests addressed to the 
EMCDDA. The risk level is presently seen as medium although on the rise.
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External events that might have an impact on the implementation of the annual work programme as a whole
6. Natural catastrophes: earthquakes (leading to possible 
tsunamis), landslides or floods
The location of the EMCDDA facilities, bordering the Tagus river, raises 
a potential risk of being affected by any of these natural catastrophes. The likely 
consequences of a major earthquake are hardly predictable and appropriate 
measures would have to be taken in order to deal with the resulting damages. 
A landslide of the building caused by earthquakes, although not very likely, 
cannot be ruled out.
As regards Tagus flooding, some information available leads us to believe that 
the potential risk here would be low. On the other hand, it is conceivable that 
a combination of heavy rain with Tagus high tides could cause flooding of the 
underground car park. Further mitigating measures to deal with this risk ought to 
be agreed with and taken by the Administration of the Port of Lisbon (APL), the 
entity that owns the Cais do Sodré building. Letters along these lines have been 
sent to the APL on multiple occasions and a meeting has been held, but so far 
without concrete results.
A very comprehensive insurance contract covering, inter alia, adverse effects 
from earthquakes, landslides and floods has been signed.
A business continuity plan (BCP) for the agency as a whole was approved in 
2013: this will help mitigate these risks and respective consequences.
7. Terrorist attacks Any activity of the EMCDDA could be affected. Recent events in some European 
countries (notably the 13 November 2015 terrorist attacks in Paris), while 
isolated, raise serious issues concerning possible collateral effects of ISIS 
activities both in North Africa and the Middle East (notably, radicalisation of 
youngsters and further home-grown terrorism).
A series of mitigating measures have been taken, notably adequate insurance 
policies of premises; reinforced building protection against bomb blasts and 
small calibre bullets; and scanning of suspicious mail. Moreover, the main 
entrances at the EMCDDA premises have been redesigned in order to create 
a second barrier to possible intruders; the immediate entrance area to the 
garage will be upgraded in order to prevent or deter entrance by a vehicle of 
would-be terrorists.
Internal risks
8.1 Information Technology (IT) governance risks, notably linked 
to:
a) suboptimal investment decisions in IT;
b) certain weaknesses in the management of IT projects; and
c) inadequate licensing and asset management procedures
A vast number of mitigating measures to deal with these risks have been 
implemented, namely:
a) setting up of a register with a categorisation of ICT investments; elaboration of 
a detailed report on ICT activities from 2010 onwards; setting up of a project 
catalogue for ICT; creation of an ICT Investments Steering Committee which 
reviews and control investments in the area; implementation of a project 
portfolio management process; adoption of the 2013–15 ICT strategic plan; 
improved documentation of procedures leading to decisions taken on IT 
investments; and setting up of shared high-speed internet access (in 
cooperation with EMSA);
b) setting up of the ICT Advisory Committee; participation of the EMCDDA in 
interinstitutional framework contracts; adoption of a ‘turnkey’ approach to 
projects; definition and implementation of a project management methodology 
for ICT managed projects; and implementation of a project management 
framework using an enhanced methodology;
c) use of suitable tools in supporting sound asset management and reliability of 
licensing.
A wide range of additional measures and actions is expected to further reduce 
existing risks levels to tolerable levels: (a) implementation of a framework 
targeting investment optimisation; (b) aligning of perspectives and strategy 
covering elements such as the ‘cloud’ with the overall strategy finalised in 2016; 
(c) enhancing planning and control of license and assets utilisation; and (d) 
setting up the ICT Services Catalogue on the basis of the new Service Request 
Management Tool.
PROGRAMMING DOCUMENT 2017–19
79 / 86 
Risk factors identified for delivery of the 2017 work programme Likelihood of risk and respective impact on the 2017 work programme
8.2 Information Technology (IT) technical risks, notably linked to:
a) software configuration management problems resulting from 
installations of software not being properly planned;
b) inconsistent application of patching procedures, compounded 
by insufficient documentation of interventions and system 
updates;
c) difficulties in ensuring business continuity and swift recovery in 
cases of incidents or disasters, due to both governance-related 
and technical risks; and
d) security violations, due to some lack of adequate procedures, 
policies and documentation in the IT area
Most relevant mitigating measures have already been implemented, such as:
a) setting up of an automatic monitoring system to deal with installed 
configurations; configuration audit exercises; implementation of technical tools 
addressing management of software configuration issues; and conception of 
a ‘documentation tree’ as the basis for a future documentation set covering risk 
management, security and governance in IT;
b) ad hoc testing of potential consequences emerging from patching procedural 
weaknesses and systematic registration of interventions performed; setting up 
of a Definitive Software Library (DSL), indicating software versions in use and 
patches installed; and extension of the scope of Windows 7 in order to include 
the configuration of patching capabilities;
c) adoption of an EMCDDA BCP as a whole (thus also covering IT); initiation of 
service continuity and disaster recovery plans; implementation of an external 
facility for backup tape storage; use of a framework contract for the backup 
consolidation project supporting business continuity; procurement of 
specialised assistance services in cases of disaster; and documentation of key 
technical dependencies in ICT;
d) installation of network management software combined with an update of 
the software version of Firewalls; introduction of modules for intrusion detection 
and prevention; and increased protection against malware and virus threats.
Furthermore, a comprehensive set of additional measures has been planned in 
order to further reduce present risk levels:
a) establishment of standard documentation on the EMCDDA ICT technical 
infrastructure;
b) definition of specific guidelines for patching in servers; creation of 
documentation on processes used for patching of desktops; and alignment of 
software configurations and use of patching capabilities also on Citrix servers;
c) finalisation of the work started in implementing the service continuity and 
disaster recovery plans, notably in view of the setting up of the future disaster 
recovery centre in Madrid;
d) contracting and carrying out telecom security-related services, as well as 
external audits on sensitive areas of the EMCDDA core business (for instance 
public websites and the Fonte data collection application); and outsourcing of 
ex-post assessments on ICT security-related areas and ensuring follow-up of 
the respective recommendations.
In view of the above, these IT technical risks are presently within the medium to 
high range.
9. Unexpected departure of key members of staff, which could 
have a negatively impact on the quality of the scientific output of 
the EMCDDA
Given the highly specialised and technical nature of much of the agency’s work, 
finding suitable replacements can be a time-consuming task. Redeployment 
could prove to be unfeasible, as it would require the existence of a pool of staff 
members with very comprehensive skills and expertise in the areas at stake.
The readjustment inside the Scientific Division has provided some backup 
arrangements for all staff concerned, while allowing a wider decentralisation of 
responsibilities in this key area. Even so, these might turn out to be insufficient, 
notably in the event of long-term absence of key staff, which could hinder the 
EMCDDA’s core operations.
Investment in human resources ensures that arising needs are treated with 
minimum delay in most cases; a recruitment tool was developed by the 
EMCDDA with a view to further accelerating recruitment procedures. Job 
profiles have been designed with a view to recruiting staff for transversal tasks 
and facilitating sharing of knowledge and expertise within small working groups. 
A stable contracts policy with key staff, notably in scientific areas, has been 
pursued and ought to be reinforced.
In view of the mitigation measures already taken and planned the risk level can 
be assessed as low to medium.
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|  ANNEX IX Procurement plan 2017
Pursuant to the applicable financial regulation, this annex 
indicates the procurements for non-administrative activities 
that have been envisaged for the implementation of the 
EMCDDA 2017 work programme the value of which is equal to 
or greater than EUR 60 000, to be covered by appropriations 
entered into Title 3 of the relevant EMCDDA budget.
No such procurements have been envisaged for the 
implementation of the 2017 work programme. In the event 
that such procurements are launched during 2017 the 
EMCDDA Management Board will be duly and promptly 
informed.
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|  ANNEX X Organisation chart 2017
Director:
Alexis Goosdeel (DIR)
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|  ANNEX XI List of the beneficiaries of Reitox grants (national focal points)
■■ AUSTRIA: Gesundheit Österreich GmbH (Austrian Health 
Institute), Vienna.
■■ BELGIUM: Institute of Public Health — Patrimoine (IPH-
Patrimoine), Brussels.
■■ BULGARIA: National Centre for Addictions (NCA BG), Sofia.
■■ CROATIA: Vlada Republike Hrvatske — Ured za suzbijanje 
zlouporabe droga (Office for Combating Drugs Abuse of 
the Government of the Republic of Croatia), Zagreb.
■■ CYPRUS: Antinapkωtiko Σymboyλio Kyπpoy (Cyprus 
Anti-Drugs Council — CAC), Nicosia.
■■ CZECH REPUBLIC: Úřad vlády České republiky (Office of 
the Government of the Czech Republic), Prague.
■■ DENMARK: Danish Health Authority, Copenhagen.
■■ ESTONIA: Tervise Arengu Instituut (National Institute for 
Health Development — NIHD), Tallinn.
■■ FINLAND: Terveyden Ja Hyvinvoinnin Laitos (National 
Institute for Health and Welfare — THL), Helsinki.
■■ FRANCE: Observatoire Français des Drogues et des 
Toxicomanies (French Monitoring Centre for Drugs and 
Drug Addiction), Saint-Denis.
■■ GERMANY: Institut für Therapieforschung (Institute for 
Therapy Research), Munich.
■■ GREECE: Εθνικό Κέντρο Τεκμηρίωσης και Πληροφόρησης 
για τα Ναρκωτικά — ΕΚΤΕΠΝ (University Mental Health 
Research Institute), Athens.
■■ HUNGARY: Nemzeti Egészségfejlesztési Intézet (National 
Institute for Health Development), Budapest.
■■ IRELAND: Health Research Board (HRB) — Drugs Misuse 
Research Division, Dublin.
■■ ITALY: Presidenza del Consiglio dei Ministri — Dipartimento 
per le Politiche Antidroga (Presidency of the Council of 
Ministers — Department for Antidrug Policies), Rome.
■■ LATVIA: Slimību profilakses un kontroles centra (Centre for 
Disease Prevention and Control of Latvia), Riga.
■■ LITHUANIA: Narkotikų, Tabako ir Alkoholio Kontrolés 
Departhamentas (Drug, Tobacco and Alcohol Control 
Department), Vilnius.
■■ LUXEMBOURG: Luxembourg Institute of Health (LIH), 
Luxembourg.
■■ MALTA: Ministry for the Family and Social Solidarity 
(MFSS), Valletta.
■■ NETHERLANDS: Stichting Trimbos Instituut, Utrecht.
■■ POLAND: Krajowe Biuro Do Spraw Przeciwdziałania 
Narkomanii (National Bureau for Drugs Prevention), 
Warsaw.
■■ PORTUGAL: Serviço de Intervenção nos Comportamentos 
Aditivos e nas Dependências (SICAD), Lisbon.
■■ ROMANIA: Agenţia Natională Antidrog (National Anti-drug 
Agency), Bucharest.
■■ SLOVAKIA: Ministerstvo zdravotníctva Slovenskej 
republiky — MZ SR (Ministry of Health of the Slovak 
Republic), Bratislava.
■■ SLOVENIA: Inštitut za Varovanje Zdravja Republike 
Slovenije — NIJZ (National Institute of Public Health of the 
Republic of Slovenia), Ljubljana.
■■ SPAIN: Delegación del Gobierno para el Plan Nacional 
sobre Drogas (Government Delegation for the National 
Plan on Drugs — GDNPD), Madrid.
■■ SWEDEN: Folkhälsomyndigheten (Public Health Agency of 
Sweden), Östersund.
■■ UNITED KINGDOM: Public Health England, Alcohol and 
Drug, London.
Full contact details are available at: http://www.emcdda.
europa.eu/about/partners/reitox-network
PROGRAMMING DOCUMENT 2017–19
83 / 86 
|  ANNEX XII Template of the 2017 Reitox grant agreement
The current grant agreement template is available at: 
www.emcdda.europa.eu/about/partners/reitox-network
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|  ANNEX XIII Technical assistance projects — IPA 5 2017 implementation plan
In 2017, the EMCDDA will implement one technical assistance 
project for third countries, as follows:
■■ IPA 5 — the fifth project funded under the Instrument for 
Pre-Accession Assistance (IPA) started in 2015 and has 
a budget of EUR 600 000. It aims to further support IPA 
beneficiaries in their preparation for participation in the 
EMCDDA activities and in the Reitox network. The project 
will be finalised in June 2017.
The 2017 implementation plan for this project is presented 
below.
Depending on the date of the signature of the IPA 6 project, in 
2017 the EMCDDA may also implement the first months of the 
IPA 6 project with the Western Balkans.
Interventions Activities Expected results
Specific objective 1. To consolidate the institutionalisation of the cooperation
1.1. Support to NFP/National 
Drug Observatories (NDO) 
building
High-level visit to the EMCDDA
National meetings with participation of the 
EMCDDA
Increased knowledge about the EMCDDA
IPA beneficiary countries have improved their national drug 
monitoring systems institutional capacity
1.2. Strengthening of the EU 
and international 
partnerships
Ad hoc input/review project proposals
Coordination and regular communication 
with international organisations, EU 
institutions and EU delegations
Contribution to the 2017 progress reports 
on the ‘enlargement package’
Support to strengthen National Drug Information Systems is 
coordinated among different players at EU and national levels
1.3. Fulfil the IPA 5 
contractual commitments
Prepare final activity report Final activity report drafted and delivered on time to the EC
1.4. Implement the 
EMCDDA’s international 
cooperation strategy
Keep Management Board informed on the 
progress of implementation of the IPA 5 
project
Management Board provided with updated progress information at 
the December meeting
Specific objective 2. To foster scientific cooperation in relation to data collection, analysis and interpretation
2.1. Direct support for data 
collection and reporting
National data collection exercises in line 
with the EMCDDA guidelines (e.g. GPS in 
Montenegro — see 3.1 below)
Prevalence and patterns of drug use among the general population 
available for the first time from Montenegro and the former Yugoslav 
Republic of Macedonia
New information on treatment systems and on the availability of 
services in the IPA beneficiaries
New data sets available on drug seizures
2.2. Capacity development Organise Reitox academies and provide ad 
hoc support activities (e.g. study visits, 
country visits, ad hoc participation of IPA 
national experts in EU expert groups, etc.)
Increased capacity at national level (heads of existing/future NFPs 
and their staff, and national experts) for analysis and interpretation 
(including data on NPS)
2.3. EU expert meetings Ad hoc participation of IPA national experts 
in EU expert groups
Increased exchange of information on the drugs situation and related 
monitoring challenges between the EU Member States and CC and 
PCC
2.4. Support for 
development of national 
EWS
Training and meetings on building national 
EWS (at request)
Proposals for organisational structure of national EWS discussed in 
all countries which committed to establish a national EWS with 
support of the EMCDDA
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Interventions Activities Expected results
Specific objective 3. To develop, increase and promote the added value of the cooperation
3.1. Enhance the knowledge 
about the drugs situation in 
IPA beneficiaries
Disseminate the information and 
knowledge arising from the project 
(through outputs, online communication, 
presentations at national and international 
events)
Decision-makers at national and EU level are better informed on the 
drugs situation and on the need for interventions through the 
following project outputs:
updated country overviews
specific reports forwarded to EU sub-committees, EU political 
dialogue, etc. (upon request)
GPS report of Montenegro (provided that the GPS is implemented in 
the country in 2016)
promotion of the ESPAD results
articles published in Drugnet —EMCDDA newsletter
methodological tools translated into national languages
Final IPA5 conference organised
Regular updates through the EMCDDA website and social media
3.2. Support to national 
strategies and action plans
Share know-how on evaluation of national 
drug strategies (upon request)
Provide information to decision-makers on 
demand reduction, treatment, supply 
reduction and legal practices at EU level 
(ad hoc and on demand)
Information collected and produced by EMCDDA and by IPA 
beneficiaries supports the implementation and evaluation of national 
strategies
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